<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002487</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>134</s160></s100><s200><s210>1</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Xaa can be K, A, T, or V (Lys, Ala, Thr, or      Val)</s223></s220></s200><s400> 1Xaa Gln Ser Tyr Phe Arg Arg Thr1               5</s400><s200><s210>2</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 2Ala Gln Ser Tyr Phe Arg Arg Thr1               5</s400><s200><s210>3</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 3Thr Gln Ser Tyr Phe Arg Arg Thr1               5</s400><s200><s210>4</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 4Val Gln Ser Tyr Phe Arg Arg Thr1               5</s400><s200><s210>5</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 5Lys Gln Ser Tyr Phe Arg Arg Thr1               5</s400><s200><s210>6</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(1)..(1)</s222><s223>Ala or Val</s223></s220><s220><s221>MOD_RES</s221><s222>(7)..(7)</s222><s223>Arg or Gln</s223></s220></s200><s400> 6Xaa Arg Asp Ala Tyr Gly Xaa Tyr Phe Tyr Asp Val1               5                   10</s400><s200><s210>7</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(12)..(12)</s222><s223>Gly, Met, Asn, or Arg</s223></s220></s200><s400> 7Lys Ser Ser Gln Ser Leu Leu Asn Ala Arg Thr Xaa Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>8</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 8Lys Ser Ser Gln Ser Leu Leu Asn Ala Arg Thr Gly Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>9</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 9Lys Ser Ser Gln Ser Leu Leu Asn Ala Arg Thr Arg Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>10</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 10Trp Ala Ser Thr Arg Glu Ser1               5</s400><s200><s210>11</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 11Trp Ala Ser Thr Arg Ser Ser1               5</s400><s200><s210>12</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(3)..(3)</s222><s223>Ile, Asn, or Val</s223></s220><s220><s221>MOD_RES</s221><s222>(8)..(8)</s222><s223>Met or Ile</s223></s220></s200><s400> 12Phe Asn Xaa Lys Asp Tyr Tyr Xaa His1               5</s400><s200><s210>13</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 13Phe Asn Ile Lys Asp Tyr Tyr Met His1               5</s400><s200><s210>14</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220><s220><s221>MOD_RES</s221><s222>(5)..(5)</s222><s223>Glu or Asn</s223></s220><s220><s221>MOD_RES</s221><s222>(13)..(13)</s222><s223>Ala, His, or Thr</s223></s220><s220><s221>MOD_RES</s221><s222>(15)..(15)</s222><s223>Phe or Leu</s223></s220></s200><s400> 14Trp Ile Asp Leu Xaa Asn Ala Asn Thr Val Tyr Asp Xaa Lys Xaa Gln1               5                   10                  15Gly</s400><s200><s210>15</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 15Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>16</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 16Trp Ile Asp Leu Glu Asn Ala Asn Thr Ile Tyr Asp Ala Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>17</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 17Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>18</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 18Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>19</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 19Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>20</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 20Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Ala Arg Asp Thr Ser Ala Ser Thr Val Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>21</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 21Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Ile Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>22</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 22Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Ala Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>23</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 23Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Val Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>24</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 24Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Gly Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>25</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 25Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Ala Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>26</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 26Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Val Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>27</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 27Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Thr Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>28</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 28Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Val Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>29</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 29Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>30</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 30Gln Val Gln Leu Val Gln Ser Glu Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>31</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 31Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Asn Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>32</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 32Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Gln Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>33</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 33Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Val Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>34</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 34Asp Ile Val Met Ser Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Ser Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Val Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>35</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 35Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Leu    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Gly Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>36</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 36Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>37</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 37Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Leu        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>38</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 38Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Ala Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>39</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 39Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Glu Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>40</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 40Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>41</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 41Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Phe Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>42</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 42Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Met Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Ser Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>43</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 43Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Asn Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>44</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 44Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Gly Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>45</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 45Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Met Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Ala Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>46</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 46Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Thr Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Val Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>47</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 47Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Ala Ala Val Tyr Tyr Cys Ala Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>48</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 48Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Arg Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Gly Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Lys Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>49</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 49Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Glu Glu Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>50</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 50Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Pro Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>51</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 51Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>52</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 52Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Ala Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>53</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 53Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Gly Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Val Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>54</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 54Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Ala Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>55</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 55Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Ile Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>56</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 56Gln Ala Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Thr Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>57</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 57Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp His Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>58</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 58Gln Ala Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Pro Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ala Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>59</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 59Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Gly Thr Ala His65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Pro Val Thr Val Ser Ser        115</s400><s200><s210>60</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 60Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Asn Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>61</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 61Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>62</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 62Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Leu    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Gly Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Pro Val Thr Val Ser Ser        115</s400><s200><s210>63</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 63Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Ala Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>64</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 64Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Val Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>65</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 65Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Thr Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>66</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 66Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Thr Ser Gln Gly Leu Leu Asn Ala            20                  25                  30Arg Thr Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Val Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>67</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 67Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Pro Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Ala Ala Ala Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>68</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 68Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ala            20                  25                  30Arg Thr Gly Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln        35                  40                  45Pro Pro Glu Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val    50                  55                  60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65                  70                  75                  80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Thr Gln                85                  90                  95Ser Tyr Phe Arg Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys            100                 105                 110</s400><s200><s210>69</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 69Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Asn Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>70</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 70Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr            20                  25                  30Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Arg Pro Glu Trp Ile        35                  40                  45Gly Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe    50                  55                  60Gln Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr65                  70                  75                  80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ala Tyr Tyr Cys                85                  90                  95Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val Trp Gly Gln Gly            100                 105                 110Thr Leu Val Thr Val Ser Ser        115</s400><s200><s210>71</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 71Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly            20                  25</s400><s200><s210>72</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 72Gln Ala Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly            20                  25</s400><s200><s210>73</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 73Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Glu Glu Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly            20                  25</s400><s200><s210>74</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 74Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Pro Val Lys Val Ser Cys Lys Ala Ser Gly            20                  25</s400><s200><s210>75</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 75Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Thr Val Lys Val Ser Cys Lys Ala Ser Gly            20                  25</s400><s200><s210>76</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 76Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly            20                  25</s400><s200><s210>77</s210><s211>26</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 77Gln Val Gln Leu Val Gln Ser Glu Ala Glu Val Lys Lys Pro Gly Ala1               5                   10                  15Ser Val Lys Val Ser Cys Lys Ala Ser Gly            20                  25</s400><s200><s210>78</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 78Phe Asn Asn Lys Asp Tyr Tyr Met His1               5</s400><s200><s210>79</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 79Phe Asn Ile Lys Asp Tyr Tyr Ile His1               5</s400><s200><s210>80</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 80Phe Asn Val Lys Asp Tyr Tyr Met His1               5</s400><s200><s210>81</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 81Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile Gly1               5                   10</s400><s200><s210>82</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 82Trp Val Arg Gln Ala Pro Gly Gln Arg Pro Glu Trp Ile Gly1               5                   10</s400><s200><s210>83</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 83Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Leu Gly1               5                   10</s400><s200><s210>84</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 84Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Ala Lys Leu Gln1               5                   10                  15Gly</s400><s200><s210>85</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 85Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp Thr Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>86</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 86Trp Ile Asp Leu Glu Asn Ala Asn Thr Val Tyr Asp His Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>87</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 87Trp Ile Asp Leu Asn Asn Ala Asn Thr Val Tyr Asp Ala Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>88</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 88Trp Ile Asp Leu Glu Asn Ala Asn Ala Val Tyr Asp Ala Lys Phe Gln1               5                   10                  15Gly</s400><s200><s210>89</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 89Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>90</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 90Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Asn Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>91</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 91Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Ala Ala Ala Tyr Tyr Cys            20                  25                  30</s400><s200><s210>92</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 92Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ala Tyr Tyr Cys            20                  25                  30</s400><s200><s210>93</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 93Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Gly Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>94</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 94Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Gly Thr Ala His Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>95</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 95Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Ile Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>96</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 96Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Ala Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>97</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 97Arg Val Ala Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>98</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 98Arg Val Thr Ile Ala Arg Asp Thr Ser Ala Ser Thr Val Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>99</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 99Arg Val Thr Ile Thr Arg Asp Ala Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>100</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 100Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Gly Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>101</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 101Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu1               5                   10                  15Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>102</s210><s211>30</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 102Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Gly Thr Ala Tyr Met Glu1               5                   10                  15Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>103</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 103Ala Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val1               5                   10</s400><s200><s210>104</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 104Ala Arg Asp Ala Tyr Gly Gln Tyr Phe Tyr Asp Val1               5                   10</s400><s200><s210>105</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 105Val Arg Asp Ala Tyr Gly Arg Tyr Phe Tyr Asp Val1               5                   10</s400><s200><s210>106</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 106Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser1               5                   10</s400><s200><s210>107</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 107Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser1               5                   10</s400><s200><s210>108</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 108Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys            20</s400><s200><s210>109</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 109Asp Ile Val Met Ser Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Thr Ile Asn Cys            20</s400><s200><s210>110</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 110Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Gly Arg Ala Thr Ile Asn Cys            20</s400><s200><s210>111</s210><s211>23</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 111Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1               5                   10                  15Glu Arg Ala Ile Ile Asn Cys            20</s400><s200><s210>112</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 112Lys Thr Ser Gln Gly Leu Leu Asn Ala Arg Thr Asn Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>113</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 113Lys Ser Ser Gln Ser Leu Leu Asn Ala Arg Thr Arg Arg Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>114</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 114Lys Ser Ser Gln Glu Leu Leu Asn Ala Arg Thr Gly Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>115</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 115Lys Ser Ser Gln Ser Leu Leu Asn Ala Arg Thr Met Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>116</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 116Lys Thr Ser Gln Ser Leu Leu Asn Ala Arg Thr Asn Lys Asn Tyr Leu1               5                   10                  15Ala</s400><s200><s210>117</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 117Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr1               5                   10                  15</s400><s200><s210>118</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 118Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Glu Leu Leu Ile Tyr1               5                   10                  15</s400><s200><s210>119</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 119Trp Tyr Gln Gln Lys Pro Gly Arg Pro Pro Lys Leu Leu Ile Tyr1               5                   10                  15</s400><s200><s210>120</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 120Trp Ala Ser Ala Arg Glu Ser1               5</s400><s200><s210>121</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 121Trp Gly Ser Thr Arg Glu Ser1               5</s400><s200><s210>122</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 122Trp Ala Phe Thr Arg Glu Ser1               5</s400><s200><s210>123</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 123Trp Ala Ser Met Arg Glu Ser1               5</s400><s200><s210>124</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 124Trp Ala Ser Thr Arg Glu Asn1               5</s400><s200><s210>125</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 125Ala Ala Ser Thr Arg Glu Ser1               5</s400><s200><s210>126</s210><s211>32</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 126Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr1               5                   10                  15Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>127</s210><s211>32</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 127Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr1               5                   10                  15Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Ala Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>128</s210><s211>32</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      polypeptide</s223></s220></s200><s400> 128Gly Val Pro Asp Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr1               5                   10                  15Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys            20                  25                  30</s400><s200><s210>129</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 129Ser Gln Ser Tyr Phe Arg Arg Thr1               5</s400><s200><s210>130</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Description of Artificial Sequence Synthetic      peptide</s223></s220></s200><s400> 130Phe Gly Gly Gly Thr Lys Val Glu Ile Lys1               5                   10</s400><s200><s210>131</s210><s211>335</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 131Gln Asp Gly Asn Glu Glu Met Gly Gly Ile Thr Gln Thr Pro Tyr Lys1               5                   10                  15Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Pro Gln Tyr Pro            20                  25                  30Gly Ser Glu Ile Leu Trp Gln His Asn Asp Lys Asn Ile Gly Gly Asp        35                  40                  45Glu Asp Asp Lys Asn Ile Gly Ser Asp Glu Asp His Leu Ser Leu Lys    50                  55                  60Glu Phe Ser Glu Leu Glu Gln Ser Gly Tyr Tyr Val Cys Tyr Pro Arg65                  70                  75                  80Gly Ser Lys Pro Glu Asp Ala Asn Phe Tyr Leu Tyr Leu Arg Ala Arg                85                  90                  95Val Cys Glu Asn Cys Met Glu Met Asp Gly Gly Ser Asp Lys Thr His            100                 105                 110Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val        115                 120                 125Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr    130                 135                 140Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu145                 150                 155                 160Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys                165                 170                 175Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser            180                 185                 190Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys        195                 200                 205Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile    210                 215                 220Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro225                 230                 235                 240Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu                245                 250                 255Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn            260                 265                 270Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser        275                 280                 285Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg    290                 295                 300Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu305                 310                 315                 320His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys                325                 330                 335</s400><s200><s210>132</s210><s211>326</s211><s212>PRT</s212><s213>Cynomolgus</s213></s200><s400> 132Gln Asp Gly Asn Glu Glu Met Gly Ser Ile Thr Gln Thr Pro Tyr Gln1               5                   10                  15Val Ser Ile Ser Gly Thr Thr Val Ile Leu Thr Cys Ser Gln His Leu            20                  25                  30Gly Ser Glu Ala Gln Trp Gln His Asn Gly Lys Asn Lys Glu Asp Ser        35                  40                  45Gly Asp Arg Leu Phe Leu Pro Glu Phe Ser Glu Met Glu Gln Ser Gly    50                  55                  60Tyr Tyr Val Cys Tyr Pro Arg Gly Ser Asn Pro Glu Asp Ala Ser His65                  70                  75                  80His Leu Tyr Leu Lys Ala Arg Val Cys Glu Asn Cys Met Glu Met Asp                85                  90                  95Gly Gly Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu            100                 105                 110Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp        115                 120                 125Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp    130                 135                 140Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly145                 150                 155                 160Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala                165                 170                 175Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp            180                 185                 190Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro        195                 200                 205Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu    210                 215                 220Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn225                 230                 235                 240Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile                245                 250                 255Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr            260                 265                 270Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys        275                 280                 285Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys    290                 295                 300Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu305                 310                 315                 320Ser Leu Ser Pro Gly Lys                325</s400><s200><s210>133</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial Sequence Synthetic peptide</s223></s220><s220><s221>misc_feature</s221><s222>(6)..(6)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220></s200><s400> 133Trp Ala Ser Thr Arg Xaa Ser1               5</s400><s200><s210>134</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Artificial Sequence Synthetic peptide</s223></s220><s220><s221>misc_feature</s221><s222>(1)..(1)</s222><s223>Xaa can be any naturally occurring amino acid</s223></s220></s200><s400> 134Xaa Gln Ser Tyr Phe Arg Arg Thr1               5</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002488A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002488</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17773240</doc-number><date>20201105</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>68</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2809</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>35</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>32</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2863</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>2878</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20170801</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>47</main-group><subgroup>6889</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>505</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62931307</doc-number><date>20191106</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62984731</doc-number><date>20200303</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>62991042</doc-number><date>20200317</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>SYSTIMMUNE, INC.</orgname><address><city>Redmond</city><state>WA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.</orgname><address><city>Chengdu, Sichuan</city><country>CN</country></address></addressbook><residence><country>CN</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Goulet</last-name><first-name>Dennis R.</first-name><address><city>Redmond</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Chatterjee</last-name><first-name>Soumili</first-name><address><city>Bothell</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Tsai</last-name><first-name>Tsung-I</first-name><address><city>Redmond</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Renshaw</last-name><first-name>Blair</first-name><address><city>Renton</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Waight</last-name><first-name>Andrew</first-name><address><city>Kenmore</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>Mak</last-name><first-name>Nga Sze Amanda</first-name><address><city>Mukilteo</city><state>WA</state><country>US</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>ZHU</last-name><first-name>Yi</first-name><address><city>Redmond</city><state>WA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/059230</doc-number><date>20201105</date></document-id><us-371c12-date><date>20220429</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The application provides a multi-specific antibody-like protein having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first binding domain (D1) at the N-terminal, a second binding domain (D2) comprising a light chain moiety, a Fc region, a third binding domain (D3), and a fourth binding domain (D4) at the C-terminal, wherein the light chain moiety comprises a fifth binding domain (D5) covalently attached to the C-terminal, a sixth binding domain (D6) covalently attached to the N-terminal, or both, and wherein the D1, D2, D3, D4, D5 and D6 each has a binding specificity against a tumor antigen, an immune signaling antigen, or a combination thereof.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="77.89mm" wi="155.87mm" file="US20230002488A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="79.93mm" wi="157.90mm" file="US20230002488A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="68.16mm" wi="163.49mm" file="US20230002488A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="144.70mm" wi="153.50mm" file="US20230002488A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="148.84mm" wi="153.33mm" file="US20230002488A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="74.00mm" wi="154.94mm" file="US20230002488A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="100.67mm" wi="155.53mm" file="US20230002488A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="130.64mm" wi="150.79mm" file="US20230002488A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="74.68mm" wi="92.54mm" file="US20230002488A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="114.22mm" wi="169.42mm" file="US20230002488A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="111.68mm" wi="165.86mm" file="US20230002488A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="77.39mm" wi="146.47mm" file="US20230002488A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="81.36mm" wi="159.60mm" file="US20230002488A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="63.08mm" wi="161.37mm" file="US20230002488A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="66.21mm" wi="162.31mm" file="US20230002488A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="76.03mm" wi="94.15mm" file="US20230002488A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CROSS REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application claims the benefit of the filing date of U.S. Provisional Application Ser. No. 62/931,307 filed Nov. 6, 2019, U.S. Provisional Application Ser. No. 62/984,731 filed Mar. 3, 2020, and U.S. Provisional Application Ser. No. 62/991,042 filed Mar. 17, 2020 under 35 U.S.C. 119(e), the entire disclosures of which are incorporated by reference herein.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">TECHNICAL FIELD</heading><p id="p-0003" num="0002">The present application relates to the technical field of multi-specific antibody for immunotherapy and more particularly relates to making and using Guidance and Navigation Control (GNC) antibodies with multiple binding activities against surface molecules of immune cells and tumor cells.</p><heading id="h-0003" level="1">BACKGROUND</heading><p id="p-0004" num="0003">Cancer develop by gaining mutations that enable the cancer cells to transform, proliferate, and metastasize while escaping from the immune surveillance and response. Antibody therapy for treating cancer recruits multiple distinct mechanisms. For example, monoclonal antibodies targeting growth receptors (EGFR, HER2, etc.) that are overexpressed on tumor cells can be used to block tumor cell proliferation. Using antibodies to block inhibitory T cell checkpoint signals (anti-PDL1, anti-PD1, anti-CTLA4) is a strategy to prevent tumor cells from weakening the immune response that would otherwise seek to control their growth. Another therapeutic strategy is to inhibit angiogenesis (e.g., anti-VEGF), where the reduced access to oxygen and nutrients slows the growth of tumor cells. Monoclonal antibodies and antibody-drug conjugates (ADCs) are initially effective at controlling tumors. However, cancer resistance to antibody therapy often occurs through escape mechanisms, such as ectodomain shedding, receptor downregulation and receptor mutation (Miller et al. Clin Cancer Res. 2017; Reslan et al. Mabs. 2009; Loganzo et al. Mol Cancer Ther. 2016). For example, resistance to anti-HER2 mAb trastuzumab may occur through ectodomain shedding of HER2 or through occlusion of the trastuzumab epitope on HER2 (Fiszman and Jasnis. International Journal of Breast Cancer, 2011).</p><p id="p-0005" num="0004">Combinational therapies combining multiple therapeutic mechanisms including that of chemotherapy, radiation therapy and antibody therapy have become a mainstream therapeutic strategy. In this context, multi-specific antibodies combine different antibody therapies and mechanisms into a single agent (Boumandi and de Sauvage. Nat Rev Drug Discov. 2020).</p><heading id="h-0004" level="1">SUMMARY</heading><p id="p-0006" num="0005">The following summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features will become apparent by reference to the drawings and the following detailed description.</p><p id="p-0007" num="0006">In one aspect, the application provides guidance and navigation control (GNC) proteins that can simultaneously bind effector cells and target cells. The GNC protein may be a monomer or a dimer of the monomer. The GNC protein may be an antibody or an antibody-like protein. The GNC protein may have at least 5 or at least 6 binding domains.</p><p id="p-0008" num="0007">In one embodiment, the application provides multi-specific antibody-like proteins having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first binding domain (D1) at the N-terminal, a second binding domain (D2) comprising a light chain moiety, a Fc region, a third binding domain (D3), and a fourth binding domain (D4) at the C-terminal. The light chain moiety comprises a fifth binding domain (D5) covalently attached to the C-terminal, a sixth binding domain (D6) covalently attached to the N-terminal, or both. The D1, D2, D3, D4, D5 and D6 each has a binding specificity to a tumor antigen, an immune signaling antigen, or a combination thereof.</p><p id="p-0009" num="0008">The tumor antigen may be a tissue antigen, a neoantigen, a tumor-specific antigen (TSA), a tumor-associated antigen (TAA), or a combination there.</p><p id="p-0010" num="0009">The D2 may include C<sub>H1</sub>. In one embodiment, the light chain moiety in the D2 may include C<sub>L</sub>. In one embodiment, the light chain moiety may include C&#x3ba;/C&#x3bb;.</p><p id="p-0011" num="0010">The D2 may include a dimer.</p><p id="p-0012" num="0011">In on embodiment, the D2 may include a Fab region. In one embodiment, the Fab region may have a disulfide bond between V<sub>L </sub>and V<sub>H</sub>. In one embodiment, the D2 may include a V<sub>L </sub>and a V<sub>H</sub>.</p><p id="p-0013" num="0012">In one embodiment, the D2 may include a receptor. In one embodiment, the receptor may be NKG2D. In one embodiment, the D2 may include NKG2D connected to C<sub>H1 </sub>and C<sub>L</sub>. In one embodiment, the D2 may have an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 155 and 116.</p><p id="p-0014" num="0013">The D2 may be connected to the Fc region through a hinge.</p><p id="p-0015" num="0014">The Fc region may include null mutation, which may have the effect to reduce or eliminate effector functions. In one embodiment, the Fc region may be wild-type Fc. In one embodiment, the Fc region may include LALAKA mutations for null Fc. In one embodiment, the LALAKA mutations for null Fc may include L234A/L235A/K322A (Eu numbering) mutations. In one embodiment, the Fc region may include G237A (Eu numbering) mutation. In one embodiment, the Fc region may include N297A (Eu numbering) mutation. In one embodiment, the Fc region may include a glycosylated Fc. In one embodiment, the Fc region may be an aglycosylated Fc to reduce effector function.</p><p id="p-0016" num="0015">In one embodiment, the application may provide a multi-specific antibody-like protein having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal, a first binding domain (D1) at the N-terminal, a second binding domain (D2) comprising a dimer connected to C<sub>L </sub>and C<sub>H1</sub>, a Fc region comprising CH2 and CH3, wherein the CH2 is connected to the C<sub>H1 </sub>through a hinge, a third binding domain (D3), and a fourth binding domain (D4) at the C-terminal. The light chain moiety may have a fifth binding domain (D5) covalently attached to the C-terminal, a sixth binding domain (D6) covalently attached to the N-terminal, or both. The D1, D2, D3, D4, D5 and D6 each may have a binding specificity to a tumor antigen, an immune signaling antigen, or a combination thereof.</p><p id="p-0017" num="0016">The dimer in the D2 may include V<sub>L </sub>and V<sub>H </sub>pair connected to C<sub>L </sub>and C<sub>H </sub>respectively, in which case the D2 domain may be a Fab region, and the GNC protein may be a multi-specific antibody monomer or a multi-specific antibody.</p><p id="p-0018" num="0017">In one embodiment, the multi-specific antibody-like protein may be either penta-specific or hexa-specific.</p><p id="p-0019" num="0018">In one embodiment, the light chain moiety in the D2 may have a fifth binding domain (D5) covalently attached to the C-terminal, and the multi-specific antibody-like protein is penta-specific. In one embodiment, the light chain moiety may have a sixth binding domain (D6) covalently attached to the N-terminal, and the multi-specific antibody-like protein is penta-specific. In one embodiment, the light chain moiety may have a fifth binding domain (D5) covalently attached to the C-terminal and a sixth binding domain (D6) covalently attached to the N-terminal simultaneously, which makes the multi-specific antibody-like protein to be hexa-specific.</p><p id="p-0020" num="0019">The D1, D2, D3, D4, D5, and D6 may be independently a scFv domain, a receptor, or a ligand.</p><p id="p-0021" num="0020">The scFv domain may have the configuration of V<sub>L</sub>V<sub>H </sub>or V<sub>H</sub>V<sub>L </sub>from the N terminal to the C terminal. In one embodiment, the scFv domain may include R19S (Kabat) mutation. In one embodiment, the scFv domain may include a disulphide bond between V<sub>L </sub>and V<sub>H</sub>. In one embodiment, the disulfide bond may be between vL100 and vH44 (Kabat) of the scFv domain. In one embodiment, the scFv domain may have an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 72-112.</p><p id="p-0022" num="0021">In one embodiment, the D1, D2, D3, D4, D5, and D6 may all be scFv domains.</p><p id="p-0023" num="0022">In one embodiment, the D1, D2, D3, D4, D5 and D6 each may be independently a receptor or a ligand. In one embodiment, at least one, two, three, four, or five of the D1, D2, D3, D4, D5, and D6 may be a receptor or a ligand. In one embodiment, the D1, D2 D3, D4, D5, and D6 may all be receptors or ligands. In one embodiment, the D4, D5 or D6 may be a receptor or a ligand. In one embodiment, the receptor or a ligand may have an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 113-116.</p><p id="p-0024" num="0023">In one embodiment, the D2 has a binding specificity to CD3 or a tumor associated antigen (TAA).</p><p id="p-0025" num="0024">In one embodiment, the D1, D2, D3, D4, D5, and D6 independently has a binding specificity to an antigen selected from a receptor on a T cell, an immune checkpoint receptor, a co-stimulation receptor, a receptor of a lymphocyte or a myeloid cell, a tumor associated antigen (TAA), a tissue antigen, a neoantigen, a tumor-specific antigen (TSA), a glycoprotein, or a combination thereof.</p><p id="p-0026" num="0025">In one embodiment, the binding domain for the receptor on the T cell may be adjacent to the binding domain for the tumor associated antigen (TAA). In one embodiment, the binding domain for the receptor on the T cell is adjacent to the binding domain for the receptor of a lymphocyte or a myeloid cell.</p><p id="p-0027" num="0026">In one embodiment, the receptor on the T cell may be CD3, T cell receptor, or a complex thereof. In one embodiment, the immune checkpoint receptor may be PD-L1, PD-1, TIGIT, TIM-3, LAG-3, CTLA4, BTLA, VISTA, PDL2, CD160, LOX-1, siglec-15, CD47, SIRP&#x3b1;, or a combination thereof. In one embodiment, the co-stimulating receptor may be 4-1BB, CD28, OX40, GITR, CD40, ICOS, CD27, CD30, CD226, or a combination thereof. In one embodiment, the tumor associated antigen (TAA) may be EGFR, HER2, HER3, HER4, EGRFVIII, CD19, claudin 18.2, BCMA, CD20, CD33, CD123, CD22, CD30, ROR1, CEA, cMET, LMP1, LMP2A, Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TACI, TROP2, NKG2D ligands, PD-L1, or a combination thereof.</p><p id="p-0028" num="0027">In one embodiment, the D1, D2, D3, D4, D5 and D6 each independently may have a binding specificity to an antigen selected from EGFR, HER2, HER3, EGFRvIII, ROR1, CD3, CD28, CEA, LMP1, LMP2A, Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TROP2, NKG2D ligands, BCMA, CD19, CD20, CD33, CD123, CD22, CD30, PD-L1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, LIGHT, HVEM, CSF1R, CD73, and CD39, CLDN18.2, CSF1R, and wherein the Fc region comprises a human IgG Fc region.</p><p id="p-0029" num="0028">In one embodiment, the D2 and D5 each independently has a binding specificity to a tumor associated antigen, a neoantigen, or a tumor-specific antigen (TSA).</p><p id="p-0030" num="0029">In one embodiment, the D1 has a binding specificity to CD3, CD20, EGFR, or their derivative thereof. In one embodiment, the D2 has the binding specificity to EGFR, CD3, HER2, MSLN, NKG2D ligands, or their derivative thereof. In one embodiment, the D3 has a binding specificity to PD-L1. In one embodiment, the D4 may include a 4-1BBL trimer or has a binding specificity to 4-1BB or its derivative thereof. In one embodiment, the D5 has a binding specificity to HER3, CD19, NKG2D ligands, or their derivative thereof. In one embodiment, the D6 has a binding specificity to CD19.</p><p id="p-0031" num="0030">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD3, D2 has a binding specificity to EGFR, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D5 has a binding specificity to HER3. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 1-8.</p><p id="p-0032" num="0031">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD20, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 9-12.</p><p id="p-0033" num="0032">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD20, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D5 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 13-16.</p><p id="p-0034" num="0033">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD3, D2 has a binding specificity to MSLN, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D5 has a binding specificity to NKG2D ligands. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 17-20.</p><p id="p-0035" num="0034">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD3, D2 has a binding specificity to HER2, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D5 has a binding specificity to NKG2D ligands. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 21-24.</p><p id="p-0036" num="0035">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to EGFR, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 25-28.</p><p id="p-0037" num="0036">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to EGFR, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 comprises 4-1BB ligand trimer, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 29-32.</p><p id="p-0038" num="0037">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to EGFR, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 33-36.</p><p id="p-0039" num="0038">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to EGFR, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 comprises 4-1BB ligand trimer, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 37-40.</p><p id="p-0040" num="0039">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD3, D2 has a binding specificity to EGFR, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 41-44.</p><p id="p-0041" num="0040">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to EGFR, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 45-48.</p><p id="p-0042" num="0041">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to EGFR, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 comprises 4-1BB ligand trimer, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 49-52.</p><p id="p-0043" num="0042">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD3, D2 comprises NKG2D, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, D6 has the binding specificity to EGFR. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 117-120.</p><p id="p-0044" num="0043">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD3, D2 comprises NKG2D, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, D6 has the binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 123-126.</p><p id="p-0045" num="0044">In one embodiment, the multi-specific antibody-like protein is penta-specific, and wherein the D1 has a binding specificity to CD3, D2 comprises NKG2D, D3 has a binding specificity to PD-L1, D4 comprises 4-1BB ligand trimer, D6 has the binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 127-130.</p><p id="p-0046" num="0045">In one embodiment, the multi-specific antibody-like protein is hexa-specific, and wherein the D1 has a binding specificity to EGFR, D2 has a binding specificity to CD3, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, D5 has the binding specificity to HER3, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 53-60.</p><p id="p-0047" num="0046">In one embodiment, the multi-specific antibody-like protein is hexa-specific, and wherein the D1 has a binding specificity to CD3, D2 has a binding specificity to EGFR, D3 has a binding specificity to PD-L1, D4 has a binding specificity to 4-1BB, D5 has the binding specificity to HER3, and D6 has a binding specificity to CD19. In one embodiment, the multi-specific antibody-like protein has an amino acid sequence having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% of sequence identity to SEQ ID NO. 61-68.</p><p id="p-0048" num="0047">In one embodiment, the D1, D3, D4, D5 or D6 may include a (G<sub>x</sub>S<sub>y</sub>)<sub>n </sub>linker. n may be an integer from 1 to 10. x may be an integer from 1 to 10. y may be an integer from 1 to 10.</p><p id="p-0049" num="0048">In one embodiment, the application may provide a guidance navigation control (GNC) protein that include the multi-specific antibody-like protein as described thereof. In one embodiment, such GNC protein may be a dimer of the multi-specific antibody-like protein as described herein.</p><p id="p-0050" num="0049">In one aspect, the application provides isolated nucleic acid sequences encoding an amino acid sequence of the multi-specific antibody-like protein or its fragments or derivatives as disclosed herein.</p><p id="p-0051" num="0050">In one aspect, the application provides expression vector including the isolated nucleic acid sequence as described herein.</p><p id="p-0052" num="0051">In one aspect, the application provides host cells comprising the isolated nucleic acid sequence as disclosed thereof. In one embodiment, the host cell may be a prokaryotic cell or a eukaryotic cell.</p><p id="p-0053" num="0052">In one aspect, the application provides methods for producing GNC proteins as disclosed herein. In one embodiment, the method for producing a multi-specific antibody or monomer as disclosed herein may include the steps of culturing a host cell comprising an isolated nucleic acid sequence such that the DNA sequence encoding the multi-specific antibody or monomer is expressed, and purifying said multi-specific antibody, wherein the isolated nucleic acid sequence encodes an amino acid of the multi-specific antibody-like protein as disclosed herein.</p><p id="p-0054" num="0053">In one aspect, the application provides immuno-conjugate comprising a cytotoxic agent or an imaging agent linked to the GNC protein such as a multi-specific antibody-like protein or a multi-specific antibody disclosed herein through a linker. The linker may include a covalent bond such as an ester bond, an ether bond, an amid bond, a disulphide bond, an imide bond, a sulfone bond, a phosphate bond, a phosphorus ester bond, a peptide bond, a hydrophobic poly(ethylene glycol) linker, or a combination thereof.</p><p id="p-0055" num="0054">In one embodiment, the cytotoxic agent or the imaging agent may be a chemotherapeutic agent, a growth inhibitory agent, a cytotoxic agent from class of calicheamicin, an antimitotic agent, a toxin, a radioactive isotope, a toxin, a therapeutic agent, or a combination thereof.</p><p id="p-0056" num="0055">In one aspect, the application provides pharmaceutical composition for treating, preventing or controlling conditions such as cancer, autoimmune diseases, or infectious diseases. In one embodiment, the composition may include a pharmaceutically acceptable carrier and a GNC protein such as a multi-specific antibody or a multi-specific antibody-like protein, their immuno-conjugate or their fragment thereof.</p><p id="p-0057" num="0056">In one embodiment, the pharmaceutical composition may further include a therapeutic agent selected from a radioisotope, radionuclide, a toxin, a chemotherapeutic agent or a combination thereof.</p><p id="p-0058" num="0057">In one aspect, the application provides methods for treating, preventing or controlling conditions such as cancer, autoimmune diseases, or an infectious disease. In one embodiment, the method includes the steps of administering a pharmaceutical composition comprising a purified multi-specific antibody, the multi-specific antibody-like protein or its fragments, as disclosed herein.</p><p id="p-0059" num="0058">In one aspect, the application provides methods for treating a human subject with a cancer, an autoimmune disease, or an infection. In one embodiment, the method includes the step of administering to the subject an effective amount of the GNC protein such as the purified multi-specific antibody or the multi-specific antibody-like protein or their fragments as disclosed herein.</p><p id="p-0060" num="0059">In one embodiment, the method may further include the step of co-administering an effective amount of a therapeutic agent, wherein the therapeutic agent comprises an antibody, a chemotherapy agent, an enzyme, an anti-estrogen agent, a receptor tyrosine kinase inhibitor, a kinase inhibitor, a cell cycle inhibitor, a check point inhibitor, a DNA, RNA or protein synthesis inhibitor, a RAS inhibitor, an inhibitor of PD1, PD-L1, CTLA4, 4-1BB, OX40, GITR, ICOS, LIGHT, TIM3, LAG3, TIGIT, CD40, CD27, HVEM, BTLA, VISTA, B7H4, CSF1R, NKG2D, CD73, or a combination thereof.</p><p id="p-0061" num="0060">In one aspect, the application provides a solution comprising an effective concentration of the GNC protein such as the multi-specific antibody or the multi-specific antibody-like protein or their fragments thereof. In one embodiment, the solution may be blood plasma in a human subject.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0005" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0062" num="0061">The foregoing and other features of this disclosure will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that these drawings depict only several embodiments arranged in accordance with the disclosure and are, therefore, not to be considered limiting of its scope, the disclosure will be described with additional specificity and detail through use of the accompanying drawings, in which:</p><p id="p-0063" num="0062"><figref idref="DRAWINGS">FIG. <b>1</b></figref> shows a schematic configuration of antigen binding domains in (A) a penta-GNC antibody and (B) a hexa-GNC antibody: the variable regions (replaceable by a receptor or ligand) of Fab in black (D2); both the constant region of Fab and the Fc region in white; additional scFv antigen binding domains in shaded boxes (each replaceable by a receptor-ligand binding); a heavy chain monomer linking D1 to its N-terminus and D3 and D4 tandemly to its C-terminus through D4; and a light chain moiety monomer linking D5 and/or D6 to its N- and C-terminus;</p><p id="p-0064" num="0063"><figref idref="DRAWINGS">FIG. <b>2</b></figref> shows that the penta-GNC antibody (SI-1P1) exerts maximized T-cell activation in the presence of human pancreatic cancer cells (BxPC3) that express high levels of EGFR and low levels of HER3, with similar potency to that of tetra-GNC antibodies targeting either HER3 (Tetra) or no tumor antigen (Tetra, FITC), as well as the bispecific antibody only targeting tumor antigens (BI);</p><p id="p-0065" num="0064"><figref idref="DRAWINGS">FIG. <b>3</b></figref> shows the high potency of SI-1P1 in TDCC assay by using cancer cell lines expressing high levels of EGFR and low levels of HER3 in (A) human breast cancer cells (MDA-MB-231) and (B) human cervical cancer cells (HeLa), and control antibodies including a comparable tetra-GNC antibody lacking the binding to HER3, a tetra-GNC control antibody lacking the binding to both tumor antigens, and a bispecific antibody targeting tumor antigens only;</p><p id="p-0066" num="0065"><figref idref="DRAWINGS">FIG. <b>4</b></figref> shows the effect of having NKG2D receptor as a binding domain for the GNC antibodies: (A) the potency of SI-49P3 mediated T cell activation using human pancreatic cancer cells (BxPC3); and (B) high potency of SI-49P1 in TDCC assay using human breast cancer cells (MDA-MB-231) that express tumor antigens (MICA and mesothelin) other than EGFR and HER3, and two control antibodies: a tetra-GNC antibody lacking NKG2D and a tri-GNC antibody lacking binding specificities to both PD-L1 and 4-1BB;</p><p id="p-0067" num="0066"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows that the 4-1BBL-trimer-Fc fusion protein mediates robust activation of 4-1BB signaling as measured by a reporter bioassay using Jurkat cells, when compared to other molecules containing monomeric 4-1BB ligand, monomeric Fc, or an anti-4-1BB scFv;</p><p id="p-0068" num="0067"><figref idref="DRAWINGS">FIG. <b>6</b></figref> shows the Octet binding analysis of penta-GNC antibodies comprising humanized anti-huEGFR domains, indicating that variants of humanized EGFR binding domains (H1, H4, or H7) retain tight binding to human EGFR with little positional effect as either a scFv domain in SI-55P3, SI-79P2, SI55P9, and SI-79P3 or Fab in SI-77P1;</p><p id="p-0069" num="0068"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows the potency of penta-GNC antibodies in TDCC assay using human pancreatic cancer cells (BxPC3) as targeted cells and the EC50 values: (A) SI-1P1, 0.2814 pM; (B) SI-55P9, 0.4871 pM; and (C) SI-55P10, 0.7358 pM;</p><p id="p-0070" num="0069"><figref idref="DRAWINGS">FIG. <b>8</b></figref> shows the potency of penta-GNC proteins containing NKG2D at position D2 in TDCC assay using human breast cancer cells (MDA-MB-231, with MICA expression) as targeted cells, with the resulting the EC50 values: SI-49P6, 0.7366 pM and SI-49P7, 0.1094 pM;</p><p id="p-0071" num="0070"><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows that a tetra-GNC antibody, SI-35E20, induces RTCC to NucRed-transduced lung cancer cells A549 and suppresses the growth of lung adenocarcinoma cells in the presence of PBMC;</p><p id="p-0072" num="0071"><figref idref="DRAWINGS">FIG. <b>10</b></figref> shows that a tetra-GNC antibody, SI-38E17, induces RTCC to Nuc-GFP Nalm-6 leukemic cells, in the presence and absence of and donor PBMC;</p><p id="p-0073" num="0072"><figref idref="DRAWINGS">FIG. <b>11</b></figref> shows that a tetra-GNC antibody, SI-39E18, induces RTCC to kill NucRed+UMUC3viii cells derived from human bladder cancer, in the presence of donor PBMC versus a vehicle control;</p><p id="p-0074" num="0073"><figref idref="DRAWINGS">FIG. <b>12</b></figref> shows that a tetra-GNC antibody, SI-38E17, is effective in suppressing the growth of human B cell leukemia cells in a human tumor xenograft model by administrating JVM-3 cells and donor PBMC (5&#xd7;10<sup>6 </sup>and 2&#xd7;10<sup>7</sup>, respectively) into NCG mice;</p><p id="p-0075" num="0074"><figref idref="DRAWINGS">FIG. <b>13</b></figref> shows that a tetra-GNC antibody, SI-39E18 is effective in suppressing the growth of human bladder cancer cells in a human tumor xenograft model by administrating UM-UC-3-EGFR VIII cells and human PBMC (5&#xd7;10<sup>6 </sup>and 5&#xd7;10<sup>6</sup>, respectively) into NCG mice;</p><p id="p-0076" num="0075"><figref idref="DRAWINGS">FIG. <b>14</b></figref> shows the necessity of simultaneously targeting immunomodulatory proteins, such as PD-L1 immune checkpoint and 4-1BB activation as a hexa-GNC antibody (SI-55H11) mediates more complete elimination of human cervical cancer cells (Hela) than a comparable tri-specific antibody did in a TDCC assay; and</p><p id="p-0077" num="0076"><figref idref="DRAWINGS">FIG. <b>15</b></figref> shows that the improved potency of a hexa-GNC antibody (SI-55H11) due to an additional binding to HER3 as compared to that of its parental penta-GNC antibody (SI-55H9) in TDCC assay using human pancreatic cancer cells (BxPC3) that express low levels of HER3.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0006" level="1">DETAILED DESCRIPTION</heading><p id="p-0078" num="0077">In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.</p><p id="p-0079" num="0078">The present application relates to guidance and navigation control (GNC) proteins and methods of making and using thereof. In some embodiments, the GNC proteins may be multi-specific antibody-like proteins. In some embodiments, the GNC proteins may be multi-specific antibodies, in which cases the GNC proteins may also be referred to as GNC antibodies. In some embodiments, the application provides penta-specific antibody-like proteins and hexa-specific antibody-like proteins. In some embodiments, the application provides penta-specific antibodies and hexa-specific antibodies.</p><p id="p-0080" num="0079">The GNC proteins include the proteins linking multiple functionally independent binding moieties into a single entity that is capable of bringing both effector cells and target cells together (see Applicant's application WO/2019/005642, incorporated herein in its entirety). In one embodiment, these multi-specific binding molecules targeting tumor antigens and immune-activating receptors can utilize similar mechanisms of immune effector cell-mediated killing of tumors at a fraction of the cost. Rather than genetically modifying individual patient T cells, such multi-specific binding molecules can be efficiently manufactured large-scale and administered in a more general off-the-shelf manner. Of the GNC proteins, multi-specific antibodies, such as tetra-specific antibodies, have been shown be able to exert desirable multi-facet GNC effects with structurally and functionally diverse but relatively independent binding domains (see Applicant's application WO/2019/191120, incorporated herein in its entirety).</p><p id="p-0081" num="0080">In one embodiment, the GNC protein may include a multi-specific antibody-like protein comprising a heavy chain and a light chain moiety. The antibody's Fab region is composed of one constant and one variable domain from the heavy and the light chain moiety. The heavy chain may further include three additional antigen-specific binding domains attached to the N-terminal, the C-terminal, or both terminals. The light chain moiety may include one or two additional binding domains attached to the N-terminal, C-terminal, or both terminals.</p><p id="p-0082" num="0081">In some embodiments, the GNC antibodies may be penta-GNC antibodies or hexa-GNC antibodies, as shown in <figref idref="DRAWINGS">FIG. <b>1</b></figref>. The GNC antibodies may have the ability of directing immune cells (or other effector cells) to tumor cells (or other target cells) through the binding of multiple surface molecules on an immune cell and a tumor cell. The immune cells may be the cells of human immune system, including without limitation, leukocytes, peripheral blood mononuclear cells (PBMC), T cells, and natural killer cells (NK cells). Other target cells may include, without limitations, autoimmune cells (normal B cells), tissue target cells, non-tumor cells, infected cells, inflammatory cells, and damaged cells. In some embodiments, T cells comprises human T cells, including without limitation, na&#xef;ve T cells, activated T cells, helper T cells, regulatory T cells, memory T cells, and exhausted T cells. In one embodiment, the tumor cells express tumor antigens, including without limitation, tumor-specific antigens (TSA), neoantigens, and tumor-associated antigens (TAA).</p><p id="p-0083" num="0082">In one embodiment, the GNC antibodies may include at least one binding domain capable of binding to one surface molecule on a T cell and at least one binding domain capable of binding to one surface antigen on a tumor cell (Table 1). In some embodiments, the surface molecules on a T cell comprise signaling proteins, including without limitation, CD3, NKG2D, and 4-1BB; the surface molecules on a NK cell comprise signaling proteins, including without limitation, NKG2D and 4-1BB; and the surface antigens on a tumor cell comprise tumor antigens, including without limitation, EGFR, HER2, HER3, MSLN, CD19, and PD-L1. In one embodiment, the tumor cells constitute a tumor or a cancer, including without limitation, a solid tumor, a sarcoma, a hematopoietic malignancy, a lung cancer, a pancreatic cancer, a bladder cancer, a cervical cancer, a breast cancer, a leukemia, and a lymphoma.</p><p id="p-0084" num="0083">The GNC antibodies having at least four additional binding domains in addition to the D2 may require structural stability to maintain independent function of binding specificity and affinity of each binding domain. Each additional binding domain may include a (G<sub>x</sub>S<sub>y</sub>)<sub>n </sub>peptide linker, wherein n is an integer from 1 to 10, x is an integer from 1 to 10, and y is an integer from 1 to 10.</p><p id="p-0085" num="0084">In one embodiment, the binding domain such as D1, D2, D3, D4, D5, or D6 may be a single chain variable fragment (scFv), a receptor, or a ligand (Table 1). A scFv domain may be configured to have a fusion of the variable regions of the heavy (V<sub>H</sub>) and light chain (V<sub>L</sub>) in either the V<sub>H</sub>-V<sub>L </sub>(HL) or V<sub>L</sub>-V<sub>H </sub>(LH) orientation. In one embodiment, the scFv domain may be a stapled structure by introducing a disulfide bond between V<sub>H</sub>44 and V<sub>L</sub>100 (Kabat). In one embodiment, the V<sub>H </sub>region for V<sub>H3</sub>-containing scFv on any light chain moiety has a R19S mutation (Kabat numbering).</p><p id="p-0086" num="0085">The binding domain may be configured to bind to at least one epitope of an antigen, including without limitation, CD3, 4-1BB, EGFR, HER2, HER3, MSLN, CD19, and PD-L1. The amino acid sequences selected to encode the anti-EGFR binding domain may be humanized sequences. In other embodiments, the amino acid sequences selected to encode the anti-CD19 binding domain are humanized sequences.</p><p id="p-0087" num="0086">In one embodiment, the binding domain may be receptors. In one embodiment, the receptor may be NKG2D. In one embodiment, the D2 may include NKG2D.</p><p id="p-0088" num="0087">The binding domain may be ligands for a receptor such as 4-1BBL (a 4-1BB receptor ligand) and 4-1BBL trimer for 4-1BB, a receptor.</p><p id="p-0089" num="0088">The terms &#x201c;a&#x201d;, &#x201c;an&#x201d; and &#x201c;the&#x201d; as used herein are defined to mean &#x201c;one or more&#x201d; and include the plural unless the context is inappropriate.</p><p id="p-0090" num="0089">The term &#x201c;antibody&#x201d; is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, as well as antibody fragments, such as Fab, F(ab&#x2032;)2, and Fv, so long as they exhibit the desired biological activity. In some embodiments, the antibody may be monoclonal, chimeric, single chain, multi-specific, multi-effective, human and humanized antibodies. Examples of active antibody fragments that bind to known antigens include Fab, F(ab&#x2032;)2, scFv, and Fv fragments, as well as the products of a Fab immunoglobulin expression library and epitope-binding fragments of any of the antibodies and fragments mentioned above. In some embodiments, antibody may include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain a binding site that immunospecifically bind to an antigen. The immunoglobulin can be of any type (IgG, IgM, IgD, IgE, IgA and IgY) or class (IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclasses of immunoglobulin molecule. In one embodiment, the antibody may be whole antibodies and any antigen-binding fragment derived from the whole antibodies. A typical antibody refers to heterotetrameric protein comprising typically of two heavy (H) chains and two light (L) chains. Each heavy chain is comprised of a heavy chain variable domain (abbreviated as V<sub>H</sub>) and a heavy chain constant domain. Each light chain moiety is comprised of a light chain moiety variable domain (abbreviated as V<sub>L</sub>) and a light chain moiety constant domain. The V<sub>H </sub>and V<sub>L </sub>regions can be further subdivided into domains of hypervariable complementarity determining regions (CDR), and more conserved regions called framework regions (FR). Each variable domain (either V<sub>H </sub>or V<sub>L</sub>) is typically composed of three CDRs and four FRs, arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from amino-terminus to carboxy-terminus. Within the variable regions of the heavy and light chain there are binding regions that interacts with the antigen.</p><p id="p-0091" num="0090">The term of &#x201c;monoclonal&#x201d; antibody as used herein include &#x201c;monoclonal mono-specific&#x201d;, &#x201c;chimeric&#x201d;, and &#x201c;multi-specific&#x201d; antibodies (immunoglobulins) in which a portion of the heavy and/or light chain moiety is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; and Morrison et al., PNAS USA, 1984). Monoclonal antibodies can be produced using various methods, including without limitation, mouse hybridoma, phage display, recombinant DNA, molecular cloning of antibodies directly from primary B cells, and antibody discovery methods (see Siegel. Transfus. Clin. Biol. 2002; Tiller. New Biotechnol. 2011; Seeber et al. PLOS One. 2014).</p><p id="p-0092" num="0091">The term &#x201c;multi-specific&#x201d; antibody as used herein denotes an antibody that has at least two binding sites each having a binding affinity to an epitope of an antigen. The term &#x201c;bi-specific, tri-specific, tetra-specific, penta-specific, or hexa-specific&#x201d; antibody as used herein denotes an antibody that has two, three, four, five, or six antigen-binding sites. For example, the antibodies disclosed herein with five binding sites are penta-specific, with six binding sites are hexa-specific.</p><p id="p-0093" num="0092">The term &#x201c;guidance and navigation control (GNC)&#x201d; protein refers to a multi-specific protein capable of binding to at least one effector cell (such as immune cell) antigen and at least one target cell (such as tumor cell, immune cell, or microbial cell) antigen. The GNC protein may adopt an antibody-core structure including a Fab region and Fc region with various binding domains attached to the antibody-core, in which case the GNC protein is also termed GNC antibody. The GNC protein may adopt an antibody-like structure, in which case the Fv fragment may be replaced with a non-antibody based binding domain such as NKG2D, 4-1BBL (a 4-1BB receptor ligand), 4-1BBL trimer for 4-1BB, or a receptor.</p><p id="p-0094" num="0093">The term &#x201c;GNC antibody&#x201d; refers to a GNC protein had an antibody structure that is capable of binding to at least one effector cell (such as immune cell) and at least one target cell (such as tumor cell, immune cell, or microbial cell) simultaneously. The term &#x201c;bi-GNC, tri-GNC, tetra-GNC, penta-GNC, or hexa-GNC&#x201d; antibody as used herein denotes a GNC antibody that has two, three, four, five, or six antigen-binding sites, of which at least one antigen-binding site has the binding affinity to an immune cell and at least one antigen-binding site has the binding affinity to a tumor cell. In one embodiment, the GNC antibodies disclosed herein have five to six binding sites (or binding domain) and are penta-GNC and hexa-GNC antibodies, respectively. In some embodiments, the GNC antibodies include antibody binding domains (such as Fab and scFv) without the requirement for additional protein engineering in the Fc region. In one embodiment, the GNC antibody may include a Fc region that is engineered to eliminate effector cell function such as ADCC, ADCP, CDC. Mutations include, but are not limited to L234A/L235A/G237A/K322A and L234A/L235A/K322A (Eu numbering). In one embodiment, mutation of the Fc glycosylation site, e.g, N297A (Eu), may be used to prevent glycosylation and disrupt Fc effector functions. In one embodiment, the GNC antibody as used herein comprises symmetric antibodies that do not require Fc engineering to drive proper assembly of the full protein. In contrast, many existing bi-specific and multi-specific antibody formats require a heterodimerizing Fc in order to combine different specificities into asymmetric molecules. In one embodiment, the GNC antibodies additionally have the advantage of retaining bivalency for each targeted antigen. Further in one embodiment, the GNC antibodies have the advantage of avidity effects that result in higher affinity for antigens and slower dissociation rates. This bivalency for each antigen is in contrast to many multi-specific platforms that are monovalent for each targeted antigen, and thus often lose the beneficial avidity effects that make antibody binding so strong.</p><p id="p-0095" num="0094">The term &#x201c;humanized antibody&#x201d; antibody refers to a type of engineered antibody having its CDRs derived from a non-human donor immunoglobulin, the remaining immunoglobulin-derived parts of the molecule being derived from one (or more) human immunoglobulin(s). In addition, framework support residues may be altered to preserve binding affinity. Methods to obtain &#x201c;humanized antibodies&#x201d; are well known to those skilled in the art (see Queen et al., Proc. Natl Acad Sci USA, 1989; Hodgson et al., Bio/Technology, 1991). In one embodiment, the &#x201c;humanized antibody&#x201d; may be obtained by genetic engineering approach that enables production of affinity-matured humanlike polyclonal antibodies in large animals such as, for example, rabbits (see U.S. Pat. No. 7,129,084).</p><p id="p-0096" num="0095">The term &#x201c;antigen&#x201d; refers to an entity or fragment thereof which can induce an immune response in an organism, particularly an animal, more particularly a mammal including a human. The term includes immunogens and regions thereof responsible for antigenicity or antigenic determinants.</p><p id="p-0097" num="0096">The term &#x201c;epitope&#x201d;, also known as &#x201c;antigenic determinant&#x201d;, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells, and is the specific piece of the antigen to which an antibody binds.</p><p id="p-0098" num="0097">The term &#x201c;immunogenic&#x201d; refers to substances which elicit or enhance the production of antibodies, T-cells, or other reactive immune cells directed against an immunogenic agent and contribute to an immune response in humans or animals. An immune response occurs when an individual produces sufficient antibodies, T-cells, and other reactive immune cells against administered immunogenic compositions of the present application to moderate or alleviate the disorder to be treated.</p><p id="p-0099" num="0098">The term &#x201c;tumor antigen&#x201d; as used herein means an antigenic molecule produced in tumor cells. A tumor antigen may trigger an immune response in the host. In one embodiment, the tumor cells express tumor antigens, including without limitation, tumor-specific antigens (TSA), neoantigens, and tumor-associated antigens (TAA).</p><p id="p-0100" num="0099">The term &#x201c;specific binding to&#x201d; or &#x201c;specifically binds to&#x201d; or &#x201c;specific for&#x201d; a particular antigen or an epitope as used herein means the binding that is measurably different from a non-specific interaction. Specific binding can be measured by determining binding of a molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity. Specific binding can be determined by competition with a control molecule that is similar to the target. Specific binding for a particular antigen or an epitope can be exhibited by an antibody having a KD for an antigen or epitope of at least about 10<sup>&#x2212;4 </sup>M, at least about 10<sup>&#x2212;5 </sup>M, at least about 10<sup>&#x2212;6 </sup>M, at least about 10<sup>&#x2212;7 </sup>M, at least about 10<sup>&#x2212;8 </sup>M, at least about 10<sup>&#x2212;9</sup>, alternatively at least about 10<sup>&#x2212;10 </sup>M, at least about 10<sup>&#x2212;11 </sup>M, at least about 10<sup>&#x2212;12 </sup>M, or greater, where KD refers to a dissociation rate of a particular antibody-antigen interaction. In some embodiments, a multi-specific antibody that specifically binds to an antigen will have a KD that is 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for a control molecule relative to the antigen or epitope. Also, specific binding for a particular antigen or an epitope can be exhibited by an antibody having a KA or Ka for an antigen or epitope of at least 20-, 50-, 100-, 500-, 1000-, 5,000-, 10,000- or more times greater for the epitope relative to a control, where KA or Ka refers to an association rate of a particular antibody-antigen interaction.</p><p id="p-0101" num="0100">The term &#x201c;stapled&#x201d; means two domains are covalently linked. In one embodiment, the two domains may be covalently linked through at least one disulfide bond. For example, a scFv domain that has at least one disulfide bond linking VH and VL is called a stapled scFv; and a Fab region that has at least one disulfide bond linking the light chain moiety and the heavy chain is called a stapled Fab.</p><heading id="h-0007" level="1">EXAMPLES</heading><p id="p-0102" num="0101">While the following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of non-critical parameters that could be changed or modified to yield essentially the same or similar results.</p><heading id="h-0008" level="1">Example 1. Stapled Binding Domains and Stability of Penta- and Hexa-GNC Antibody</heading><p id="p-0103" num="0102">In multi-specific GNC antibodies such as tetra-GNC antibodies, the heavy chain may comprise up to three scFv domains plus the Fab region to constitute four binding specificities, whereas the light chain remains unmodified. In penta-GNC antibodies, one scFv domain is added to either N-terminus or C-terminus of the light chain to gain the fifth binding specificity, as shown in <figref idref="DRAWINGS">FIG. <b>1</b></figref> and Table 1. When an scFv domain is attached to each of the N- and C-terminus of the light chain, the antibody gains the fifth and sixth binding specificity and is classified as a hexa-GNC antibody. The modifications to both heavy chain and light chain posed uncertainty to the stability of the antibody. To maintain the stability and independence of all individual binding domains in either a penta- or a hexa-GNC antibody, one option is to introduce, i.e. staple, a disulfide bond at V<sub>L</sub>100 and V<sub>H</sub>44 (Kabat) to each Fv fragment and scFv domain. A disulfide bond between V<sub>L </sub>and V<sub>H </sub>may be used for all scFv domains to stabilize the overall structure. Alternatively, a disulphide bond may be introduced into at least one selected scFv domain at any position.</p><p id="p-0104" num="0103">A pair of penta-GNC antibodies (SI-1P1 and SI-1P2) (SEQ ID NO. 1-4 and 5-8, respectively) with identical binding specificities were created for analysing the effect of stapled scFv domains. The heavy chain of the two antibodies comprises &#x3b1;CD3 scFv at D1, &#x3b1;EGFR V<sub>H </sub>at D2 (in the Fv-CH1-Fc configuration), &#x3b1;PD-L1 at D3, and &#x3b1;4-1BB at D4, and the light chain comprises &#x3b1;EGFR V<sub>L </sub>and &#x3b1;HER3 scFv at D5 according to the naming system in <figref idref="DRAWINGS">FIG. <b>1</b></figref>. SI-1P2, but not SI-1P1, comprises &#x201c;stapled&#x201d; scFv domains at D1, D3, D4, and D4, namely, &#x3b1;CD3 scFv[V<sub>H</sub>44 G-&#x3e;C V<sub>L</sub>100 G-&#x3e;C] at D1, &#x3b1;PD-L1 scFv[V<sub>H</sub>44 G-&#x3e;C V<sub>L</sub>100 G-&#x3e;C] at D3, &#x3b1;4-1BB scFv[V<sub>H</sub>44 G-&#x3e;C V<sub>L</sub>100 G-&#x3e;C] at D4 on its heavy chain, and &#x3b1;HER3 scFv[V<sub>H</sub>44 G-&#x3e;C V<sub>L</sub>100 G-&#x3e;C] on its light chain (Kabat numbering) as listed Table 1.</p><p id="p-0105" num="0104">Both SI-1P1 and SI-1P2 were cloned into vector pTT5 following a modular cloning strategy using restriction sites HindIII/SalI/NheI/BamHI/BspEI/PacI. These penta-GNC antibody constructs were expressed with acceptable titers using both HEK and ExpiCHO expression systems for 5 and 9 days, respectively, and purified with 5 mL MabSelect protein A columns followed by Size Exclusion using a hiload 16/600 200 pg preparative SEC column on either an Akta Avant or Purifier system. SEC aggregates were analyzed using a waters HPLC linked to multi angle light scattering (MALS, Wyatt systems) to identify correct molecular weight by do/dc calculated methods. Dynamic light scattering (Wyatt systems) was used in the further analysis to determine the melting temperature of the produced protein. With all of the analyses conducted as shown in Table 2, the disulfide bonded, i.e. &#x201c;stapled&#x201d;, penta-GNC antibodies displayed more stable characteristics.</p><p id="p-0106" num="0105">Antibody-based proteins are most often purified via protein A affinity chromatography, where the protein A resin captures the antibody at a binding site at the C<sub>H2</sub>-C<sub>H3 </sub>interface in the Fc domain. However, protein A also binds to the V<sub>H </sub>domain of V<sub>H3 </sub>family Fvs. For most antibody-based platforms this is not a problem, since V<sub>H </sub>domains are generally on the heavy chain. However, when scFvs containing V<sub>H3 </sub>are attached to the light chain, the V<sub>H </sub>domain can bind to protein A resin during purification, causing light chain monomers and dimers to contaminate the desired heavy-light chain heterotetramer. Thus, a potential hurdle when producing multi-specific antibodies containing any V<sub>H3 </sub>domain on the light chain is the presence of additional contaminants in the protein A elution. This is especially problematic when the light chain expresses more efficiently than the heavy chain, causing an abundance of light chain contaminants to be purified along with the desired protein assembly.</p><p id="p-0107" num="0106">In order to rationally disrupt protein A binding of V<sub>H3 </sub>family members, a structural approach was taken to interrupt the binding interface. Crystal structure 1DEE (Graille M. et al. Proc. Nat. Acad. Sci. 2000.) showed that residue R19 in V<sub>H3 </sub>(Kabat numbering) is in direct contact with two side chains of protein A domain D. In particular, contact with Q32 and D36 could be eliminated to significantly weaken the interaction. Thus, R19 was mutated to serine, which does not form these interactions due to its shorter side-chain. Additionally, S19 exists naturally in other VH family members, suggesting that it may be less immunogenic than other substitutions.</p><p id="p-0108" num="0107">The mutation R19S (Kabat numbering) was incorporated into the FR1 region of the VH domain for V<sub>H3</sub>-containing scFvs on the GNC light chain. Specifically, the penta-GNC antibody, SI-77P1 (SEQ ID NO. 41-44), harbored R19S mutation in its light chain sequence encoding the anti-CD19 scFv at domain 6, and the hexa-GNC antibodies, SI-55-H11 (SEQ ID NO. 53-56), SI-55H12 (SEQ ID NO. 57-60), SI-77H4 (SEQ ID NO. 61-64), and SI-77H5 (SEQ ID NO. 65-68) harbored R19S mutation in their light chain sequences encoding the anti-HER3 scFv domain at D5 and the anti-CD19 scFv at domain 6. The residue of interest is at the protein A binding interface (4), and therefore mutation of R to S disrupts the interaction with protein A. Elimination of protein A binding in light chain scFvs prevents light chain monomers and dimers from binding to protein A during purification. As a result, a more homogeneous product without light chain contaminants can be obtained. For hexa-GNC, which may contain up to two V<sub>H3 </sub>scFvs per light chain, this mutation is especially important in allowing efficient purification of the desired product.</p><p id="p-0109" num="0108">Wild-type IgG1 antibodies contain an active Fc domain which binds to Fc gamma receptors on immune cells, as well as C1q, the first component of the complement cascade. These binding capabilities allow antibodies with active Fc to elicit effector functions including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent dependent cytotoxicity toward antigen-bearing cells. However, in the context of T cell redirection, an active Fc domain can exacerbate cytokine release syndrome and cause off-target cytotoxicity (Strohl &#x26; Naso, Antibodies, 2019). Therefore, null Fc domains incorporating silencing mutations that weaken binding to Fc gamma receptors and complement can decrease cytokine release syndrome, and even increase efficacy of T cell redirecting antibodies by increasing infiltration into the tumor (Wang et al., Cancer Immunol. Res. 2019). Many point mutations have been introduced to weaken interaction with Fc gamma receptors or C1q, and to lessen Fc effector functions (Saunders, Frontiers Immunol. 2019). Among these, the L234A, L235A, and G237A mutations have been shown to decrease ADCC and ADCP through decreased binding to Fc gamma receptors. The mutation K322A has been shown to decrease binding to C1q, and therefore ablate CDC. Furthermore, mutation of N297A removes the Fc glycosylation site, generating aglycosylated Fc domain that does not interact as strongly with its receptors.</p><p id="p-0110" num="0109">Fc silencing mutations were incorporated into the GNC platform in order to generate therapeutics with mitigated risk of cytokine storm and improved tumor penetration qualities due to less binding of Fc gamma receptors in the periphery. Example molecules contained different null Fc versions to demonstrate that an array of Fc archetypes could be used in the GNC platform. Thus, mutations used to modulate effector function of monoclonal and multi-specific antibodies can also be efficiently incorporated into the GNC platform.</p><heading id="h-0009" level="1">Example 2. Optimizing Binding Domains</heading><p id="p-0111" num="0110">While selecting binding specificities dictates the utility of a multi-specific GNC antibody, optimizing commonly used binding domains may improve the efficacy of the antibody. The penta-GNC and hexa-GNC antibodies (collectively known as GNC antibodies as listed in Table 1) were cloned, expressed, and produced following the similar materials and methods as described for producing SI-1P1 and SI-1P2 antibodies in Example 1.</p><p id="p-0112" num="0111">The anti-CD3 variable domain sequences, 284A10 (Applicant's application No. PCT/US2018/039143, incorporated herein in its entirety), were used as unmodified, stapled (284A10 stapled, SEQ ID NO. 89-92), humanized (284A10 H1, SEQ ID NO. 93-96), or humanized and stapled (284A10 H1 stapled, SEQ ID NO. 97-100) sequences to encode either a scFv (in either V<sub>H</sub>-V<sub>L </sub>or V<sub>L</sub>-V<sub>H </sub>orientation) or a Fab of the heavy chain monomer. The other anti-CD3 variable domain sequences, 283E3, were identified, cloned, and humanized as 283E3 H1 (SEQ ID NO. 101-104), which were used to encode the Fab region at D2 of the heavy chain monomer for each of seven penta-GNC antibodies as indicated in Table 1.</p><p id="p-0113" num="0112">The anti-PD-L1 variable domain sequences, PL221G5 (Applicant's application No. PCT/US2018/039144, incorporated herein in its entirety), were humanized and used to encode either a &#x201c;unstapled&#x201d; or a &#x201c;stapled&#x201d; (SEQ ID NO. 105-108) scFv domain at D3 of the heavy chain monomer.</p><p id="p-0114" num="0113">The anti-4-1BB variable domain sequences, 466F6 (Applicant's application No. PCT/US2018/039155 incorporated herein in its entirety), were humanized and used to encode either a &#x201c;unstapled&#x201d; or a &#x201c;stapled&#x201d; (SEQ ID NO. 109-112) scFv domain at D4 of the heavy chain monomer.</p><heading id="h-0010" level="1">Example 3. Octet Analysis of Binding Affinity</heading><p id="p-0115" num="0114">To assess the functionality of the GNC antibodies, the binding affinity of each individual domain of penta-GNC antibodies was carried out by Biolayer Interferometry (Octet 384 system). The penta-GNC antibodies were captures onto the probe using anti-human Fc (AHC tips), and individual epitopes (CD3&#x3b5;/&#x3b4; and EGFR were produced, 4-1BB and PD-L1 (Acro Biosystems) were used as analyte to determine the disassociation constant (K<sub>D</sub>) by kinetic methods (K<sub>off</sub>/K<sub>on</sub>). As shown in Table 3, all of the binding constants of the individual domains in either SI-1P1 or SI-1P2 were within the reported ranges and the previously determined individual affinities of either monoclonal antibodies or scFv molecules alone.</p><p id="p-0116" num="0115">Octet analysis was used to ensure that GNC antibodies retain their binding to all of their cognate antigens. GNC antibodies were loaded onto AHC sensors for 180 seconds at 10 ug/ml, followed by a 60-second baseline step, a 180-second association step with 100 nM of commercially purchased human antigen, and a 360-second dissociation step. Samples for all steps were in Octet buffer (PBS containing 0.1% Tween 20 and 1% BSA). Fits were performed using a 1:1 binding model to extract affinity KD values, reported in Table 4. The data implies that each binding domain retains its binding affinity when placed at different positions of the GNC antibodies.</p><heading id="h-0011" level="1">Example 4. T-Cell Activation</heading><p id="p-0117" num="0116">To validate the functionality of the GNC antibodies, penta-GNC antibodies were assessed for T cell activation. The T cell activation assay was performed to compare the potency of SI-1P1, which binds to both EGFR and HER3, with that of an EGFR-tetra-GNC antibody (which binds to EGFR but not HER3), a FITC-tetra-specific antibody (which does not bind to either EGFR or HER3), and a bispecific antibody (which only binds to EGFR and HER3). Human pancreatic cancer cells (BxPC3) were used as target cells, which express high levels of EGFR and low levels of HER3 (Table 5). BxPC3 cells were plated in quadruplicate using a BioTek EL406 in 384 well plates at a density of 1500 cells/well after lifting with disassociation reagent (TrypLE Express) and allowed to adhere for 24 hours. Following this, Jurkat CD3 NFAT Effector cells were added at a cellular ratio of 5:1 (Jurkat Lucia Cells, Invivogen) and the GNC antibody was added in a 10-point 10-fold serial dilution from 50 nM to 0.5 fM and incubated for 4 Hours. Readout was performed by the addition of Promega Bright-Glo reagent and luminescence was measured on a Clariostar Plus microplate reader (BMG-Labtech). Data was plotted in log scale with Graphpad prism and fit to a nonlinear variable slope equation (<figref idref="DRAWINGS">FIG. <b>2</b></figref>). The data indicates that the penta-GNC antibody (SI-1P1) exerts similar potency (SI-1P1=1.456 pM, EGFR-tetra-GNC=1.028 pM, FITC-tetra-GNC=13.41 pM) and higher maximum T-cell activation (SI-1P1=6464, EGFR-tetra-GNC=5161, FITC-tetra-GNC=2835) as compared to control antibodies (EGFR-tetra-GNC antibody, FITC-tetra-GNC antibody, and a control bispecific antibody (Table 6).</p><heading id="h-0012" level="1">Example 5. T-Cell Dependent Cellular Cytotoxicity (TDCC)</heading><p id="p-0118" num="0117">TDCC is a standard feature of antibody therapy for treating cancer other diseases. To assess the TDCC mediated by the GNC antibodies, SI-1P1 (a penta-GNC antibody capable of binding to tumor antigens EGFR and HER3) was used to compare with control antibodies, including a EGFR-tetra-GNC antibody that only binds to EGFR, a FITC-tetra-specific antibody that does not bind either EGFR or HER3, and a control bispecific antibody that only binds to tumor antigens EGFR and HER3 (Table 6). Serial dilutions (0 to 30 nM; 1 to 5 dilution factor) of antibodies were added to a white 384-well plate containing luciferized MDA-MB-231 or HeLa cells (both have high EGFR and low HER3, see Table 5 and plated 24 hours prior and grown at 37&#xb0; C.) and activated T cells (plated immediately before drug; effector:target=5:1) in a total volume of 50 ul. After an additional 72 hours, 20 ul of Bright-Glo (Promega) was added to wells, and luminescence corresponding to viability of luciferized tumor cells was determined using a CLARIOstar plate reader. Data were fit to a sigmoidal function to calculate EC50 values (<figref idref="DRAWINGS">FIG. <b>3</b></figref>). For MDA-MB-231 cells as shown in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>, the EC50 was 0.01575 pM (SI-1P1), 0.01646 pM (an EGFR-tetra-GNC control antibody), and 1.882 pM (FITC-tetra-specific control antibody), and for HeLa cells as shown in <figref idref="DRAWINGS">FIG. <b>3</b>B</figref>, the EC50 was 1.161 pM (SI-1P1), 1.635 pM (EGFR-tetra-GNC control antibody), 3736200 pM (FITC-tetra-specific antibody), and 4500 pM (bispecific control antibody). The data demonstrate that, with an increased number of binding specificities, the penta-GNC antibody exerts higher TDCC potency as compared to control antibodies with fewer binding specificities.</p><heading id="h-0013" level="1">Example 6. NKG2D Receptor as a Binding Domain</heading><p id="p-0119" num="0118">An increase number of binding specificities allows the GNC antibodies to bind not only T cells but also subsets of T cells, natural killer cells, and other types of immune cells. On the hand, an added binding specificity may replace the cellular response to or recognition of targeted cells. For example, NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of viral infection or genomic stress such as in cancer. In humans, NKG2D is expressed by NK cells, &#x3b3;&#x3b4; T cells, and CD8+ &#x3b1;&#x3b2; T cells. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity, whereas on CD8<sup>+</sup> T cells the function of NKG2D is to send co-stimulatory signals to activate them. The addition of NKG2D as a binding specificity for the GNC antibodies may improve the cytotoxicity and efficacy of the antibody as a single multi-functional therapeutic agent. In this context, penta-GNC antibodies, SI-49P1 and SI-49P3 (SEQ ID NO. 17-20 and SEQ ID NO. 21-24, respectively), were created by adding NKG2D receptor as a binding domain at D5 (Table 1). The affinity of NKG2D of SI-49P3 (Table 4) for human MICA was founded to be within the expected range, indicating that NKG2D can act as a receptor for the penta-GNC antibody to bind its ligand.</p><p id="p-0120" num="0119">Both SI-49P3 and SI-49P1 are capable of recognizing one tumor antigen via the Fab region while extending multiple binding specificities to CD3, PD-L1, 4-1BB, and NKG2D. To demonstrate that SI-49P3 retains its ability in T cell activation, BxPC3 target cells were plated in quadruplicate using a BioTek EL406 in 384 well plates at a density of 1500 cells/well after lifting with disassociation reagent (TrypLE Express) and allowed to adhere for 24 hours. Following this, Jurkat CD3 NFAT Effector cells were added at a cellular ratio of 5:1 (Jurkat Lucia Cells, Invivogen) and GNC reagent was added in a 10-point 10-fold serial dilution from 50 nM to 0.5 fM and incubated for 4 Hours. Readout was performed by the addition of Promega Bright-Glo reagent and luminescence was measured on a Clariostar Plus microplate reader (BMG-Labtech). Data was plotted in log scale with Graphpad prism and fit to a nonlinear variable slope equation as shown in <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>. The data demonstrate that the addition of NKG2D receptor does not affect T cell activation and the penta-GNC antibody is capable of eliciting potent T cell activation (EC50=88.1 pM) while simultaneous engaging T cell antigens and targeting tumor cells.</p><p id="p-0121" num="0120">To assess TDCC of the NKG2D class of penta-GNC antibodies, SI-49P1 was used. The control antibodies included a tri-GNC antibody lacking the binding specificities to both PD-L1 and 4-1BB, and a tetra-GNC antibody lacking NKG2D receptor. Serial dilutions (0 to 30 nM; 1 to 5 dilution factor) of GNC protein were added to a white 384-well plate containing luciferized MDA-MB-231 cells (MICA and mesothelin expression; plated 24 hours prior and grown at 37&#xb0; C.) and activated T cells (plated immediately before drug; effector:target=5:1) in a total volume of 50 ul. After an additional 72 hours, 20 ul of Bright-Glo (Promega) was added to wells, and luminescence corresponding to viability of luciferized tumor cells was determined using a CLARIOstar plate reader. Data were fit to a sigmoidal function to calculate EC50 values of 0.1865 pM (SI-49P1), 0.3433 pM (tri-GNC control antibody), and 5.356 pM (tetra-GNC control antibody) (<figref idref="DRAWINGS">FIG. <b>4</b>B</figref>). The data indicates that the addition of NKG2D receptor to the tetra-GNC antibody improves the potency of TDCC, and that the addition of both &#x3b1;PD-L1 and &#x3b1;4-1BB domains to a tri-GNC antibody with its binding specificity to NKG2D significantly improves the potency of TDCC. In other words, the GNC antibodies can accommodate multiple binding specificities to modulate, cooperate, and direct an optimized immune response to targeted cells, such as cancer.</p><heading id="h-0014" level="1">Example 7: NKG2D Receptor at D2 of the Antibody-Like GNC Protein</heading><p id="p-0122" num="0121">To test the utility of antibody-like GNC proteins with natural receptors at position D2, the sequence for human NKG2D (residues F78 through V216) was cloned in place of V<sub>H </sub>and V<sub>L </sub>domains at position D2 in the context of expression plasmids encoding SI-49P10 (&#x3b1;CD3&#xd7;NKG2D&#xd7;&#x3b1;PD-L1&#xd7;&#x3b1;4-1BB&#xd7;&#x3b1;EGFR, SEQ ID NO. 117-200). SI-49P10 was expressed following the materials and methods above, and had exceptionally low aggregation (95.64% peak of interest by analytical SEC) after protein A purification, indicating that the antibody-like GNC proteins containing a non-antibody binding moiety, such as NKG2D receptor, in the D2 position of the heavy chain have the potential to be highly stable. Penta GNC proteins SI-49P6 (&#x3b1;CD3&#xd7;NKG2D&#xd7;&#x3b1;PD-L1&#xd7;&#x3b1;4-1BB&#xd7;&#x3b1;CD19, SEQ ID 123-126) and SI-49P7 (&#x3b1;CD3&#xd7;NKG2D&#xd7;&#x3b1;PD-L1&#xd7;41BBL trimer&#xd7;&#x3b1;CD19, SEQ ID 127-130) were similarly cloned, expressed, and purified.</p><p id="p-0123" num="0122">To ensure that the NKG2D dimer retained full functionality, Octet binding to human MICA was assessed. SI-49P10 was loaded onto AHC tips and bound to His-tagged MICA. The extracted KD values confirmed that NKG2D retains binding activity when present in the D2 position (Table 4). SI-49P10 had a K<sub>D </sub>value of 1.84 nM. As a comparison, SI-49P3 (NKG2D dimer in D5) had a similar K<sub>D </sub>value of 1.39 nM. The other domains of SI-49P10 also retained high binding affinity to their cognate antigens (Table 4). Similarly, binding of SI-49P6 and SI-49P7 for MICA was determined by loading biotinylated human MICA onto SA tips and observing binding to serial dilution of GNC proteins (0 to 100 nM) as analytes. The KD resulting K<sub>D </sub>values were 7.763 nM (SI-49P6) and 10.67 nM (SI-49P7), again confirming the retention of target binding by receptor proteins in the D2 position (Table 4). These K<sub>D </sub>values with antigen as the loaded ligand were slightly lower affinity compared to the experiment in which GNC protein was loaded, possibly due to inactive conformation or incompletely exposed epitope of the MICA protein when it is loaded as ligand. Nevertheless, the potent femtomolar (&#x3c;1 pM) TDCC elicited by these proteins with NKG2D in D2 position toward MICA-bearing MDA-MB-231 cells (<figref idref="DRAWINGS">FIG. <b>8</b></figref>), suggests that the NKG2D receptor retains active binding in the D2 position. Thus, the GNC platform is highly adaptable with regard to where each domain is placed.</p><heading id="h-0015" level="1">Example 8. 4-1BB Ligand as a Binding Domain</heading><p id="p-0124" num="0123">4-1BB is a co-stimulatory immune checkpoint TNFR receptor expressed by activated T cells and NK cells. Its activation by 4-1BB ligand or by an agonist antibody on CD8+ T cells results in increased proliferation, cytokine production, and survival. To optimize the 4-1BB mediated immune response, 4-1BB activation reporter bioassay was performed to assess the functionality of different domains. The 4-1BB activation assay is based on the methods followed by Promega 4-1BB Bioassay kit (SKU: JA2351). The assay consists of a genetically engineered Jurkat T cell line that expresses human 4-1BB and a luciferase reporter driven by a response element that can respond to 4-1BB ligand/agonist antibody stimulation, called 4-1BB Effector Cells. 4-1BB effector cells are cultured in RPMI-1640 with 10% FBS. Before the assay, the cells are counted and re-plated into 384 well (Corning 3570) at 500 cell/well. Test article experiments are conducted in quadruplicate as the 96 well dilution block is stamped into 384 well quadrants robotically (Opentrons OT-2 liquid handling robot). The 4-1BB assay plate was incubated for 6 hours. Readout of the 4-1BB activation curve was accomplished by the use of the Promega Bright-Glo luciferase assay kit. Briefly, 20 uL were added to the 4-1BB assay plate and incubated for <sup>&#x2dc;</sup>15 min before measuring the resultant luminescence on a BMG Clariostar plate reader. Activation curves were analyzed and plotted in GraphPad Software by 4PL curve (<figref idref="DRAWINGS">FIG. <b>5</b></figref>). The results show that the 4-1BB ligand trimer (4-1BBL trimer, SEQ ID NO. 113-114) elicits robust activation of 4-1BB signaling when compared to monomeric 4-1BB ligand, monomeric Fc, and an anti-4-1BB scFv. The penta-GNC antibodies, SI-55P4, SI-55P10, and SI-79P3 (SEQ ID NO. 29-32; 37-40; 49-52, respectively) were created to have 4-1BBL trimer as a binding domain all at D4 (see Table 1, and <figref idref="DRAWINGS">FIG. <b>7</b></figref> below).</p><p id="p-0125" num="0124">Biological activity of the GNC proteins with NKG2D in D2 position was determined using TDCC assay with MICA-bearing MDA-MB-231 target cells (<figref idref="DRAWINGS">FIG. <b>8</b></figref>). The ratio of target to effector cells was 1:5 and the assay was conducted for 72 hours after adding drug dilutions and T cells to the tumor cells. The resulting EC50 values were quite potent (SI-49P6, 0.7366 pM and SI-49P7, 0.1094), confirming the ability of NKG2D to target T cells to kill tumor cells. Thus, placing the receptor NKG2D as binding domains in the GNC D2 position results in stable GNC proteins that elicit potent TDCC.</p><heading id="h-0016" level="1">Example 9. Humanized EGFR Binding Domain</heading><p id="p-0126" num="0125">Cetuximab is a chimeric mouse/human monoclonal antibody for treating EGFR-expressing metastatic colorectal cancer, non-small cell lung cancer, and head and neck cancer. Humanized antibody is obtained. In this example, humanized sequences encoding anti-EGFR binding (H1, H4, H7, and H7-stapled) (SEQ ID NO. 69-72; 73-76; 77-80, and 81-84, respectively), were cloned into an expression cassette for producing anti-EGFR (D2) penta-GNC antibody (51-77P1) and anti-EGFR (D1) penta-GNC antibodies (SI-55P3, SI-55P4, SI-79P2, SI-79P3, and SI-55P9)(SEQ ID NO. 25-28; 29-32; 45-48; 49-52; 33-36, respectively) as listed in Table 7. Each expression cassette was transfected into 25 mL of ExpiCHO and expressed for 8 days followed by protein-A affinity chromatography for harvesting and purifying each penta-GNC antibody. The antibodies were produced with good titer (Table 7). Analytical SEC data after protein-A purification demonstrates that the penta-GNC antibody containing a humanized anti-EGFR domain can be expressed with low aggregation (Table 7). Octet was used to verify that the penta-GNC antibodies containing humanized anti-EGFR domains, H1, H4, or H7, can bind to human EGFR, respectively (<figref idref="DRAWINGS">FIG. <b>6</b></figref> and Table 7). Each penta-GNC antibody was loaded via AHC sensors at 10 &#x3bc;g/ml and bound to a serial dilution (highest 200 nM, 1:2.5 dilutions) or a single 100-nM concentration of His-tagged human EGFR. The resulting global fit to a 1:1 binding model demonstrated that the penta-GNC antibodies bind to EGFR with affinities in the low nanomolar range (Table 7).</p><p id="p-0127" num="0126">To produce hexa-GNC antibodies, the humanized anti-EGFR domain, H7 (SEQ ID NO. 77-80), was cloned into an expression cassette for producing anti-EGFR hexa-GNC antibodies. The humanized binding domain was placed at either Fab or as scFv at D1 in hexa-GNC antibodies, SI-77H4 (SEQ ID NO. 61-64) and SI-55H11 (SEQ ID NO. 53-56), respectively. The control antibody, SI-77H5 (SEQ ID NO. 65-68), comprises the anti-EGFR binding Fab region encoded by the Cetuximab mouse sequences. The expression cassette was transfected into 25 mL of ExpiCHO and expressed for 8 days followed by protein A affinity chromatography for harvesting and purifying each hexa-GNC antibody. The hexa-GNC antibodies were produced with good titer (Table 8). Analytical SEC data after protein A purification demonstrates that each hexa-GNC antibody containing a humanized anti-EGFR domain can be expressed with low aggregation (Table 8). Octet was used to verify that each of these hexa-GNC antibodies containing a humanized anti-EGFR domain can bind to human EGFR (Table 4 and 8). The hexa-GNC antibodies were loaded via AHC sensors at 10 &#x3bc;g/ml and bound to a serial dilution (highest 200 nM, 1:2.5 dilutions) or a single 100-nM concentration of His-tagged human EGFR. The resulting global fit to a 1:1 binding model demonstrated that the affinity of each hexa-GNC antibody binding to EGFR was in the low nanomolar range (Table 8).</p><heading id="h-0017" level="1">Example 10. Humanized CD19 Binding Domain</heading><p id="p-0128" num="0127">CD19 is a biomarker for B lymphocyte development and lymphoma diagnosis. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CAR-T) have been utilized for their antitumor abilities in patients with CD19<sup>+</sup> lymphoma and leukemia, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and acute lymphocytic leukemia. In this context, a humanized CD19 binding domain is desirable.</p><p id="p-0129" num="0128">All computational steps were performed in the Discovery Studio package (Dassault Systemes). First a structural model was generated using the mouse BU12 sequence. Antibody framework regions in the input sequence were identified and aligned to a database of antibody variable domains using Hidden Markov Models (HMM), and this alignment was used to build and score models using the MODELLER software. CDR loop modelling was performed by a structural mapping of the CDRL1 CDRL2 CDRL3 CDRH1 and CDRH2 regions to known canonical classes and loop models were built similarly to the framework. The framework regions from the mouse BU12 antibody were aligned and matched to the closest human germline sequence and CDRs regions were copied into the human sequence with the exception of important structural residues (Vernier residues [Almagro and Fransson, 2008]). Mutations predicted to stabilize the previously build structural model were evaluated computationally by 1000 steps of Steepest Descent with a RMS gradient tolerance of 3, followed by Conjugate Gradient minimization and stabilizing mutations matching frequent human residues were chosen on the basis of individual and combined &#x2212;&#x394;&#x394;G versus the initial model. The resulting final sequences were tested for humanness using the Abysis webserver based on the method of Abhinandan and Martin (2007).</p><p id="p-0130" num="0129">To equip penta- or hexa-GNC antibodies with the binding specificity to CD19 for targeting B cell malignancies, the sequences encoding anti-CD19 V<sub>L </sub>and V<sub>H </sub>domains were selected from SEQ ID NO. 87, 88, 121, 122, 131, 132 carrying modified V<sub>L</sub>; and SEQ ID NO. 85, 86, 87, 88 also carrying modified V<sub>L </sub>along with V<sub>H </sub>containing R19S mutation (Table 1, also see Example 1 for R19S mutation) and connected with a (G<sub>4</sub>S)x4 linker to form the anti-CD19 scFv domain. The corresponding gene sequence was cloned into different positions of penta- or hexa-GNC antibodies using restriction digest into the pTT5 expression plasmid for the appropriate heavy or light chain moiety. The anti-CD19 penta-GNC and hexa-GNA antibodies as listed in Table 1 were produced and characterized as described above. Octet analysis of CD19 binding affinity indicated that each GNC antibody retains CD19 binding affinity in an expected range. when placed on the light chain moiety monomer of the GNC antibodies (Table 4).</p><heading id="h-0018" level="1">Example 11. Penta-GNC Antibodies with Optimized Binding Domains</heading><p id="p-0131" num="0130">With the optimized specific binding for EGFR, CD19, and 4-1BB receptor, the penta-GNC antibodies were assessed in TDCC assay. SI-55P9 and SI-55P10 (SEQ ID NO. 33-36 and 37-40, respectively) are a pair of penta-GNC antibodies with identical binding specificities, except SI-55P9 has a humanized anti-EGFR binding domain and SI-55P10 uses 4-1BBL trimer, as to anti-4-1BB binding domain in SI-55P9, to activate 4-1BB signaling. To assess the effect of these differences in TDCC assay, serial dilutions (0 to 30 nM; 1 to 5 dilution factor) of Penta GNC protein SI-1P1, SI-55P9, and SI-55P10 were added to a white 384-well plate containing luciferized BxPC3 (high EGFR expression) cells (plated 24 hours prior and grown at 37&#xb0; C.) and activated T cells (plated immediately before drug; effector:target=5:1 for SI-1P1 and 7:1 for SI-55P9 and SI-55P10) in a total volume of 50 ul. After an additional 72 hours, 20 ul of Bright-Glo (Promega) was added to wells, and luminescence corresponding to viability of luciferized tumor cells was determined using a CLARIOstar plate reader. As shown in <figref idref="DRAWINGS">FIG. <b>7</b></figref>, the potency of SI-55P9 and SI-55P10 were similar to each other, when compared to that of SI-1P1. Data were fit to a sigmoidal function to calculate EC50 values of 0.2814 pM (SI-1P1), 0.4871 pM (SI-55P9), and 0.7358 pM (SI-55P10), all in the picomolar ranger. The finding implies that the composition of binding specificities dictates the potency of penta-GNC antibodies in the TDCC assay and that other in vitro and in vivo analyses may be used to better evaluate the optimization of each binding domain.</p><heading id="h-0019" level="1">Example 12. Redirected T Cell Cytotoxicity</heading><p id="p-0132" num="0131">Any antibody-based binding domain may be converted to Fab or scFv format and plugged directly into a GNC antibody. For example, the GNC antibodies are characterized by adding the fifth and/or sixth binding domains to the light chain moiety. If the binding specificities on the heavy chain can be dedicated to frequently used targets, such as CD3, PD-L1, and 4-1BB, the utilities of GNC platform may become flexible in terms of selecting targeted tumor antigens and paring the less flexible heavy chain with a desirable light chain moiety. In this context, three tetra-GNC antibodies were selected (from Applicant's application No. PCT/US2019/024105, incorporated herein in its entirety) and evaluated using the in vitro redirected T cell cytotoxicity (RTCC) assay and in vivo human tumor xenograft models.</p><p id="p-0133" num="0132">SI-35E20 is a tetra-GNC antibody capable of binding to 4-1BB (D1), PD-L1 (D2), ROR1 (D3), and CD3 (D4) (Table 1). The ability of SI-35E20 to induce RTCC was determined using live cell imaging of cultures containing PBMC (single donor) and red fluorescence-labeled tumor cells over a 4-day period. PBMC (50,000 cells/mL) were used against NucRed-transduced A549 lung adenocarcinoma cells at a ratio of 4:1 for PBMC and A549. The assay wells were set up in triplicate with 1 nM of SI-35E20 or no GNC (buffer alone) as negative control, and proliferation of target cells was monitored over time for 94 hours. The data shows that SI-35E20 is capable of suppressing the growth of targeted cancer cells over time (<figref idref="DRAWINGS">FIG. <b>9</b></figref>).</p><p id="p-0134" num="0133">SI-38E17 is a tetra-GNC antibody capable of binding to CD3 (D1), CD19 (D2), PD-L1 (D3), and 4-1BB (D4) (Table 1). To evaluate the effect of SI-38E17-mediated RTCC on cancer cells, Nalm-6 Nuc-GFP (a human leukemic cell line) was used as target cells and PBMC from one donor was used as effector cells. RTCC assay was conducted at E:T ratio=1. At 100 pM, the SI-38E17-mediated RTCC was traced by IncuCyte to detect the proliferation of target cells for 48 hours. SI-38E17 mediated strong RTCC functional activity against Nalm-6 (<figref idref="DRAWINGS">FIG. <b>10</b></figref>). The data supports the notion that the tetra-GNC antibody, such as SI-38E17, is capable of suppressing the growth of targeted cancer cells over time.</p><p id="p-0135" num="0134">SI-39E18 is a tetra-GNC antibody capable of binding to CD3, EGFRvIII, PD-L1, and 4-1BB. The RTCC assay confirms that SI-39E18 elicits more cell killing than vehicle control as shown in <figref idref="DRAWINGS">FIG. <b>11</b></figref>, where the measurement of red fluorescence intensity over time averaged for the three different PBMC donors. In the presence of both SI-39E18 or buffer control, target cells increased in number as measured by fluorescence intensity for the first 24 hours of culture, where the effector cells were preincubated for 3 days with SI-39E18 or control prior to target cell addition. Between 24-48 hours after addition of targets to the culture, the number of target cells began to decline in the presence of SI-39E18 stimulation, but not in the wells containing the buffer control. The more modest loss of target cells in the buffer control sample in both conditions after 48 hours was most likely attributable to depletion of nutrients or an allogeneic T cell response toward the MHC mismatched target cells. The data supports the notion that the tetra-GNC antibody, such as SI-39E18, can prevent the growth of targeted cells over time.</p><heading id="h-0020" level="1">Example 13. Human Tumor Xenograft Models</heading><p id="p-0136" num="0135">SI-38E17 was tested in a mouse xenograft model to examine its ability to slow tumor growth in vivo (<figref idref="DRAWINGS">FIG. <b>12</b></figref>). Human B-cell leukemia cells (JVM-3) were subcutaneously transplanted on the right flank of NCG mice at 5&#xd7;10<sup>6 </sup>per mice, and donor PBMC was injected intraperitoneally at 2&#xd7;10<sup>7 </sup>per mouse when tumor volume reached 50-80 mm<sup>3</sup>. Each group consisted of 5 animals, which were dosed intravenously at the labeled dose once per day. Tumor volume after SI-38E17 administration is shown in the figure. At day 16, vehicle group tumor volume was 1298 mm<sup>3</sup>. All three doses of SI-38E17 had a significant tumor inhibition effect, with intermediate dose 0.005 mg (drug:TCR=12.5:1) having the best tumor inhibition (TGI=84%). Note that while all mice in the vehicle control group had died by day 22, tumor had been eliminated in 1 mouse (low dose), 3 mice (intermediate dose), and 1 mouse (high dose) by day 40. Thus, the tetra-GNC antibody, such as SI-38E17, shows strong tumor inhibition in vivo at multiple doses.</p><p id="p-0137" num="0136">SI-39E18 was tested in a mouse xenograft model to examine its ability to slow tumor growth in vivo (<figref idref="DRAWINGS">FIG. <b>13</b></figref>). NCG mice were subcutaneously inoculated with 5&#xd7;10<sup>6 </sup>human bladder cancer-derived UM-UC-3-EGFR VIII cells on the right flank. When the tumor grew to an average volume of 50-80 mm<sup>3</sup>, 5&#xd7;10<sup>6 </sup>per mouse (100 ul) of human PBMC was injected in the abdominal cavity and different doses of SI-39E18 were given intravenously. Each group consisted of 5 animals, which were dosed intravenously at the labeled dose once per day for 18 total doses. The first day of dosing is defined as D1. The tumor growth after SI-39E18 administration is shown in the figure, which demonstrates that SI-39E18 elicits strong inhibition of tumor growth across multiple doses. As of the day of discontinuation (D18), the tumor volume of all dose groups (low dose group 0.001 mg, medium dose group 0.01 mg, and high dose group 0.1 mg) was 0 for three consecutive days, while that of the vehicle had increased significantly in size. Thus, the tetra-GNC antibody, such as SI-39E18, shows strong biological activity in vivo at multiple doses.</p><heading id="h-0021" level="1">Example 14. Exerting More Complete Cytotoxicity</heading><p id="p-0138" num="0137">Hexa-GNC antibodies were created to explore multi-functionality as a single antibody therapeutics. SI-55H11 (SEQ ID NO. 53-56) is a hexa-GNC antibody having its binding specificities to CD3 (D1), EGFR (D2), PD-L1 (D3), 4-1BB (D4) on the heavy chain monomer, and HER3 (D5) and CD19 (D6) on its light chain moiety monomer (Table 1). The TDCC assay was used to determine the effect of the presence and absence of targeting PD-L1 and 4-1BB on T cell-mediated killing of tumor cells by comparing with a tri-specific antibody targeting CD3 (D1) on T cells and both EGFR (D2) and HER3 (D5) on tumor cells (Table 4). Serial dilutions (0 to 30 nM; 1 to 5 dilution factor) of Tri or Hexa GNC were added to a white 384-well plate containing luciferized BxPC3 (high EGFR expression) cells (plated 24 hours prior and grown at 37&#xb0; C.) and activated T cells (plated immediately before drug; effector:target=5:1) in a total volume of 50 ul. After an additional 72 hours, 20 ul of Bright-Glo (Promega) was added to wells, and luminescence corresponding to viability of luciferized tumor cells was determined using a CLARIOstar plate reader. Data were fit to a sigmoidal function to calculate EC50 values and maximum killing (<figref idref="DRAWINGS">FIG. <b>14</b></figref>). The data shows that the hexa-GNC antibody exerts more complete killing than the tri-specific antibody (bottom plateau=46.92% viability; SI-55H11 bottom plateau=2.992% viability). The data implies that together with CD3 for T cell activation, simultaneously targeting immunomodulatory proteins, such as PD-L1 immune checkpoint and 4-1BB activation, is an effective combinational strategy for directing GNC response of immune system towards targeted cells and leading to more complete tumor depletion.</p><heading id="h-0022" level="1">Example 15. Targeting Multiple Tumor Antigens</heading><p id="p-0139" num="0138">While the attempt to fix the immune targets on the heavy chain may be carried out as shown by Example 12 and 13, the binding domains on the light chain moiety may be dedicated to tumor-specific antigens (TSA), tumor-associated antigens (TAA), as well as neoantigens. In this context, several hexa-GNC antibodies were created and subjected to TDCC assay. The GNC antibodies were assessed to determine if additional tumor-targeting specificity can increase T cell-mediated killing of tumor cells (<figref idref="DRAWINGS">FIG. <b>15</b></figref>). Herein, SI-55P9 (SEQ ID NO. 33-36), a penta-GNC antibody capable of binding to EGFR, CD3, PD-L1, and 4-1BB via its heavy chain monomer, and CD19 via light chain moiety monomer, was compared to SI-55H11 (SEQ ID NO. 53-56), a hexa-GNC antibody with the same binding specificities plus the sixth specificity to HER3 via the light chain moiety monomer. Serial dilutions (0 to 30 nM; 1 to 5 dilution factor) of each GNC antibody were added to a white 384-well plate containing 500 luciferized BxPC3 (high EGFR; low HER3) cells (plated 24 hours prior and grown at 37&#xb0; C.) and 2500 activated T cells (plated immediately before drug; effector:target=5:1) in a total volume of 50 ul. After an additional 72 hours, 20 ul of Bright-Glo (Promega) was added to wells, and luminescence corresponding to viability of luciferized tumor cells was determined using a CLARIOstar plate reader. Data were fit to a sigmoidal function to calculate EC50 values. The data shows that the hexa-GNC antibody displays higher potency in TDCC assay (SI-55P9 EC50=0.5727 pM; SI-55H11 EC50=0.09387 pM) when compared to the parental penta-GNC antibody lacking one of the tumor-targeting domains. Thus, an additional anti-tumor antigen binding domain can increase biological function of the GNC antibodies even against cells that express low levels of the TAA (in this case, HER3).</p><p id="p-0140" num="0139">The above specification and examples provide a complete description of the structure and use of exemplary embodiments. Although certain embodiments have been described above with a certain degree of particularity, or with reference to one or more individual embodiments, those skilled in the art could make numerous alterations to the disclosed embodiments without departing from the scope of this invention. For example, while the above examples may include binding domains at certain positions, they are provided by way of comparison only and not by way of limitation. It is specifically contemplated by this application that the configuration of binding domains and their positions on the GNC proteins could be in any combination. As such, the illustrative embodiments of the present invention are not intended to be limited to the particular embodiments disclosed. Rather, they include all modifications and alternatives falling within the scope of the disclosure. Further, where appropriate, aspects of any of the examples described above may be combined with aspects of any of the other examples described to form further examples having comparable or different properties and addressing the same or different problems. Similarly, it will be understood that the benefits and advantages described above may relate to one embodiment or may relate to several embodiments.</p><heading id="h-0023" level="1">TABLES</heading><p id="p-0141" num="0140"></p><p id="p-0142" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="329pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Configurations of example GNC antibodies and each binding domain in the structural</entry></row><row><entry>form of scFv (either V<sub>L </sub>&#x2212; V<sub>H </sub>or V<sub>H </sub>&#x2212; V<sub>L </sub>orientation, stapled or not), receptor, and ligand on heavy</entry></row><row><entry>chain (D1, D3, D4) and light chain moiety (D5, D6) (as described in FIG 1).</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="21pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="56pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="42pt" align="left"/><colspec colname="6" colwidth="49pt" align="left"/><colspec colname="7" colwidth="42pt" align="left"/><colspec colname="8" colwidth="42pt" align="left"/><tbody valign="top"><row><entry>GNC</entry><entry>Antibody</entry><entry>D1</entry><entry>D2</entry><entry>D3</entry><entry>D4</entry><entry>D5</entry><entry>D6</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry>Penta-</entry><entry>SI-1P1</entry><entry>&#x3b1;CD3<sup>a </sup>(LH)</entry><entry>&#x3b1;EGFR</entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x3b1;HER3 (LH)</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-1P2</entry><entry>&#x3b1;CD3<sup>a</sup></entry><entry>&#x3b1;EGFR</entry><entry>&#x3b1;PD-L1</entry><entry>&#x3b1;4-1BB</entry><entry>&#x3b1;HER3</entry><entry>&#x2014;</entry></row><row><entry/><entry/><entry>(LH Stapled)</entry><entry/><entry>(HL Stapled)</entry><entry>(HL Stapled)</entry><entry>(LH Stapled)</entry><entry/></row><row><entry/><entry>SI-38P12</entry><entry>&#x3b1;CD20 (LH)</entry><entry>&#x3b1;CD3<sup>a</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>d </sup>(LH)</entry></row><row><entry/><entry>SI-38P13</entry><entry>&#x3b1;CD20 (LH)</entry><entry>&#x3b1;CD3<sup>c</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x3b1;CD19<sup>d </sup>(HL)</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-49P1</entry><entry>&#x3b1;CD3<sup>b</sup></entry><entry>&#x3b1;MSLN</entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>NKG2D</entry><entry>&#x2014;</entry></row><row><entry/><entry/><entry>(LH Stapled)</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry/><entry>SI-49P3</entry><entry>&#x3b1;CD3<sup>b</sup></entry><entry>&#x3b1;HER2</entry><entry>&#x3b1;PD-L1</entry><entry>&#x3b1;4-1BB</entry><entry>NKG2D</entry><entry>&#x2014;</entry></row><row><entry/><entry/><entry>(LH Stapled)</entry><entry/><entry>(HL Stapled)</entry><entry>(HL Stapled)</entry><entry/><entry/></row><row><entry/><entry>SI-55P3</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>c</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>d </sup>(LH)</entry></row><row><entry/><entry>SI-55P4</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>c</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>4-1BBL trimer</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>d </sup>(LH)</entry></row><row><entry/><entry>SI-55P9</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>a</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>d </sup>(LH)</entry></row><row><entry/><entry>SI-55P10</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>a</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>4-1BBL trimer</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>d </sup>(LH)</entry></row><row><entry/><entry>SI-77P1</entry><entry>&#x3b1;CD3<sup>b </sup>(LH)</entry><entry>Hu-&#x3b1;EGFR</entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>e </sup>(LH)</entry></row><row><entry/><entry>SI-79P2</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>c</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>d </sup>(LH)</entry></row><row><entry/><entry>SI-79P3</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>c</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>4-1BBL trimer</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>d </sup>(LH)</entry></row><row><entry/><entry>SI-49P6</entry><entry>&#x3b1;CD3<sup>b</sup></entry><entry>NKG2D</entry><entry>&#x3b1;PD-L1</entry><entry>&#x3b1;4-1BB</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>f </sup>(LH)</entry></row><row><entry/><entry/><entry>(LH Stapled)</entry><entry/><entry>(HL Stapled)</entry><entry>(HL Stapled)</entry><entry/><entry/></row><row><entry/><entry>SI-49P7</entry><entry>&#x3b1;CD3<sup>b</sup></entry><entry>NKG2D</entry><entry>&#x3b1;PD-L1</entry><entry>4-1BBL trimer</entry><entry>&#x2014;</entry><entry>&#x3b1;CD19<sup>f </sup>(LH)</entry></row><row><entry/><entry/><entry>(LH Stapled)</entry><entry/><entry>(HL Stapled)</entry><entry/><entry/><entry/></row><row><entry/><entry>SI-49P10</entry><entry>&#x3b1;CD3<sup>b</sup></entry><entry>NKG2D</entry><entry>&#x3b1;PD-L1</entry><entry>&#x3b1;4-1BB</entry><entry>&#x2014;</entry><entry>&#x3b1;EGFR (LH)</entry></row><row><entry/><entry/><entry>(LH Stapled)</entry><entry/><entry>(HL Stapled)</entry><entry>(HL Stapled)</entry><entry/><entry/></row><row><entry>Hexa-</entry><entry>SI-55H11</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>a</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x3b1;HER3 (LH)</entry><entry>&#x3b1;CD19<sup>e </sup>(LH)</entry></row><row><entry/><entry/><entry/><entry>(Stapled)</entry><entry/><entry/><entry/><entry/></row><row><entry/><entry>SI-55H12</entry><entry>Hu-&#x3b1;EGFR (LH)</entry><entry>&#x3b1;CD3<sup>a</sup></entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x3b1;HER3 (LH)</entry><entry>&#x3b1;CD19<sup>e </sup>(LH)</entry></row><row><entry/><entry>SI-77H4</entry><entry>&#x3b1;CD3<sup>b </sup>(LH)</entry><entry>Hu-&#x3b1;EGFR</entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x3b1;HER3 (LH)</entry><entry>&#x3b1;CD19<sup>e </sup>(LH)</entry></row><row><entry/><entry/><entry/><entry>(Stapled)</entry><entry/><entry/><entry/><entry/></row><row><entry/><entry>SI-77H5</entry><entry>&#x3b1;CD3<sup>b </sup>(LH)</entry><entry>&#x3b1;EGFR</entry><entry>&#x3b1;PD-L1 (HL)</entry><entry>&#x3b1;4-1BB (HL)</entry><entry>&#x3b1;HER3 (LH)</entry><entry>&#x3b1;CD19<sup>e </sup>(LH)</entry></row><row><entry/><entry/><entry/><entry>(Stapled)</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry namest="1" nameend="8" align="left" id="FOO-00001"><sup>a</sup>284A10, see Applicant's application No. PCT/US2018/039143;</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00002"><sup>b</sup>284A10 H1 (SEQ ID NO. 93-100), humanized anti-CD3 variable domain sequences encoding either a scFv domain or the Fab region, in either a &#x201c;unstapled&#x201d; or a &#x201c;stapled&#x201d; form (SEQ ID NO. 155-108); and</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00003"><sup>c</sup>283E3 H1 (SEQ ID NO. 101-104), humanized anti-CD3 variable domain sequences encoding the Fab region.</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00004"><sup>d</sup>SI-huBU12 VH (SEQ ID NO. 121, 122) and SI-huBU12 H1 VL (SEQ ID NO. 87, 88), humanized anti-CD19 variable domain sequences carrying R19S mutation.</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00005"><sup>e</sup>SI-huBU12 H1 VH (SEQ ID NO. 85, 86) and SI-huBU12 H1 VL (SEQ ID NO. 87, 88), humanized anti-CD19 variable domain sequences.</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00006"><sup>f</sup>SI-huBU12 VH (SEQ ID NO. 121, 122) and SI-huBU12 VL (SEQ ID NO. 131, 132), humanized anti-CD19 variable domain sequences carrying R19S mutation.</entry></row></tbody></tgroup></table></tables></p><p id="p-0143" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>The example penta-GNC antibodies.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="56pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><tbody valign="top"><row><entry>Protein</entry><entry>SI-1P1</entry><entry>SI-1P2</entry><entry>Tetra control</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Format</entry><entry>Penta-GNC</entry><entry>Penta-GNC</entry><entry>Tetra-GNC</entry></row><row><entry>Specificity</entry><entry>EGFR &#xd7; CD3 &#xd7; </entry><entry>EGFR &#xd7; CD3 &#xd7; </entry><entry>EGFR &#xd7; CD3 &#xd7; </entry></row><row><entry/><entry>PDL1 &#xd7; 41BB &#xd7; </entry><entry>PDL1 &#xd7; 41BB &#xd7; </entry><entry>PDL1 &#xd7; 41BB</entry></row><row><entry/><entry>HER3</entry><entry>HER3</entry><entry/></row><row><entry>scFvs with </entry><entry>No</entry><entry>Yes</entry><entry>No</entry></row><row><entry>V<sub>H</sub>-V<sub>L </sub></entry><entry/><entry/><entry/></row><row><entry>disulfide bond</entry><entry/><entry/><entry/></row><row><entry>HMW % </entry><entry>2.27</entry><entry>3.48</entry><entry>2.38</entry></row><row><entry>(time 0)</entry><entry/><entry/><entry/></row><row><entry>HMW % </entry><entry>2.56</entry><entry>2.81</entry><entry>2.75</entry></row><row><entry>(2 weeks)</entry><entry/><entry/><entry/></row><row><entry>HMW % </entry><entry>2.35</entry><entry>nd</entry><entry>2.8</entry></row><row><entry>(4 weeks)</entry><entry/><entry/><entry/></row><row><entry>&#x394;HMW % after </entry><entry>0.08</entry><entry>&#x2212;0.67</entry><entry>0.42</entry></row><row><entry>2 (or 4) weeks</entry><entry/><entry/><entry/></row><row><entry>Melting </entry><entry>67.84</entry><entry>69.35</entry><entry>59.89</entry></row><row><entry>Temp (&#xb0; C.)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0144" num="0141">HMW % was measured using preparative SEC; melting temperature was measuring using dynamic light scattering</p><p id="p-0145" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>The kinetic parameters of example penta-</entry></row><row><entry>GNC antibody SI-1P1 versus SI-1P2,</entry></row><row><entry>where SI-1P2 contains disulfide bonds in </entry></row><row><entry>all four scFv domains (see Table 1).</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>penta-</entry><entry>Human </entry><entry/><entry/><entry>Kon </entry><entry>Kdis </entry></row><row><entry>GNC</entry><entry>Ag</entry><entry>Response</entry><entry>KD (M)</entry><entry>(1/Ms)</entry><entry>(1/s)</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="6"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="42pt" align="char" char="."/><colspec colname="4" colwidth="35pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><colspec colname="6" colwidth="35pt" align="center"/><tbody valign="top"><row><entry>SI-1P1</entry><entry>CD3 </entry><entry>0.1315</entry><entry>1.89E&#x2212;08</entry><entry>3.41E+05</entry><entry>6.43E&#x2212;03</entry></row><row><entry/><entry>&#x3b5;/&#x3b4;_His</entry><entry/><entry/><entry/><entry/></row><row><entry/><entry>4-1BB</entry><entry>0.1768</entry><entry>9.97E&#x2212;09</entry><entry>2.34E+05</entry><entry>2.33E&#x2212;03</entry></row><row><entry/><entry>PD-L1</entry><entry>0.2332</entry><entry>3.44E&#x2212;10</entry><entry>2.15E+05</entry><entry>7.37E&#x2212;05</entry></row><row><entry/><entry>EGFR</entry><entry>0.3544</entry><entry>4.61E&#x2212;09</entry><entry>2.98E+05</entry><entry>1.37E&#x2212;03</entry></row><row><entry/><entry>HER3</entry><entry>0.1927</entry><entry>1.77E&#x2212;07</entry><entry>4.97E+04</entry><entry>8.79E&#x2212;03</entry></row><row><entry>SI-1P2</entry><entry>CD3 </entry><entry>0.1204</entry><entry>2.34E&#x2212;08</entry><entry>2.81E+05</entry><entry>6.59E&#x2212;03</entry></row><row><entry/><entry>&#x3b5;/&#x3b4;_His</entry><entry/><entry/><entry/><entry/></row><row><entry/><entry>4-1BB</entry><entry>0.199</entry><entry>6.06E&#x2212;09</entry><entry>3.68E+05</entry><entry>2.23E&#x2212;03</entry></row><row><entry/><entry>PD-L1</entry><entry>0.2269</entry><entry>7.49E&#x2212;10</entry><entry>3.51E+05</entry><entry>2.63E&#x2212;04</entry></row><row><entry/><entry>EGFR</entry><entry>0.4006</entry><entry>4.07E&#x2212;09</entry><entry>3.56E+05</entry><entry>1.45E&#x2212;03</entry></row><row><entry/><entry>HER3</entry><entry>0.1822</entry><entry>3.77E&#x2212;07</entry><entry>7.71E+04</entry><entry>2.91E&#x2212;02</entry></row><row><entry namest="1" nameend="6" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0146" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="350pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>The affinity of each binding domain in example GNC antibodies</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><colspec colname="5" colwidth="49pt" align="center"/><colspec colname="6" colwidth="42pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><colspec colname="8" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>GNC Format</entry><entry>Antibody</entry><entry>D1 K<sub>D </sub>(nM)</entry><entry>D2 K<sub>D </sub>(nM)</entry><entry>D3 K<sub>D </sub>(nM)</entry><entry>D4 K<sub>D </sub>(nM)</entry><entry>D5 K<sub>D </sub>(nM)</entry><entry>D6 K<sub>D </sub>(nM)</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry>Tri-GNC</entry><entry>Control</entry><entry>CD3 (37.2)</entry><entry>EGFR (6.6)</entry><entry>&#x2014;</entry><entry>&#x2014;</entry><entry>HER3 (13.7)</entry><entry>&#x2014;</entry></row><row><entry/><entry/><entry>Stapled</entry><entry/><entry/><entry/><entry/><entry/></row><row><entry>Tetra-GNC</entry><entry>SI-35E20</entry><entry>4-1BB (4.03)</entry><entry>PD-L1 (0.379)</entry><entry>ROR1 (0.861)</entry><entry>CD3 (0.480)</entry><entry>&#x2014;</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-38E17</entry><entry>CD3 (23.5)</entry><entry>CD19 (1.48)</entry><entry>PD-L1 (0.524)</entry><entry>4-1BB (8.19)</entry><entry>&#x2014;</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-39E18</entry><entry>CD3 (30.2)</entry><entry>EGFRvIII (16.4)</entry><entry>PD-L1 (0.421)</entry><entry>4-1BB (18.1)</entry><entry>&#x2014;</entry><entry>&#x2014;</entry></row><row><entry>Penta-GNC</entry><entry>SI-1P1</entry><entry>18.9</entry><entry>4.61</entry><entry>0.344</entry><entry>9.97</entry><entry>177</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-1P2</entry><entry>23.4</entry><entry>4.07</entry><entry>0.749</entry><entry>6.06</entry><entry>377</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-38P12</entry><entry>744</entry><entry>12.5</entry><entry>0.195</entry><entry>4.85</entry><entry>&#x2014;</entry><entry>1.11</entry></row><row><entry/><entry>SI-38P13</entry><entry>644</entry><entry>15.1</entry><entry>0.731</entry><entry>8.54</entry><entry>0.181</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-49P3</entry><entry>4.42</entry><entry>0.029</entry><entry>nq*</entry><entry>2.75</entry><entry>1.39</entry><entry>&#x2014;</entry></row><row><entry/><entry>SI-49P6</entry><entry>nd**</entry><entry>7.763***</entry><entry>nd**</entry><entry>nd**</entry><entry>&#x2014;</entry><entry>nd**</entry></row><row><entry/><entry>SI-49P7</entry><entry>nd**</entry><entry>10.67***</entry><entry>nd**</entry><entry>nd**</entry><entry>&#x2014;</entry><entry>nd**</entry></row><row><entry/><entry>SI-49P10</entry><entry>2.23</entry><entry>1.84</entry><entry>nq*</entry><entry>2.79</entry><entry>&#x2014;</entry><entry>nq*</entry></row><row><entry/><entry>SI-55P9</entry><entry>7.41</entry><entry>20.8</entry><entry>0.407</entry><entry>7.55</entry><entry>&#x2014;</entry><entry>nq*</entry></row><row><entry/><entry>SI-55P10</entry><entry>7.48</entry><entry>19.6</entry><entry>0.521</entry><entry>65.5</entry><entry>&#x2014;</entry><entry>nq*</entry></row><row><entry>Hexa-GNC</entry><entry>SI-55H11</entry><entry>4.65</entry><entry>15.2</entry><entry>0.737</entry><entry>4.91</entry><entry>9.23</entry><entry>6.80</entry></row><row><entry/><entry>SI-55H12</entry><entry>7.87</entry><entry>1.58</entry><entry>0.25</entry><entry>7.87</entry><entry>9.11</entry><entry>nq*</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry namest="1" nameend="8" align="left" id="FOO-00007">*Not quantified (strong binding was observed relative to reference sensor, but dissociation was too slow to quantify K<sub>D</sub>).</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00008">**KD not determined.</entry></row><row><entry namest="1" nameend="8" align="left" id="FOO-00009">***GNC protein as analyte, antigen as ligand.</entry></row></tbody></tgroup></table></tables></p><p id="p-0147" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>The levels of EGFR and HER3 expression </entry></row><row><entry>in the example cancer cell lines.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="35pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><tbody valign="top"><row><entry/><entry>Tumor cell Line</entry><entry>Description</entry><entry>EGFR</entry><entry>HER3</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>BxPC3</entry><entry>human pancreatic </entry><entry>High</entry><entry>Low</entry></row><row><entry/><entry/><entry>cancer cells</entry><entry/><entry/></row><row><entry/><entry>MDA-MB-231</entry><entry>human breast </entry><entry>High</entry><entry>Low</entry></row><row><entry/><entry/><entry>cancer cells</entry><entry/><entry/></row><row><entry/><entry>Hela</entry><entry>human cervical </entry><entry>High</entry><entry>Low</entry></row><row><entry/><entry/><entry>cancer cells</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0148" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="322pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>The example penta-GNC antibody targeting two tumor antigens in EGFR and HER3</entry></row><row><entry>displays higher potency in T cell activation and similar cytotoxicity as compared to its parental</entry></row><row><entry>control antibodies (see FIG. 2 and 3).</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="203pt" align="center"/><colspec colname="2" colwidth="35pt" align="left"/><colspec colname="3" colwidth="84pt" align="center"/><tbody valign="top"><row><entry>GNC Antibody</entry><entry>NFAT</entry><entry>TDCC</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="105pt" align="left"/><colspec colname="4" colwidth="28pt" align="left"/><colspec colname="5" colwidth="35pt" align="left"/><colspec colname="6" colwidth="49pt" align="left"/><colspec colname="7" colwidth="35pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Tumor</entry><entry>BxPC3</entry><entry>MDA-MB-231</entry><entry>Hela</entry></row><row><entry>Name</entry><entry>GNC Format</entry><entry>Binding Specificity</entry><entry>Antigen</entry><entry>EC50 (nM)</entry><entry>EC50 (nM)</entry><entry>EC50 (nM)</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>SI-1P1</entry><entry>penta-</entry><entry>CD3, EGFR, PD-L1, 4-1BB, HER3</entry><entry>2</entry><entry>1.46E&#x2212;03</entry><entry>2.85E&#x2212;05</entry><entry>1.03E&#x2212;03</entry></row><row><entry>Control</entry><entry>EGF-tetra-</entry><entry>CD3, EGFR, PD-L1, 4-1BB</entry><entry>1</entry><entry>1.03E&#x2212;03</entry><entry>3.13E&#x2212;05</entry><entry>1.71E&#x2212;03</entry></row><row><entry>Control</entry><entry>FITC-tetra-</entry><entry>CD3, FITC, PD-L1, 4-1BB</entry><entry>None</entry><entry>1.34E&#x2212;02</entry><entry>1.23E&#x2212;03</entry><entry>n/a</entry></row><row><entry>Control</entry><entry>bispecific</entry><entry>EGFR, HER3</entry><entry>Only</entry><entry>n/a</entry><entry>n/a</entry><entry>n/a</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0149" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="322pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Characterization of example penta-GNC antibodies comprising a humanized anti-</entry></row><row><entry>EGFR scFv domain or Fab domain.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="77pt" align="left"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="42pt" align="center"/><colspec colname="8" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>GNC</entry><entry>&#x3b1;EGFR</entry><entry>Anti-EGFR</entry><entry>Specificities of Other</entry><entry>Titer</entry><entry>aSEC</entry><entry>huEGFR K<sub>D</sub></entry><entry>TDCC</entry></row><row><entry>Antibody</entry><entry>Variant</entry><entry>Domain</entry><entry>Binding Domains</entry><entry>(&#x3bc;g/ml)</entry><entry>% POI</entry><entry>(nM)</entry><entry>EC50 (pM)</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="77pt" align="left"/><colspec colname="5" colwidth="28pt" align="char" char="."/><colspec colname="6" colwidth="28pt" align="char" char="."/><colspec colname="7" colwidth="42pt" align="char" char="."/><colspec colname="8" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>SI-55P3</entry><entry>H1</entry><entry>scFv (D1)</entry><entry>&#x3b1;CD3 (2), &#x3b1;PD-L1 (3), </entry><entry>175.9</entry><entry>86.13</entry><entry>18.1</entry><entry>nd</entry></row><row><entry/><entry/><entry/><entry>&#x3b1;4-1BB (4), &#x3b1;CD19 (6)</entry><entry/><entry/><entry/><entry/></row><row><entry>SI-55P4</entry><entry>H1</entry><entry>scFv (D1)</entry><entry>&#x3b1;CD3 (2), &#x3b1;PD-L1 (3), </entry><entry>59.6</entry><entry>93.22</entry><entry>nd</entry><entry>nd</entry></row><row><entry/><entry/><entry/><entry>41BBLT (4), &#x3b1;CD19 (6)</entry><entry/><entry/><entry/><entry/></row><row><entry>SI-79P2</entry><entry>H4</entry><entry>scFv (D1)</entry><entry>&#x3b1;CD3 (2), &#x3b1;PD-L1 (3), </entry><entry>68.9</entry><entry>87.74</entry><entry>4.3</entry><entry>nd</entry></row><row><entry/><entry/><entry/><entry>&#x3b1;4-1BB (4), &#x3b1;CD19 (6)</entry><entry/><entry/><entry/><entry/></row><row><entry>SI-79P3</entry><entry>H4</entry><entry>scFv (D1)</entry><entry>&#x3b1;CD3 (2), &#x3b1;PD-L1 (3), </entry><entry>70.3</entry><entry>92.8</entry><entry>5.21</entry><entry>nd</entry></row><row><entry/><entry/><entry/><entry>41BBLT (4), &#x3b1;CD19 (6) </entry><entry/><entry/><entry/><entry/></row><row><entry>SI-55P9</entry><entry>H7</entry><entry>scFv (D1)</entry><entry>&#x3b1;CD3 (2), &#x3b1;PD-L1 (3), </entry><entry>118</entry><entry>85.96</entry><entry>7.41</entry><entry>0.5727</entry></row><row><entry/><entry/><entry/><entry>&#x3b1;4-1BB (4), &#x3b1;CD19 (6)</entry><entry/><entry/><entry/><entry/></row><row><entry>SI-77P1</entry><entry>H7</entry><entry>Fab (D2)</entry><entry>&#x3b1;CD3 (1), &#x3b1;PD-L1 (3), </entry><entry>98.1</entry><entry>77.94</entry><entry>2.17</entry><entry>0.0826</entry></row><row><entry/><entry/><entry/><entry>&#x3b1;4-1BB (4), &#x3b1;CD19 (6)</entry><entry/><entry/><entry/><entry/></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0150" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="308pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Characterization of example hexa-GNC antibodies comprising a humanized anti-</entry></row><row><entry>EGFR scFv domain or Fab region</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="77pt" align="left"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><colspec colname="8" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>GNC</entry><entry>&#x3b1;EGFR</entry><entry>Anti-EGFR</entry><entry>Specificities of Other</entry><entry>Titer</entry><entry>aSEC</entry><entry>huEGFR</entry><entry>TDCC</entry></row><row><entry>Antibody</entry><entry>Variant</entry><entry>Domain</entry><entry>Binding domains</entry><entry>(&#x3bc;g/ml)</entry><entry>% POI</entry><entry>K<sub>D </sub>(nM)</entry><entry>EC50 (pM)</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="8"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="77pt" align="left"/><colspec colname="5" colwidth="28pt" align="char" char="."/><colspec colname="6" colwidth="28pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><colspec colname="8" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>SI-77H5</entry><entry>C*</entry><entry>Fab (D2)</entry><entry>&#x3b1;CD3 (1), &#x3b1;PD-L1 (3), </entry><entry>35</entry><entry>72.02</entry><entry>3.39</entry><entry>nd</entry></row><row><entry/><entry/><entry/><entry>&#x3b1;4-1BB (4), &#x3b1;HER3 (5), </entry><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry>&#x3b1;CD19 (6)</entry><entry/><entry/><entry/><entry/></row><row><entry>SI-77H4</entry><entry>H7</entry><entry>Fab (D2)</entry><entry>&#x3b1;CD3 (1), &#x3b1;PD-L1 (3), </entry><entry>61.1</entry><entry>77.25</entry><entry>3.29</entry><entry>nd</entry></row><row><entry/><entry/><entry/><entry>&#x3b1;4-1BB (4), &#x3b1;HER3 (5), </entry><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry>&#x3b1;CD19 (6)</entry><entry/><entry/><entry/><entry/></row><row><entry>SI-55H11</entry><entry>H7</entry><entry>scFv (D1)</entry><entry>&#x3b1;CD3 (2), &#x3b1;PD-L1 (3), </entry><entry>30</entry><entry>84.42</entry><entry>4.65</entry><entry>0.09387</entry></row><row><entry/><entry/><entry/><entry>&#x3b1;4-1BB (4), &#x3b1;HER3 (5), </entry><entry/><entry/><entry/><entry/></row><row><entry/><entry/><entry/><entry>&#x3b1;CD19 (6)</entry></row><row><entry namest="1" nameend="8" align="center" rowsep="1"/></row><row><entry namest="1" nameend="8" align="left" id="FOO-00010">*Mouse sequences derived from Cetuximab.</entry></row></tbody></tgroup></table></tables></p><p id="p-0151" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>SEQUENCE LISTING</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="70pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>SEQ ID NO.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>GNC </entry><entry/><entry>Chain/</entry><entry>Amino </entry><entry>Nucleo-</entry></row><row><entry>Protein</entry><entry>Name</entry><entry>Monomer</entry><entry>acid</entry><entry>tide</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="28pt" align="char" char="."/><colspec colname="5" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>Penta-</entry><entry>SI-1P1</entry><entry>H</entry><entry>1</entry><entry>2</entry></row><row><entry/><entry/><entry>L</entry><entry>3</entry><entry>4</entry></row><row><entry/><entry>SI-1P2</entry><entry>H</entry><entry>5</entry><entry>6</entry></row><row><entry/><entry/><entry>L</entry><entry>7</entry><entry>8</entry></row><row><entry/><entry>SI-38P12</entry><entry>H</entry><entry>9</entry><entry>10</entry></row><row><entry/><entry/><entry>L</entry><entry>11</entry><entry>12</entry></row><row><entry/><entry>SI-38P13</entry><entry>H</entry><entry>13</entry><entry>14</entry></row><row><entry/><entry/><entry>L</entry><entry>15</entry><entry>16</entry></row><row><entry/><entry>SI-49P1</entry><entry>H</entry><entry>17</entry><entry>18</entry></row><row><entry/><entry/><entry>L</entry><entry>19</entry><entry>20</entry></row><row><entry/><entry>SI-49P3</entry><entry>H</entry><entry>21</entry><entry>22</entry></row><row><entry/><entry/><entry>L</entry><entry>23</entry><entry>24</entry></row><row><entry/><entry>SI-55P3</entry><entry>H</entry><entry>25</entry><entry>26</entry></row><row><entry/><entry/><entry>L</entry><entry>27</entry><entry>28</entry></row><row><entry/><entry>SI-55P4</entry><entry>H</entry><entry>29</entry><entry>30</entry></row><row><entry/><entry/><entry>L</entry><entry>31</entry><entry>32</entry></row><row><entry/><entry>SI-55P9</entry><entry>H</entry><entry>33</entry><entry>34</entry></row><row><entry/><entry/><entry>L</entry><entry>35</entry><entry>36</entry></row><row><entry/><entry>SI-55P10</entry><entry>H</entry><entry>37</entry><entry>38</entry></row><row><entry/><entry/><entry>L</entry><entry>39</entry><entry>40</entry></row><row><entry/><entry>SI-77P1</entry><entry>H</entry><entry>41</entry><entry>42</entry></row><row><entry/><entry/><entry>L</entry><entry>43</entry><entry>44</entry></row><row><entry/><entry>SI-79P2</entry><entry>H</entry><entry>45</entry><entry>46</entry></row><row><entry/><entry/><entry>L</entry><entry>47</entry><entry>48</entry></row><row><entry/><entry>SI-79P3</entry><entry>H</entry><entry>49</entry><entry>50</entry></row><row><entry/><entry/><entry>L</entry><entry>51</entry><entry>52</entry></row><row><entry/><entry>SI-49P10</entry><entry>H</entry><entry>117</entry><entry>118</entry></row><row><entry/><entry/><entry>L</entry><entry>119</entry><entry>120</entry></row><row><entry/><entry>SI-49P6</entry><entry>H</entry><entry>123</entry><entry>124</entry></row><row><entry/><entry/><entry>L</entry><entry>125</entry><entry>126</entry></row><row><entry/><entry>SI-49P7</entry><entry>H</entry><entry>127</entry><entry>128</entry></row><row><entry/><entry/><entry>L</entry><entry>129</entry><entry>130</entry></row><row><entry>Hexa-</entry><entry>SI-55H11</entry><entry>H</entry><entry>53</entry><entry>54</entry></row><row><entry/><entry/><entry>L</entry><entry>55</entry><entry>56</entry></row><row><entry/><entry>SI-55H12</entry><entry>H</entry><entry>57</entry><entry>58</entry></row><row><entry/><entry/><entry>L</entry><entry>59</entry><entry>60</entry></row><row><entry/><entry>SI-77H4</entry><entry>H</entry><entry>61</entry><entry>62</entry></row><row><entry/><entry/><entry>L</entry><entry>63</entry><entry>64</entry></row><row><entry/><entry>SI-77H5</entry><entry>H</entry><entry>65</entry><entry>66</entry></row><row><entry/><entry/><entry>L</entry><entry>67</entry><entry>68</entry></row><row><entry>Binding </entry><entry>&#x3b1;EGFR H1</entry><entry>VH</entry><entry>69</entry><entry>70</entry></row><row><entry>Domain</entry><entry/><entry>VL</entry><entry>71</entry><entry>72</entry></row><row><entry/><entry>&#x3b1;EGFR H4</entry><entry>VH</entry><entry>73</entry><entry>74</entry></row><row><entry/><entry/><entry>VL</entry><entry>75</entry><entry>76</entry></row><row><entry/><entry>&#x3b1;EGFR H7</entry><entry>VH</entry><entry>77</entry><entry>78</entry></row><row><entry/><entry/><entry>VL</entry><entry>79</entry><entry>80</entry></row><row><entry/><entry>&#x3b1;EGFR H7</entry><entry>VH</entry><entry>81</entry><entry>82</entry></row><row><entry/><entry>stapled</entry><entry>VL</entry><entry>83</entry><entry>84</entry></row><row><entry/><entry>&#x3b1;CD19 </entry><entry>VH</entry><entry>121</entry><entry>122</entry></row><row><entry/><entry>SI-huBU12</entry><entry>VL</entry><entry>131</entry><entry>132</entry></row><row><entry/><entry>&#x3b1;CD19 SI-</entry><entry>VH</entry><entry>85</entry><entry>86</entry></row><row><entry/><entry>huBU12 H1</entry><entry>VL</entry><entry>87</entry><entry>88</entry></row><row><entry/><entry>&#x3b1;CD3 284A10</entry><entry>VH</entry><entry>89</entry><entry>90</entry></row><row><entry/><entry>stapled</entry><entry>VL</entry><entry>91</entry><entry>92</entry></row><row><entry/><entry>&#x3b1;CD3 </entry><entry>VH</entry><entry>93</entry><entry>94</entry></row><row><entry/><entry>284A10 H1</entry><entry>VL</entry><entry>95</entry><entry>96</entry></row><row><entry/><entry>&#x3b1;CD3 </entry><entry>VH</entry><entry>97</entry><entry>98</entry></row><row><entry/><entry>284A10 H1</entry><entry>VL</entry><entry>99</entry><entry>100</entry></row><row><entry/><entry>stapled</entry><entry/><entry/><entry/></row><row><entry/><entry>&#x3b1;CD3 </entry><entry>VH</entry><entry>101</entry><entry>102</entry></row><row><entry/><entry>283E3 H1</entry><entry>VL</entry><entry>103</entry><entry>104</entry></row><row><entry/><entry>&#x3b1;PD-L1 </entry><entry>VH</entry><entry>105</entry><entry>106</entry></row><row><entry/><entry>PL221G5</entry><entry>VL</entry><entry>107</entry><entry>108</entry></row><row><entry/><entry>stapled</entry><entry/><entry/><entry/></row><row><entry/><entry>&#x3b1;41BB 466F6</entry><entry>VH</entry><entry>109</entry><entry>110</entry></row><row><entry/><entry>stapled</entry><entry>VL</entry><entry>111</entry><entry>112</entry></row><row><entry/><entry>4-1BB </entry><entry>&#x2014;</entry><entry>113</entry><entry>114</entry></row><row><entry/><entry>ligand trimer</entry><entry/><entry/><entry/></row><row><entry/><entry>NKG2D </entry><entry>&#x2014;</entry><entry>115</entry><entry>116</entry></row><row><entry/><entry>dimer</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0152" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="273pt" align="left"/><colspec colname="2" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;1:&#x2003;SI-1P1&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry><entry/></row><row><entry>DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKGGGGSGGGGSGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYA</entry></row><row><entry> </entry></row><row><entry>SWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSTGGGG</entry></row><row><entry> </entry></row><row><entry>SGGGGSQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTD</entry></row><row><entry> </entry></row><row><entry>YNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSSAST</entry></row><row><entry> </entry></row><row><entry>KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry> </entry></row><row><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPK</entry></row><row><entry> </entry></row><row><entry>DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD</entry></row><row><entry> </entry></row><row><entry>WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD</entry></row><row><entry> </entry></row><row><entry>IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS</entry></row><row><entry> </entry></row><row><entry>LSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEW</entry></row><row><entry> </entry></row><row><entry>IACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSEDYAMDLW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLN</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVD</entry></row><row><entry> </entry></row><row><entry>NVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPG</entry></row><row><entry> </entry></row><row><entry>KGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLS</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYV</entry></row><row><entry> </entry></row><row><entry>GGAFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;2:&#x2003;SI-1P1&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGAGGATCAGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>TGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCA</entry></row><row><entry> </entry></row><row><entry>GGCTCCAGGGAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCG</entry></row><row><entry> </entry></row><row><entry>AGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAA</entry></row><row><entry> </entry></row><row><entry>TGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGC</entry></row><row><entry> </entry></row><row><entry>TATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCGACAGGCGGTGGAGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCGGTGGTGGATCACAGGTGCAGCTGAAGCAGTCAGGACCTGGCCTAGTGCAGCCCTCAC</entry></row><row><entry> </entry></row><row><entry>AGAGCCTGTCCATCACCTGCACAGTCTCTGGTTTCTCATTAACTAACTATGGTGTACACTGGGT</entry></row><row><entry> </entry></row><row><entry>TCGCCAGTCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGTGATATGGAGTGGTGGAAACACAGAC</entry></row><row><entry> </entry></row><row><entry>TATAATACACCTTTCACATCCAGACTGAGCATCAACAAGGACAATTCCAAGAGCCAAGTTTTCT</entry></row><row><entry> </entry></row><row><entry>TTAAAATGAACAGTCTGCAATCTAATGACACAGCCATATATTACTGTGCCAGAGCCCTCACCTA</entry></row><row><entry> </entry></row><row><entry>CTATGATTACGAGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTAGCGCTAGCACC</entry></row><row><entry> </entry></row><row><entry>AAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCC</entry></row><row><entry> </entry></row><row><entry>TGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCT</entry></row><row><entry> </entry></row><row><entry>GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC</entry></row><row><entry> </entry></row><row><entry>GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC</entry></row><row><entry> </entry></row><row><entry>CCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC</entry></row><row><entry> </entry></row><row><entry>ACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG</entry></row><row><entry> </entry></row><row><entry>GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAG</entry></row><row><entry> </entry></row><row><entry>ACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC</entry></row><row><entry> </entry></row><row><entry>GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC</entry></row><row><entry> </entry></row><row><entry>TGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA</entry></row><row><entry> </entry></row><row><entry>AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG</entry></row><row><entry> </entry></row><row><entry>GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGAC</entry></row><row><entry> </entry></row><row><entry>ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGC</entry></row><row><entry> </entry></row><row><entry>TGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA</entry></row><row><entry> </entry></row><row><entry>GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGG</entry></row><row><entry> </entry></row><row><entry>AGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT</entry></row><row><entry> </entry></row><row><entry>CTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>ATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGT</entry></row><row><entry> </entry></row><row><entry>TCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA</entry></row><row><entry> </entry></row><row><entry>GGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCG</entry></row><row><entry> </entry></row><row><entry>GTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAAC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAG</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGAT</entry></row><row><entry> </entry></row><row><entry>AATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCT</entry></row><row><entry> </entry></row><row><entry>CCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTC</entry></row><row><entry> </entry></row><row><entry>CTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGG</entry></row><row><entry> </entry></row><row><entry>AAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTA</entry></row><row><entry> </entry></row><row><entry>GAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCT</entry></row><row><entry> </entry></row><row><entry>GAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCG</entry></row><row><entry> </entry></row><row><entry>GCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGA</entry></row><row><entry> </entry></row><row><entry>CCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTT</entry></row><row><entry> </entry></row><row><entry>GGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;3:&#x2003;SI-1P1&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSG</entry></row><row><entry> </entry></row><row><entry>TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY</entry></row><row><entry> </entry></row><row><entry>ACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGY</entry></row><row><entry> </entry></row><row><entry>NFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSS</entry></row><row><entry> </entry></row><row><entry>STHVIFGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLRLSCAASGFTF</entry></row><row><entry> </entry></row><row><entry>SSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAV</entry></row><row><entry> </entry></row><row><entry>YYCARDRGVGYFDLWGRGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;4:&#x2003;SI-1P1&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACATCTTGCTGACTCAGTCTCCAGTCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGTTTCT</entry></row><row><entry> </entry></row><row><entry>CCTGCAGGGCCAGTCAGAGTATTGGCACAAACATACACTGGTATCAGCAAAGAACAAATGGTTC</entry></row><row><entry> </entry></row><row><entry>TCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATCTCTGGGATTCCTTCCAGGTTTAGTGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCAGGGACAGATTTTACTCTTAGCATCAACAGTGTGGAGTCTGAAGATATTGCAGATT</entry></row><row><entry> </entry></row><row><entry>ATTACTGTCAACAAAATAATAACTGGCCAACCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAA</entry></row><row><entry> </entry></row><row><entry>ACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA</entry></row><row><entry> </entry></row><row><entry>ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGG</entry></row><row><entry> </entry></row><row><entry>TGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG</entry></row><row><entry> </entry></row><row><entry>CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC</entry></row><row><entry> </entry></row><row><entry>GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT</entry></row><row><entry> </entry></row><row><entry>GTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTC</entry></row><row><entry> </entry></row><row><entry>TGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTAT</entry></row><row><entry> </entry></row><row><entry>AACTTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATCTATGATGTCA</entry></row><row><entry> </entry></row><row><entry>GTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTCCGGCTCCAAGTCTGGCAACACGGCCTCCCT</entry></row><row><entry> </entry></row><row><entry>GATCATCTCTGGCCTCCAGGCTGACGACGAGGCTGATTATTACTGCAGCTCATATGGGAGCAGC</entry></row><row><entry> </entry></row><row><entry>AGCACTCATGTGATTTTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTGGAGGCGGTTCAGGCG</entry></row><row><entry> </entry></row><row><entry>GAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTGCAATTGCAGGAGTCGGG</entry></row><row><entry> </entry></row><row><entry>GGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTT</entry></row><row><entry> </entry></row><row><entry>AGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTGGCCAACA</entry></row><row><entry> </entry></row><row><entry>TAAACCGCGATGGAAGTGCGAGTTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAG</entry></row><row><entry> </entry></row><row><entry>AGACGACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTG</entry></row><row><entry> </entry></row><row><entry>TATTACTGTGCGAGAGATCGTGGGGTGGGCTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCA</entry></row><row><entry> </entry></row><row><entry>CCGTCTCGAGCTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;5:&#x2003;SI-1P2&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKVEIKGGGGSGGGGSGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKCLEWIGVITGRDITYYA</entry></row><row><entry> </entry></row><row><entry>SWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSTGGGG</entry></row><row><entry> </entry></row><row><entry>SGGGGSQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTD</entry></row><row><entry> </entry></row><row><entry>YNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSSAST</entry></row><row><entry> </entry></row><row><entry>KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry> </entry></row><row><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK</entry></row><row><entry> </entry></row><row><entry>DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD</entry></row><row><entry> </entry></row><row><entry>WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD</entry></row><row><entry> </entry></row><row><entry>IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKS</entry></row><row><entry> </entry></row><row><entry>LSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKCLEW</entry></row><row><entry> </entry></row><row><entry>IACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLN</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVD</entry></row><row><entry> </entry></row><row><entry>NVFGCGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPG</entry></row><row><entry> </entry></row><row><entry>KCLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLS</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYV</entry></row><row><entry> </entry></row><row><entry>GGAFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;6:&#x2003;SI-1P2&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCTGTGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAAGGTGGAGGCGGTTCAGGCGGAGGTGGAAGTGGTGGTGGCGGCTCTGGA</entry></row><row><entry> </entry></row><row><entry>GGCGGCGGATCTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>TGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCA</entry></row><row><entry> </entry></row><row><entry>GGCTCCAGGGAAGTGCCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCG</entry></row><row><entry> </entry></row><row><entry>AGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAA</entry></row><row><entry> </entry></row><row><entry>TGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGC</entry></row><row><entry> </entry></row><row><entry>TATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCGACAGGCGGTGGAGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCGGTGGTGGATCACAGGTGCAGCTGAAGCAGTCAGGACCTGGCCTAGTGCAGCCCTCAC</entry></row><row><entry> </entry></row><row><entry>AGAGCCTGTCCATCACCTGCACAGTCTCTGGTTTCTCATTAACTAACTATGGTGTACACTGGGT</entry></row><row><entry> </entry></row><row><entry>TCGCCAGTCTCCAGGAAAGGGTCTGGAGTGGCTGGGAGTGATATGGAGTGGTGGAAACACAGAC</entry></row><row><entry> </entry></row><row><entry>TATAATACACCTTTCACATCCAGACTGAGCATCAACAAGGACAATTCCAAGAGCCAAGTTTTCT</entry></row><row><entry> </entry></row><row><entry>TTAAAATGAACAGTCTGCAATCTAATGACACAGCCATATATTACTGTGCCAGAGCCCTCACCTA</entry></row><row><entry> </entry></row><row><entry>CTATGATTACGAGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTAGCGCTAGCACC</entry></row><row><entry> </entry></row><row><entry>AAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCC</entry></row><row><entry> </entry></row><row><entry>TGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCT</entry></row><row><entry> </entry></row><row><entry>GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC</entry></row><row><entry> </entry></row><row><entry>GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC</entry></row><row><entry> </entry></row><row><entry>CCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC</entry></row><row><entry> </entry></row><row><entry>ACCGTGCCCAGCACCTGAAGCCGCGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG</entry></row><row><entry> </entry></row><row><entry>GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAG</entry></row><row><entry> </entry></row><row><entry>ACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC</entry></row><row><entry> </entry></row><row><entry>GCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC</entry></row><row><entry> </entry></row><row><entry>TGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA</entry></row><row><entry> </entry></row><row><entry>AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG</entry></row><row><entry> </entry></row><row><entry>GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGAC</entry></row><row><entry> </entry></row><row><entry>ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGC</entry></row><row><entry> </entry></row><row><entry>TGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA</entry></row><row><entry> </entry></row><row><entry>GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGG</entry></row><row><entry> </entry></row><row><entry>AGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT</entry></row><row><entry> </entry></row><row><entry>CTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGTGCCTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>ATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGT</entry></row><row><entry> </entry></row><row><entry>TCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA</entry></row><row><entry> </entry></row><row><entry>GGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGTGGAAGTGGTG</entry></row><row><entry> </entry></row><row><entry>GTGGCGGCTCTGGAGGCGGCGGATCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAAC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAG</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGAT</entry></row><row><entry> </entry></row><row><entry>AATGTTTTCGGCTGCGGGACCAAGGTGGAGATCAAAGGTGGTGGCGGCTCTGGAGGAGGAGGGT</entry></row><row><entry> </entry></row><row><entry>CCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTC</entry></row><row><entry> </entry></row><row><entry>CTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGGCAGGCACCTGGG</entry></row><row><entry> </entry></row><row><entry>AAGTGCCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTA</entry></row><row><entry> </entry></row><row><entry>GAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCT</entry></row><row><entry> </entry></row><row><entry>GAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCG</entry></row><row><entry> </entry></row><row><entry>GCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGA</entry></row><row><entry> </entry></row><row><entry>CTTGGAACCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTT</entry></row><row><entry> </entry></row><row><entry>GGCGGTGCTTTCGGCTGTGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;7:&#x2003;SI-1P2&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSG</entry></row><row><entry> </entry></row><row><entry>TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY</entry></row><row><entry> </entry></row><row><entry>ACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDVGGY</entry></row><row><entry> </entry></row><row><entry>NFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCSSYGSS</entry></row><row><entry> </entry></row><row><entry>STHVIFGCGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLRLSCAASGFTF</entry></row><row><entry> </entry></row><row><entry>SSYWMSWVRQAPGKCLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRAEDTAV</entry></row><row><entry> </entry></row><row><entry>YYCARDRGVGYFDLWGRGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;8:&#x2003;SI-1P2&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACATCTTGCTGACTCAGTCTCCAGTCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGTTTCT</entry></row><row><entry> </entry></row><row><entry>CCTGCAGGGCCAGTCAGAGTATTGGCACAAACATACACTGGTATCAGCAAAGAACAAATGGTTC</entry></row><row><entry> </entry></row><row><entry>TCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATCTCTGGGATTCCTTCCAGGTTTAGTGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCAGGGACAGATTTTACTCTTAGCATCAACAGTGTGGAGTCTGAAGATATTGCAGATT</entry></row><row><entry> </entry></row><row><entry>ATTACTGTCAACAAAATAATAACTGGCCAACCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAA</entry></row><row><entry> </entry></row><row><entry>ACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA</entry></row><row><entry> </entry></row><row><entry>ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGG</entry></row><row><entry> </entry></row><row><entry>TGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG</entry></row><row><entry> </entry></row><row><entry>CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC</entry></row><row><entry> </entry></row><row><entry>GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT</entry></row><row><entry> </entry></row><row><entry>GTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCCAGTCTGCCCTGACTCAGCCTGCCTCCGTGTC</entry></row><row><entry> </entry></row><row><entry>TGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGTTAT</entry></row><row><entry> </entry></row><row><entry>AACTTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCATGATCTATGATGTCA</entry></row><row><entry> </entry></row><row><entry>GTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTCCGGCTCCAAGTCTGGCAACACGGCCTCCCT</entry></row><row><entry> </entry></row><row><entry>GATCATCTCTGGCCTCCAGGCTGACGACGAGGCTGATTATTACTGCAGCTCATATGGGAGCAGC</entry></row><row><entry> </entry></row><row><entry>AGCACTCATGTGATTTTCGGCTGCGGGACCAAGGTGACCGTCCTAGGTGGAGGCGGTTCAGGCG</entry></row><row><entry> </entry></row><row><entry>GAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTGCAATTGCAGGAGTCGGG</entry></row><row><entry> </entry></row><row><entry>GGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTT</entry></row><row><entry> </entry></row><row><entry>AGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGTGCCTGGAGTGGGTGGCCAACA</entry></row><row><entry> </entry></row><row><entry>TAAACCGCGATGGAAGTGCGAGTTACTATGTGGACTCTGTGAAGGGCCGATTCACCATCTCCAG</entry></row><row><entry> </entry></row><row><entry>AGACGACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCTGTG</entry></row><row><entry> </entry></row><row><entry>TATTACTGTGCGAGAGATCGTGGGGTGGGCTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCA</entry></row><row><entry> </entry></row><row><entry>CCGTCTCGAGCTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;9:&#x2003;SI-38P12&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>QLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKG</entry></row><row><entry> </entry></row><row><entry>KATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSSGGGGSGGGG</entry></row><row><entry> </entry></row><row><entry>SEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWA</entry></row><row><entry> </entry></row><row><entry>KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSASTKGPS</entry></row><row><entry> </entry></row><row><entry>VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV</entry></row><row><entry> </entry></row><row><entry>PSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLM</entry></row><row><entry> </entry></row><row><entry>ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG</entry></row><row><entry> </entry></row><row><entry>KEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE</entry></row><row><entry> </entry></row><row><entry>WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS</entry></row><row><entry> </entry></row><row><entry>PGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACI</entry></row><row><entry> </entry></row><row><entry>AAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGT</entry></row><row><entry> </entry></row><row><entry>LVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQ</entry></row><row><entry> </entry></row><row><entry>KPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFG</entry></row><row><entry> </entry></row><row><entry>GGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLE</entry></row><row><entry> </entry></row><row><entry>YIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGT</entry></row><row><entry> </entry></row><row><entry>LVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQ</entry></row><row><entry> </entry></row><row><entry>KPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAF</entry></row><row><entry> </entry></row><row><entry>GGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;10:&#x2003;SI-38P12&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAGATCGTGCTGAGCCAGAGCCCCGCCATCCTGAGCGCCAGCCCCGGCGAGAAGGTGACCATGA</entry></row><row><entry> </entry></row><row><entry>CCTGCCGGGCCAGCAGCAGCGTGAGCTACATCCACTGGTTCCAGCAGAAGCCCGGCAGCAGCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCCCTGGATCTACGCCACCAGCAACCTGGCCAGCGGCGTGCCCGTGCGGTTCAGCGGCAGC</entry></row><row><entry> </entry></row><row><entry>GGCAGCGGCACCAGCTACAGCCTGACCATCAGCCGGGTGGAGGCCGAGGACGCCGCCACCTACT</entry></row><row><entry> </entry></row><row><entry>ACTGCCAGCAGTGGACCAGCAACCCCCCCACCTTCGGCGGCGGCACCAAGCTGACCGTGCTGGG</entry></row><row><entry> </entry></row><row><entry>TGGTGGTGGCTCTGGAGGAGGCGGGAGCGGGGGTGGTGGCTCAGGTGGTGGAGGTTCCCAGGTG</entry></row><row><entry> </entry></row><row><entry>CAGCTGCAGCAGCCCGGCGCCGAGCTGGTGAAGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGG</entry></row><row><entry> </entry></row><row><entry>CCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGACCCCCGGCCGGGGCCT</entry></row><row><entry> </entry></row><row><entry>GGAGTGGATCGGCGCCATCTACCCCGGCAACGGCGACACCAGCTACAACCAGAAGTTCAAGGGC</entry></row><row><entry> </entry></row><row><entry>AAGGCCACCCTGACCGCCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCA</entry></row><row><entry> </entry></row><row><entry>GCGAGGACAGCGCCGTGTACTACTGCGCCCGGAGCACCTACTACGGCGGCGACTGGTACTTCAA</entry></row><row><entry> </entry></row><row><entry>CGTGTGGGGCGCCGGCACCACCGTGACCGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCT</entry></row><row><entry> </entry></row><row><entry>CCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGG</entry></row><row><entry> </entry></row><row><entry>GAAGGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCG</entry></row><row><entry> </entry></row><row><entry>AAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCC</entry></row><row><entry> </entry></row><row><entry>TGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAG</entry></row><row><entry> </entry></row><row><entry>TAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGCTAGCACCAAGGGCCCATCG</entry></row><row><entry> </entry></row><row><entry>GTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGG</entry></row><row><entry> </entry></row><row><entry>TCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGT</entry></row><row><entry> </entry></row><row><entry>GCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTG</entry></row><row><entry> </entry></row><row><entry>CCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCA</entry></row><row><entry> </entry></row><row><entry>AGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGC</entry></row><row><entry> </entry></row><row><entry>ACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG</entry></row><row><entry> </entry></row><row><entry>ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCA</entry></row><row><entry> </entry></row><row><entry>AGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA</entry></row><row><entry> </entry></row><row><entry>GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGC</entry></row><row><entry> </entry></row><row><entry>AAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCA</entry></row><row><entry> </entry></row><row><entry>AAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGAC</entry></row><row><entry> </entry></row><row><entry>CAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAG</entry></row><row><entry> </entry></row><row><entry>TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACG</entry></row><row><entry> </entry></row><row><entry>GCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTT</entry></row><row><entry> </entry></row><row><entry>CTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCT</entry></row><row><entry> </entry></row><row><entry>CCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAG</entry></row><row><entry> </entry></row><row><entry>GCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAG</entry></row><row><entry> </entry></row><row><entry>CGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATT</entry></row><row><entry> </entry></row><row><entry>GCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCA</entry></row><row><entry> </entry></row><row><entry>GAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGT</entry></row><row><entry> </entry></row><row><entry>ATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACC</entry></row><row><entry> </entry></row><row><entry>CTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCG</entry></row><row><entry> </entry></row><row><entry>GTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGA</entry></row><row><entry> </entry></row><row><entry>CAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAG</entry></row><row><entry> </entry></row><row><entry>AAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCAT</entry></row><row><entry> </entry></row><row><entry>CAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGA</entry></row><row><entry> </entry></row><row><entry>TGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGC</entry></row><row><entry> </entry></row><row><entry>GGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGC</entry></row><row><entry> </entry></row><row><entry>TGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTC</entry></row><row><entry> </entry></row><row><entry>TGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAG</entry></row><row><entry> </entry></row><row><entry>TACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCA</entry></row><row><entry> </entry></row><row><entry>CCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGA</entry></row><row><entry> </entry></row><row><entry>CACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACC</entry></row><row><entry> </entry></row><row><entry>CTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCG</entry></row><row><entry> </entry></row><row><entry>GCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGA</entry></row><row><entry> </entry></row><row><entry>CAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAG</entry></row><row><entry> </entry></row><row><entry>AAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCAT</entry></row><row><entry> </entry></row><row><entry>CAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGG</entry></row><row><entry> </entry></row><row><entry>CGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTC</entry></row><row><entry> </entry></row><row><entry>GGCGGAGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;11:&#x2003;SI-38P12&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKRTVAAPSVFIFPPSDE</entry></row><row><entry> </entry></row><row><entry>QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE</entry></row><row><entry> </entry></row><row><entry>KHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;12:&#x2003;SI-38P12&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGG</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG</entry></row><row><entry> </entry></row><row><entry>CAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCA</entry></row><row><entry> </entry></row><row><entry>AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCA</entry></row><row><entry> </entry></row><row><entry>GGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAG</entry></row><row><entry> </entry></row><row><entry>AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCT</entry></row><row><entry> </entry></row><row><entry>TCAACAGGGGAGAGTGTTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;13:&#x2003;SI-38P13&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>QLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKG</entry></row><row><entry> </entry></row><row><entry>KATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSSGGGGSGGGG</entry></row><row><entry> </entry></row><row><entry>SQVQLQESGGRLVQPGEPLSLTCKTSGIDLSSNAIGWVRQAPGKGLEWIGVIFGSGNTYYASWA</entry></row><row><entry> </entry></row><row><entry>KGRFTISRSTSTVYLKMNSLRSEDTAIYYCARGGYSSDIWGQGTLVTVSSASTKGPSVFPLAPS</entry></row><row><entry> </entry></row><row><entry>SKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT</entry></row><row><entry> </entry></row><row><entry>QTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEV</entry></row><row><entry> </entry></row><row><entry>TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAV</entry></row><row><entry> </entry></row><row><entry>SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP</entry></row><row><entry> </entry></row><row><entry>ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTOKSLSLSPGGGGGS</entry></row><row><entry> </entry></row><row><entry>GGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGI</entry></row><row><entry> </entry></row><row><entry>TYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSG</entry></row><row><entry> </entry></row><row><entry>GGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPK</entry></row><row><entry> </entry></row><row><entry>LLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEI</entry></row><row><entry> </entry></row><row><entry>KGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISS</entry></row><row><entry> </entry></row><row><entry>GGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSG</entry></row><row><entry> </entry></row><row><entry>GGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPK</entry></row><row><entry> </entry></row><row><entry>LLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVE</entry></row><row><entry> </entry></row><row><entry>IK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;14:&#x2003;SI-38P13&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAGATCGTGCTGAGCCAGAGCCCCGCCATCCTGAGCGCCAGCCCCGGCGAGAAGGTGACCATGA</entry></row><row><entry> </entry></row><row><entry>CCTGCCGGGCCAGCAGCAGCGTGAGCTACATCCACTGGTTCCAGCAGAAGCCCGGCAGCAGCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCCCTGGATCTACGCCACCAGCAACCTGGCCAGCGGCGTGCCCGTGCGGTTCAGCGGCAGC</entry></row><row><entry> </entry></row><row><entry>GGCAGCGGCACCAGCTACAGCCTGACCATCAGCCGGGTGGAGGCCGAGGACGCCGCCACCTACT</entry></row><row><entry> </entry></row><row><entry>ACTGCCAGCAGTGGACCAGCAACCCCCCCACCTTCGGCGGCGGCACCAAGCTGACCGTGCTGGG</entry></row><row><entry> </entry></row><row><entry>TGGTGGTGGCTCTGGAGGAGGCGGGAGCGGGGGTGGTGGCTCAGGTGGTGGAGGTTCCCAGGTG</entry></row><row><entry> </entry></row><row><entry>CAGCTGCAGCAGCCCGGCGCCGAGCTGGTGAAGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGG</entry></row><row><entry> </entry></row><row><entry>CCAGCGGCTACACCTTCACCAGCTACAACATGCACTGGGTGAAGCAGACCCCCGGCCGGGGCCT</entry></row><row><entry> </entry></row><row><entry>GGAGTGGATCGGCGCCATCTACCCCGGCAACGGCGACACCAGCTACAACCAGAAGTTCAAGGGC</entry></row><row><entry> </entry></row><row><entry>AAGGCCACCCTGACCGCCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCA</entry></row><row><entry> </entry></row><row><entry>GCGAGGACAGCGCCGTGTACTACTGCGCCCGGAGCACCTACTACGGCGGCGACTGGTACTTCAA</entry></row><row><entry> </entry></row><row><entry>CGTGTGGGGCGCCGGCACCACCGTGACCGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGA</entry></row><row><entry> </entry></row><row><entry>TCACAAGTGCAGTTGCAAGAAAGTGGTGGTAGACTGGTTCAGCCTGGTGAACCCTTGTCACTGA</entry></row><row><entry> </entry></row><row><entry>CGTGTAAAACAAGCGGCATTGATCTGTCCTCTAACGCCATCGGATGGGTCCGACAGGCCCCAGG</entry></row><row><entry> </entry></row><row><entry>AAAAGGTCTGGAGTGGATCGGAGTTATCTTCGGGAGCGGCAATACATACTACGCAAGCTGGGCA</entry></row><row><entry> </entry></row><row><entry>AAAGGGCGATTTACGATATCACGGAGCACCTCTACAGTTTATTTGAAAATGAACTCCCTCCGGT</entry></row><row><entry> </entry></row><row><entry>CCGAGGATACCGCGATATATTACTGTGCCAGAGGGGGGTACTCCTCTGATATCTGGGGGCAGGG</entry></row><row><entry> </entry></row><row><entry>TACACTGGTTACAGTTTCATCCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCC</entry></row><row><entry> </entry></row><row><entry>TCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAAC</entry></row><row><entry> </entry></row><row><entry>CGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCT</entry></row><row><entry> </entry></row><row><entry>ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC</entry></row><row><entry> </entry></row><row><entry>CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGC</entry></row><row><entry> </entry></row><row><entry>CCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACC</entry></row><row><entry> </entry></row><row><entry>GTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACG</entry></row><row><entry> </entry></row><row><entry>GCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGT</entry></row><row><entry> </entry></row><row><entry>GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTC</entry></row><row><entry> </entry></row><row><entry>TCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAG</entry></row><row><entry> </entry></row><row><entry>AACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGAC</entry></row><row><entry> </entry></row><row><entry>CTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG</entry></row><row><entry> </entry></row><row><entry>GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCA</entry></row><row><entry> </entry></row><row><entry>AGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGA</entry></row><row><entry> </entry></row><row><entry>GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCC</entry></row><row><entry> </entry></row><row><entry>GGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT</entry></row><row><entry> </entry></row><row><entry>CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGT</entry></row><row><entry> </entry></row><row><entry>CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATC</entry></row><row><entry> </entry></row><row><entry>ACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGC</entry></row><row><entry> </entry></row><row><entry>TGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGC</entry></row><row><entry> </entry></row><row><entry>GTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGT</entry></row><row><entry> </entry></row><row><entry>GGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCC</entry></row><row><entry> </entry></row><row><entry>AGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCA</entry></row><row><entry> </entry></row><row><entry>GGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAG</entry></row><row><entry> </entry></row><row><entry>CTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT</entry></row><row><entry> </entry></row><row><entry>CTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTG</entry></row><row><entry> </entry></row><row><entry>CCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATC</entry></row><row><entry> </entry></row><row><entry>AAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCT</entry></row><row><entry> </entry></row><row><entry>TGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTA</entry></row><row><entry> </entry></row><row><entry>CCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGT</entry></row><row><entry> </entry></row><row><entry>GGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCA</entry></row><row><entry> </entry></row><row><entry>AGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGC</entry></row><row><entry> </entry></row><row><entry>GAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTG</entry></row><row><entry> </entry></row><row><entry>TGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCA</entry></row><row><entry> </entry></row><row><entry>GGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAG</entry></row><row><entry> </entry></row><row><entry>CTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT</entry></row><row><entry> </entry></row><row><entry>CTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTG</entry></row><row><entry> </entry></row><row><entry>TCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAG</entry></row><row><entry> </entry></row><row><entry>ATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;15:&#x2003;SI-38P13&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DPVLTQSPSSLSASVGDRVTISCQSSQSVAKNNNLAWFQQKPGQAPKLLIYSASTLAAGVPSRF</entry></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLTISSVQPEDFATYYCSARDSGNIQSFGGGTKVEIKRTVAAPSVFIFPPSDEQL</entry></row><row><entry> </entry></row><row><entry>KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH</entry></row><row><entry> </entry></row><row><entry>KVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQVTLKESGPGLVQPGQTLRLTCAF</entry></row><row><entry> </entry></row><row><entry>SGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVYLQMNSLD</entry></row><row><entry> </entry></row><row><entry>AEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSENVLTQSPASLS</entry></row><row><entry> </entry></row><row><entry>ASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGSGSGNDHTLTISS</entry></row><row><entry> </entry></row><row><entry>MEPEDFATYYCFQGSVYPFTFGQGTKVTVL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;16:&#x2003;SI-38P13&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GATCCAGTTCTGACACAAAGTCCATCCAGCCTGTCTGCCTCAGTCGGCGACAGAGTGACCATCA</entry></row><row><entry> </entry></row><row><entry>GTTGCCAGAGCTCACAGTCTGTGGCTAAGAACAACAACTTGGCGTGGTTCCAACAGAAACCTGG</entry></row><row><entry> </entry></row><row><entry>ACAGGCTCCGAAATTGCTGATCTATTCTGCTTCCACGCTTGCTGCTGGTGTTCCTTCCCGCTTT</entry></row><row><entry> </entry></row><row><entry>TCAGGTAGTGGTAGCGGGACAGACTTCACTTTGACTATAAGCAGCGTGCAGCCTGAAGATTTTG</entry></row><row><entry> </entry></row><row><entry>CGACCTACTATTGTTCTGCTAGAGACAGTGGAAATATTCAGTCCTTTGGGGGGGGAACGAAGGT</entry></row><row><entry> </entry></row><row><entry>CGAAATAAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG</entry></row><row><entry> </entry></row><row><entry>AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC</entry></row><row><entry> </entry></row><row><entry>AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG</entry></row><row><entry> </entry></row><row><entry>CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC</entry></row><row><entry> </entry></row><row><entry>AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA</entry></row><row><entry> </entry></row><row><entry>GGGGAGAGTGTGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCCAGGTCAC</entry></row><row><entry> </entry></row><row><entry>ATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTC</entry></row><row><entry> </entry></row><row><entry>AGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAG</entry></row><row><entry> </entry></row><row><entry>GTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAG</entry></row><row><entry> </entry></row><row><entry>TCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGAC</entry></row><row><entry> </entry></row><row><entry>GCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATT</entry></row><row><entry> </entry></row><row><entry>GGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGG</entry></row><row><entry> </entry></row><row><entry>CGGTGGCGGCTCCGGTGGAGGCGGCTCTGAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGT</entry></row><row><entry> </entry></row><row><entry>GCCTCACCTGGGGAAAGGGTAACTATCACTTGCTCTGCATCAAGCAGCGTCTCATACATGCATT</entry></row><row><entry> </entry></row><row><entry>GGTATCAACAAAAGCCTGGACAGGCCCCCAAGCTCTGGATATACGATACGAGCAAGCTGGCTTC</entry></row><row><entry> </entry></row><row><entry>CGGCGTACCTAGCCGCTTCAGTGGTTCCGGCTCAGGCAACGATCACACCCTTACGATTTCCAGT</entry></row><row><entry> </entry></row><row><entry>ATGGAACCCGAAGATTTTGCAACTTATTATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCG</entry></row><row><entry> </entry></row><row><entry>GGCAGGGGACAAAAGTGACGGTACTGTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;17:&#x2003;SI-49P1&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKLTVLGGGGSGGGGSGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLVESGGGLVQPGGSLRLSCTASGFTISTNAMSWVRQAPGKCLEWVGVITGRDITYYA</entry></row><row><entry> </entry></row><row><entry>SWAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSTGGGG</entry></row><row><entry> </entry></row><row><entry>SGGGGSQVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGAS</entry></row><row><entry> </entry></row><row><entry>SYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSSAST</entry></row><row><entry> </entry></row><row><entry>KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry> </entry></row><row><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPK</entry></row><row><entry> </entry></row><row><entry>DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQD</entry></row><row><entry> </entry></row><row><entry>WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD</entry></row><row><entry> </entry></row><row><entry>IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS</entry></row><row><entry> </entry></row><row><entry>LSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKCLEW</entry></row><row><entry> </entry></row><row><entry>IACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLN</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVD</entry></row><row><entry> </entry></row><row><entry>NVFGCGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPG</entry></row><row><entry> </entry></row><row><entry>KCLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLS</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYV</entry></row><row><entry> </entry></row><row><entry>GGAFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;18:&#x2003;SI-49P1&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGATGACCCAGAGCCCCAGCACCCTGAGCGCCAGCGTGGGCGACAGGGTGATCATCA</entry></row><row><entry> </entry></row><row><entry>CCTGCCAGGCCAGCGAGAGCATCAGCAGCTGGCTGGCCTGGTACCAGCAGAAGCCCGGCAAGGC</entry></row><row><entry> </entry></row><row><entry>CCCCAAGCTGCTGATCTACGAGGCCAGCAAGCTGGCCAGCGGCGTGCCCAGCAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGCGGCAGCGGCGCCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCCGACGACTTCGCCACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAGGGCTACTTCTACTTCATCAGCAGGACCTACGTGAACAGCTTCGGCTGCGGCAC</entry></row><row><entry> </entry></row><row><entry>CAAGCTGACCGTGCTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGAGGATCAGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCC</entry></row><row><entry> </entry></row><row><entry>TGAGGCTGAGCTGCACCGCCAGCGGCTTCACCATCAGCACCAACGCCATGAGCTGGGTGAGGCA</entry></row><row><entry> </entry></row><row><entry>GGCCCCCGGCAAGTGCCTGGAGTGGGTGGGCGTGATCACCGGCAGGGACATCACCTACTACGCC</entry></row><row><entry> </entry></row><row><entry>AGCTGGGCCAAGGGCAGGTTCACCATCAGCAGGGACACCAGCAAGAACACCGTGTACCTGCAGA</entry></row><row><entry> </entry></row><row><entry>TGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGGCGGCAGCAGCGC</entry></row><row><entry> </entry></row><row><entry>CATCACCAGCAACAACATCTGGGGCCAGGGCACCCTGGTGACCGTGTCGACAGGCGGTGGAGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCGGTGGTGGATCACAGGTACAACTGCAGCAGTCTGGGCCTGAGCTGGAGAAGCCTGGCG</entry></row><row><entry> </entry></row><row><entry>CTTCAGTGAAGATATCCTGCAAGGCTTCTGGTTACTCATTCACTGGCTACACCATGAACTGGGT</entry></row><row><entry> </entry></row><row><entry>GAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGACTTATTACTCCTTACAATGGTGCTTCT</entry></row><row><entry> </entry></row><row><entry>AGCTACAACCAGAAGTTCAGGGGCAAGGCCACATTAACTGTAGACAAGTCATCCAGCACAGCCT</entry></row><row><entry> </entry></row><row><entry>ACATGGACCTCCTCAGTCTGACATCTGAAGACTCTGCAGTCTATTTCTGTGCAAGGGGGGGTTA</entry></row><row><entry> </entry></row><row><entry>CGACGGGAGGGGTTTTGACTACTGGGGATCCGGGACCCCGGTCACCGTCTCCTCAGCTAGCACC</entry></row><row><entry> </entry></row><row><entry>AAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCC</entry></row><row><entry> </entry></row><row><entry>TGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCT</entry></row><row><entry> </entry></row><row><entry>GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC</entry></row><row><entry> </entry></row><row><entry>GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC</entry></row><row><entry> </entry></row><row><entry>CCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC</entry></row><row><entry> </entry></row><row><entry>ACCGTGCCCAGCACCTGAAGCCGCGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG</entry></row><row><entry> </entry></row><row><entry>GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAG</entry></row><row><entry> </entry></row><row><entry>ACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC</entry></row><row><entry> </entry></row><row><entry>GCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC</entry></row><row><entry> </entry></row><row><entry>TGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA</entry></row><row><entry> </entry></row><row><entry>AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG</entry></row><row><entry> </entry></row><row><entry>GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGAC</entry></row><row><entry> </entry></row><row><entry>ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGC</entry></row><row><entry> </entry></row><row><entry>TGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA</entry></row><row><entry> </entry></row><row><entry>GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGG</entry></row><row><entry> </entry></row><row><entry>AGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT</entry></row><row><entry> </entry></row><row><entry>CTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGTGCCTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>ATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGT</entry></row><row><entry> </entry></row><row><entry>TCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA</entry></row><row><entry> </entry></row><row><entry>GGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGTGGAAGTGGTG</entry></row><row><entry> </entry></row><row><entry>GTGGCGGCTCTGGAGGCGGCGGATCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAAC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAG</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGAT</entry></row><row><entry> </entry></row><row><entry>AATGTTTTCGGCTGCGGGACCAAGGTGGAGATCAAAGGTGGTGGCGGCTCTGGAGGAGGAGGGT</entry></row><row><entry> </entry></row><row><entry>CCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTC</entry></row><row><entry> </entry></row><row><entry>CTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGGCAGGCACCTGGG</entry></row><row><entry> </entry></row><row><entry>AAGTGCCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTA</entry></row><row><entry> </entry></row><row><entry>GAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCT</entry></row><row><entry> </entry></row><row><entry>GAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCG</entry></row><row><entry> </entry></row><row><entry>GCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGA</entry></row><row><entry> </entry></row><row><entry>CTTGGAACCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTT</entry></row><row><entry> </entry></row><row><entry>GGCGGTGCTTTCGGCTGTGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;19:&#x2003;SI-49P1&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIKRTVAAPSVFIFPPSDEQLKSGT</entry></row><row><entry> </entry></row><row><entry>ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA</entry></row><row><entry> </entry></row><row><entry>CEVTHQGLSSPVTKSFNRGECGGGGSGGGGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNC</entry></row><row><entry> </entry></row><row><entry>YQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSIL</entry></row><row><entry> </entry></row><row><entry>SPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTVGGGGSGGGGSGGGGSGGGGSFL</entry></row><row><entry> </entry></row><row><entry>NSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQ</entry></row><row><entry> </entry></row><row><entry>DLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPN</entry></row><row><entry> </entry></row><row><entry>TYICMQRTV</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;20:&#x2003;SI-49P1&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACATCGAGCTCACTCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATGA</entry></row><row><entry> </entry></row><row><entry>CCTGCAGTGCCAGCTCAAGTGTAAGTTACATGCACTGGTACCAGCAGAAGTCAGGCACCTCCCC</entry></row><row><entry> </entry></row><row><entry>CAAAAGATGGATTTATGACACATCCAAACTGGCTTCTGGAGTCCCAGGTCGCTTCAGTGGCAGT</entry></row><row><entry> </entry></row><row><entry>GGGTCTGGAAACTCTTACTCTCTCACAATCAGCAGCGTGGAGGCTGAAGATGATGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ACTGCCAGCAGTGGAGTAAGCACCCTCTCACGTTCGGATCCGGGACCAAGGTGGAAATCAAACG</entry></row><row><entry> </entry></row><row><entry>TACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT</entry></row><row><entry> </entry></row><row><entry>GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG</entry></row><row><entry> </entry></row><row><entry>ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC</entry></row><row><entry> </entry></row><row><entry>CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCC</entry></row><row><entry> </entry></row><row><entry>TGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTG</entry></row><row><entry> </entry></row><row><entry>GCGGTGGAGGGTCCGGCGGTGGTGGATCCTTTCTTAATTCCCTTTTCAACCAAGAGGTTCAGAT</entry></row><row><entry> </entry></row><row><entry>CCCCTTGACTGAAAGCTATTGCGGCCCTTGTCCGAAAAACTGGATATGTTACAAGAATAATTGT</entry></row><row><entry> </entry></row><row><entry>TAGCAATTCTTCGAGGAAAGCAAGAACTGGTATGAGAGTGAGGCGTCTTGTATGAGTCAGAATG</entry></row><row><entry> </entry></row><row><entry>CCAGCCTGCTTAAGGTTTATTCAAAAGAAGACCAGGATCTGCTTAAGTTGGTAAAGAGCTACCA</entry></row><row><entry> </entry></row><row><entry>CTGGATGGGGCTGGTACATATCCCAACGAATGGGTCATGGCAGTGGGAGGACGGTTCTATTCTG</entry></row><row><entry> </entry></row><row><entry>AGTCCAAATCTCCTGACGATCATCGAAATGCAGAAAGGGGACTGTGCCCTGTATGCATCATCCT</entry></row><row><entry> </entry></row><row><entry>TCAAGGGGTACATCGAGAACTGCAGTACCCCAAATACCTACATTTGTATGCAAAGAACGGTTGG</entry></row><row><entry> </entry></row><row><entry>AGGCGGTGGCTCAGGCGGAGGCGGCTCAGGAGGTGGCGGTTCAGGAGGCGGCGGATCTTTCCTA</entry></row><row><entry> </entry></row><row><entry>AACTCATTATTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACTGTGGCCCATGTCCTA</entry></row><row><entry> </entry></row><row><entry>AAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAGTAAAAACTGGTATGA</entry></row><row><entry> </entry></row><row><entry>GAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATACAGCAAAGAGGACCAG</entry></row><row><entry> </entry></row><row><entry>GATTTAGTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATGGAT</entry></row><row><entry> </entry></row><row><entry>CTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAATAATTGAAATGCAGAA</entry></row><row><entry> </entry></row><row><entry>GGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAACTGTTCAACTCCAAAT</entry></row><row><entry> </entry></row><row><entry>ACGTAGATCTGCATGCAAAGGACTGTGTAG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;21:&#x2003;SI-49P3&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKLTVLGGGGSGGGGSGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLVESGGGLVQPGGSLRLSCTASGFTISTNAMSWVRQAPGKCLEWVGVITGRDITYYA</entry></row><row><entry> </entry></row><row><entry>SWAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSTGGGG</entry></row><row><entry> </entry></row><row><entry>SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT</entry></row><row><entry> </entry></row><row><entry>RYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSAS</entry></row><row><entry> </entry></row><row><entry>TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS</entry></row><row><entry> </entry></row><row><entry>SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKP</entry></row><row><entry> </entry></row><row><entry>KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQ</entry></row><row><entry> </entry></row><row><entry>DWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPS</entry></row><row><entry> </entry></row><row><entry>DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQK</entry></row><row><entry> </entry></row><row><entry>SLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKCLE</entry></row><row><entry> </entry></row><row><entry>WIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDL</entry></row><row><entry> </entry></row><row><entry>WGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHL</entry></row><row><entry> </entry></row><row><entry>NWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNV</entry></row><row><entry> </entry></row><row><entry>DNVFGCGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAP</entry></row><row><entry> </entry></row><row><entry>GKCLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPM</entry></row><row><entry> </entry></row><row><entry>WGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYL</entry></row><row><entry> </entry></row><row><entry>SWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDY</entry></row><row><entry> </entry></row><row><entry>VGGAFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;22:&#x2003;SI-49P3&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGATGACCCAGAGCCCCAGCACCCTGAGCGCCAGCGTGGGCGACAGGGTGATCATCA</entry></row><row><entry> </entry></row><row><entry>CCTGCCAGGCCAGCGAGAGCATCAGCAGCTGGCTGGCCTGGTACCAGCAGAAGCCCGGCAAGGC</entry></row><row><entry> </entry></row><row><entry>CCCCAAGCTGCTGATCTACGAGGCCAGCAAGCTGGCCAGCGGCGTGCCCAGCAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGCGGCAGCGGCGCCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCCGACGACTTCGCCACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAGGGCTACTTCTACTTCATCAGCAGGACCTACGTGAACAGCTTCGGCTGCGGCAC</entry></row><row><entry> </entry></row><row><entry>CAAGCTGACCGTGCTGGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGAGGATCAGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCC</entry></row><row><entry> </entry></row><row><entry>TGAGGCTGAGCTGCACCGCCAGCGGCTTCACCATCAGCACCAACGCCATGAGCTGGGTGAGGCA</entry></row><row><entry> </entry></row><row><entry>GGCCCCCGGCAAGTGCCTGGAGTGGGTGGGCGTGATCACCGGCAGGGACATCACCTACTACGCC</entry></row><row><entry> </entry></row><row><entry>AGCTGGGCCAAGGGCAGGTTCACCATCAGCAGGGACACCAGCAAGAACACCGTGTACCTGCAGA</entry></row><row><entry> </entry></row><row><entry>TGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGGCGGCAGCAGCGC</entry></row><row><entry> </entry></row><row><entry>CATCACCAGCAACAACATCTGGGGCCAGGGCACCCTGGTGACCGTGTCGACAGGCGGTGGAGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCGGTGGTGGATCAGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGG</entry></row><row><entry> </entry></row><row><entry>GCTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTTCAACATTAAAGACACCTATATACACTGGGT</entry></row><row><entry> </entry></row><row><entry>GCGTCAGGCCCCGGGTAAGGGCCTGGAATGGGTTGCAAGGATTTATCCTACGAATGGTTATACT</entry></row><row><entry> </entry></row><row><entry>AGATATGCCGATAGCGTCAAGGGCCGTTTCACTATAAGCGCAGACACATCCAAAAACACAGCCT</entry></row><row><entry> </entry></row><row><entry>ACCTGCAGATGAACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTTCTAGATGGGGAGG</entry></row><row><entry> </entry></row><row><entry>GGACGGCTTCTATGCTATGGACTACTGGGGTCAAGGAACCCTGGTCACCGTCTCCTCGGCTAGC</entry></row><row><entry> </entry></row><row><entry>ACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGG</entry></row><row><entry> </entry></row><row><entry>CCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGC</entry></row><row><entry> </entry></row><row><entry>CCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGC</entry></row><row><entry> </entry></row><row><entry>AGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACA</entry></row><row><entry> </entry></row><row><entry>AGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATG</entry></row><row><entry> </entry></row><row><entry>CCCACCGTGCCCAGCACCTGAAGCCGCGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCC</entry></row><row><entry> </entry></row><row><entry>AAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACG</entry></row><row><entry> </entry></row><row><entry>AAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA</entry></row><row><entry> </entry></row><row><entry>GCCGCGGGAGGAGCAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAG</entry></row><row><entry> </entry></row><row><entry>GACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCG</entry></row><row><entry> </entry></row><row><entry>AGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATC</entry></row><row><entry> </entry></row><row><entry>CCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGC</entry></row><row><entry> </entry></row><row><entry>GACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCG</entry></row><row><entry> </entry></row><row><entry>TGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCA</entry></row><row><entry> </entry></row><row><entry>GCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAG</entry></row><row><entry> </entry></row><row><entry>AGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGT</entry></row><row><entry> </entry></row><row><entry>TGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGG</entry></row><row><entry> </entry></row><row><entry>ATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGTGCCTGGAG</entry></row><row><entry> </entry></row><row><entry>TGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCC</entry></row><row><entry> </entry></row><row><entry>GGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGC</entry></row><row><entry> </entry></row><row><entry>CGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTC</entry></row><row><entry> </entry></row><row><entry>TGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGTGGAAGTG</entry></row><row><entry> </entry></row><row><entry>GTGGTGGCGGCTCTGGAGGCGGCGGATCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTC</entry></row><row><entry> </entry></row><row><entry>TGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTA</entry></row><row><entry> </entry></row><row><entry>AACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGG</entry></row><row><entry> </entry></row><row><entry>CATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAG</entry></row><row><entry> </entry></row><row><entry>CAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTT</entry></row><row><entry> </entry></row><row><entry>GATAATGTTTTCGGCTGCGGGACCAAGGTGGAGATCAAAGGTGGTGGCGGCTCTGGAGGAGGAG</entry></row><row><entry> </entry></row><row><entry>GGTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACT</entry></row><row><entry> </entry></row><row><entry>CTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGGCAGGCACCT</entry></row><row><entry> </entry></row><row><entry>GGGAAGTGCCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCG</entry></row><row><entry> </entry></row><row><entry>CTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAG</entry></row><row><entry> </entry></row><row><entry>CCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATG</entry></row><row><entry> </entry></row><row><entry>TGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTG</entry></row><row><entry> </entry></row><row><entry>GCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTC</entry></row><row><entry> </entry></row><row><entry>TGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTA</entry></row><row><entry> </entry></row><row><entry>TCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGG</entry></row><row><entry> </entry></row><row><entry>CATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAG</entry></row><row><entry> </entry></row><row><entry>CGACTTGGAACCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTAT</entry></row><row><entry> </entry></row><row><entry>GTTGGCGGTGCTTTCGGCTGTGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;23:&#x2003;SI-49P3&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG</entry></row><row><entry> </entry></row><row><entry>TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY</entry></row><row><entry> </entry></row><row><entry>ACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNN</entry></row><row><entry> </entry></row><row><entry>CYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSI</entry></row><row><entry> </entry></row><row><entry>LSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTVGGGGSGGGGSGGGGSGGGGSF</entry></row><row><entry> </entry></row><row><entry>LNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKED</entry></row><row><entry> </entry></row><row><entry>QDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTP</entry></row><row><entry> </entry></row><row><entry>NTYICMQRTV</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;24:&#x2003;SI-49P3&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GATATCCAGATGACCCAGTCCCCGAGCTCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>CCTGCCGTGCCAGTCAGGATGTGAATACTGCTGTAGCCTGGTATCAACAGAAACCAGGAAAAGC</entry></row><row><entry> </entry></row><row><entry>TCCGAAACTACTGATTTACTCGGCATCCTTCCTCTACTCTGGAGTCCCTTCTCGCTTCTCTGGC</entry></row><row><entry> </entry></row><row><entry>TCCAGATCTGGGACGGATTTCACTCTGACCATCAGCAGTCTGCAGCCGGAAGACTTCGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGTCAGCAACATTATACTACTCCTCCCACGTTCGGACAGGGTACCAAGGTGGAGATCAA</entry></row><row><entry> </entry></row><row><entry>ACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA</entry></row><row><entry> </entry></row><row><entry>ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGG</entry></row><row><entry> </entry></row><row><entry>TGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG</entry></row><row><entry> </entry></row><row><entry>CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC</entry></row><row><entry> </entry></row><row><entry>GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT</entry></row><row><entry> </entry></row><row><entry>GTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCTTTCTTAATTCCCTTTTCAACCAAGAGGTTCA</entry></row><row><entry> </entry></row><row><entry>GATCCCCTTGACTGAAAGCTATTGCGGCCCTTGTCCGAAAAACTGGATATGTTACAAGAATAAT</entry></row><row><entry> </entry></row><row><entry>TGTTACCAATTCTTCGAGGAAAGCAAGAACTGGTATGAGAGTGAGGCGTCTTGTATGAGTGAGA</entry></row><row><entry> </entry></row><row><entry>ATGCCAGCCTGCTTAAGGTTTATTCAAAAGAAGACCAGGATCTGCTTAAGTTGGTAAAGAGCTA</entry></row><row><entry> </entry></row><row><entry>CCACTGGATGGGGCTGGTACATATCCCAACGAATGGGTCATGGCAGTGGGAGGACGGTTCTATT</entry></row><row><entry> </entry></row><row><entry>CTGAGTCCAAATCTCCTGACGATCATCGAAATGCAGAAAGGGGACTGTGCCCTGTATGCATCAT</entry></row><row><entry> </entry></row><row><entry>CCTTCAAGGGGTACATCGAGAACTGCAGTACCCCAAATACCTACATTTGTATGCAAAGAACGGT</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTGGCTCAGGCGGAGGCGGCTCAGGAGGTGGCGGTTCAGGAGGCGGCGGATCTTTC</entry></row><row><entry> </entry></row><row><entry>CTAAACTCATTATTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACTGTGGCCCATGTC</entry></row><row><entry> </entry></row><row><entry>CTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAGTAAAAACTGGTA</entry></row><row><entry> </entry></row><row><entry>TGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATACAGCAAAGAGGAC</entry></row><row><entry> </entry></row><row><entry>CAGGATTTAGTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACATTCCAACAAATG</entry></row><row><entry> </entry></row><row><entry>GATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAATAATTGAAATGCA</entry></row><row><entry> </entry></row><row><entry>GAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAACTGTTCAACTCCA</entry></row><row><entry> </entry></row><row><entry>AATACGTAGATCTGCATGCAAAGGACTGTGTAG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;25:&#x2003;SI-55P3&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCRASQSIGTNIHWYQQKPGKAPKLLIYYASESISGIPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQQNNNWPTTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSE</entry></row><row><entry> </entry></row><row><entry>VQLVESGGGLVQPGGSLRLSCSVSGFSLTNYGVHWVRQAPGKGLEWVGVIWSGGNTDYNTPFTS</entry></row><row><entry> </entry></row><row><entry>RFTISRDTSKNTVYLQMNSLRAEDTAVYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>QVQLQESGGRLVQPGEPLSLTCKTSGIDLSSNAIGWVRQAPGKGLEWIGVIFGSGNTYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRSTSTVYLKMNSLRSEDTAIYYCARGGYSSDIWGQGTLVTVSSASTKGPSVFPLAPSS</entry></row><row><entry> </entry></row><row><entry>KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ</entry></row><row><entry> </entry></row><row><entry>TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVT</entry></row><row><entry> </entry></row><row><entry>CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVS</entry></row><row><entry> </entry></row><row><entry>NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE</entry></row><row><entry> </entry></row><row><entry>NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGIT</entry></row><row><entry> </entry></row><row><entry>YDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGG</entry></row><row><entry> </entry></row><row><entry>GGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKL</entry></row><row><entry> </entry></row><row><entry>LIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>GGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSG</entry></row><row><entry> </entry></row><row><entry>GNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSGG</entry></row><row><entry> </entry></row><row><entry>GGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKL</entry></row><row><entry> </entry></row><row><entry>LIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEI</entry></row><row><entry> </entry></row><row><entry>K</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;26:&#x2003;SI-55P3&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTTATGACACAGTCCCCATCCACTCTTAGCGCTTCTGTAGGGGATCGAGTGATTATCA</entry></row><row><entry> </entry></row><row><entry>CATGCCGGGCCTCCCAATCCATAGGAACCAACATACACTGGTATCAACAAAAACCAGGCAAAGC</entry></row><row><entry> </entry></row><row><entry>GCCAAAACTGCTTATCTACTACGCCTCCGAGAGTATTTCTGGAATCCCGAGTCGCTTCTCAGGT</entry></row><row><entry> </entry></row><row><entry>TCTGGAAGCGGCGCTGAGTTTACCCTCACAATTTCTTCACTCCAACCGGATGACTTCGCTACAT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAAAACAATAATTGGCCGACGACCTTTGGCCAGGGCACGAAACTTACGGTACT</entry></row><row><entry> </entry></row><row><entry>TGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGAA</entry></row><row><entry> </entry></row><row><entry>GTACAGCTTGTCGAGTCCGGTGGGGGGCTTGTTCAGCCAGGGGGTTCCTTGAGGCTTTCCTGCT</entry></row><row><entry> </entry></row><row><entry>CCGTCTCTGGGTTTAGCTTGACGAATTACGGCGTTCACTGGGTTAGACAAGCACCGGGGAAGGG</entry></row><row><entry> </entry></row><row><entry>GCTGGAATGGGTCGGTGTGATATGGTCCGGGGGTAATACGGATTACAATACACCTTTCACGTCA</entry></row><row><entry> </entry></row><row><entry>CGCTTTACGATTAGCAGGGACACGTCAAAAAATACAGTCTACTTGCAGATGAACTCTCTTAGGG</entry></row><row><entry> </entry></row><row><entry>CGGAAGATACTGCAGTTTATTACTGCGCAAGGGCTCTGACATACTACGATTATGAATTTGCATA</entry></row><row><entry> </entry></row><row><entry>TTGGGGCCAGGGGACTTTGGTCACGGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>CAAGTGCAGTTGCAAGAAAGTGGTGGTAGACTGGTTCAGCCTGGTGAACCCTTGTCACTGACGT</entry></row><row><entry> </entry></row><row><entry>GTAAAACAAGCGGCATTGATCTGTCCTCTAACGCCATCGGATGGGTCCGACAGGCCCCAGGAAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTGGAGTGGATCGGAGTTATCTTCGGGAGCGGCAATACATACTACGCAAGCTGGGCAAAA</entry></row><row><entry> </entry></row><row><entry>GGGCGATTTACGATATCACGGAGCACCTCTACAGTTTATTTGAAAATGAACTCCCTCCGGTCCG</entry></row><row><entry> </entry></row><row><entry>AGGATACCGCGATATATTACTGTGCCAGAGGGGGGTACTCCTCTGATATCTGGGGGCAGGGTAC</entry></row><row><entry> </entry></row><row><entry>ACTGGTTACAGTTTCATCCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCC</entry></row><row><entry> </entry></row><row><entry>AAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG</entry></row><row><entry> </entry></row><row><entry>TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA</entry></row><row><entry> </entry></row><row><entry>GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAG</entry></row><row><entry> </entry></row><row><entry>ACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCA</entry></row><row><entry> </entry></row><row><entry>AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTC</entry></row><row><entry> </entry></row><row><entry>AGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA</entry></row><row><entry> </entry></row><row><entry>TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG</entry></row><row><entry> </entry></row><row><entry>TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGT</entry></row><row><entry> </entry></row><row><entry>CAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCC</entry></row><row><entry> </entry></row><row><entry>AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC</entry></row><row><entry> </entry></row><row><entry>CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTG</entry></row><row><entry> </entry></row><row><entry>CCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG</entry></row><row><entry> </entry></row><row><entry>AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGC</entry></row><row><entry> </entry></row><row><entry>TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGC</entry></row><row><entry> </entry></row><row><entry>TCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>TGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCG</entry></row><row><entry> </entry></row><row><entry>CCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACT</entry></row><row><entry> </entry></row><row><entry>TACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGT</entry></row><row><entry> </entry></row><row><entry>ATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTT</entry></row><row><entry> </entry></row><row><entry>TTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGA</entry></row><row><entry> </entry></row><row><entry>GGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGA</entry></row><row><entry> </entry></row><row><entry>TGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGC</entry></row><row><entry> </entry></row><row><entry>CAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTC</entry></row><row><entry> </entry></row><row><entry>CTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTG</entry></row><row><entry> </entry></row><row><entry>GGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCA</entry></row><row><entry> </entry></row><row><entry>ACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAA</entry></row><row><entry> </entry></row><row><entry>GGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGG</entry></row><row><entry> </entry></row><row><entry>TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCA</entry></row><row><entry> </entry></row><row><entry>CATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGT</entry></row><row><entry> </entry></row><row><entry>GGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGA</entry></row><row><entry> </entry></row><row><entry>ACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAG</entry></row><row><entry> </entry></row><row><entry>AGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGT</entry></row><row><entry> </entry></row><row><entry>GGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGA</entry></row><row><entry> </entry></row><row><entry>TGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGC</entry></row><row><entry> </entry></row><row><entry>CAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTC</entry></row><row><entry> </entry></row><row><entry>CTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTG</entry></row><row><entry> </entry></row><row><entry>GGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCA</entry></row><row><entry> </entry></row><row><entry>GTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATC</entry></row><row><entry> </entry></row><row><entry>AAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;27:&#x2003;SI-55P3&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DPVLTQSPSSLSASVGDRVTISCQSSQSVAKNNNLAWFQQKPGQAPKLLIYSASTLAAGVPSRF</entry></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLTISSVQPEDFATYYCSARDSGNIQSFGGGTKVEIKRTVAAPSVFIFPPSDEQL</entry></row><row><entry> </entry></row><row><entry>KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH</entry></row><row><entry> </entry></row><row><entry>KVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;28:&#x2003;SI-55P3&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGG</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCC</entry></row><row><entry> </entry></row><row><entry>GATCCAGTTCTGACACAAAGTCCATCCAGCCTGTCTGCCTCAGTCGGCGACAGAGTGACCATCA</entry></row><row><entry> </entry></row><row><entry>GTTGCCAGAGCTCACAGTCTGTGGCTAAGAACAACAACTTGGCGTGGTTCCAACAGAAACCTGG</entry></row><row><entry> </entry></row><row><entry>ACAGGCTCCGAAATTGCTGATCTATTCTGCTTCCACGCTTGCTGCTGGTGTTCCTTCCCGCTTT</entry></row><row><entry> </entry></row><row><entry>TCAGGTAGTGGTAGCGGGACAGACTTCACTTTGACTATAAGCAGCGTGCAGCCTGAAGATTTTG</entry></row><row><entry> </entry></row><row><entry>CGACCTACTATTGTTCTGCTAGAGACAGTGGAAATATTCAGTCCTTTGGGGGGGGAACGAAGGT</entry></row><row><entry> </entry></row><row><entry>CGAAATAAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG</entry></row><row><entry> </entry></row><row><entry>AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC</entry></row><row><entry> </entry></row><row><entry>AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG</entry></row><row><entry> </entry></row><row><entry>CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC</entry></row><row><entry> </entry></row><row><entry>AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA</entry></row><row><entry> </entry></row><row><entry>GGGGAGAGTGTTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;29:&#x2003;SI-55P4&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCRASQSIGTNIHWYQQKPGKAPKLLIYYASESISGIPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQQNNNWPTTFGQGTKLTVLGGGGSGGGGSGGGGSGGGGSE</entry></row><row><entry> </entry></row><row><entry>VQLVESGGGLVQPGGSLRLSCSVSGFSLTNYGVHWVRQAPGKGLEWVGVIWSGGNTDYNTPFTS</entry></row><row><entry> </entry></row><row><entry>RFTISRDTSKNTVYLQMNSLRAEDTAVYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>QVQLQESGGRLVQPGEPLSLTCKTSGIDLSSNAIGWVRQAPGKGLEWIGVIFGSGNTYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRSTSTVYLKMNSLRSEDTAIYYCARGGYSSDIWGQGTLVTVSSASTKGPSVFPLAPSS</entry></row><row><entry> </entry></row><row><entry>KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ</entry></row><row><entry> </entry></row><row><entry>TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVT</entry></row><row><entry> </entry></row><row><entry>CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVS</entry></row><row><entry> </entry></row><row><entry>NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE</entry></row><row><entry> </entry></row><row><entry>NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGIT</entry></row><row><entry> </entry></row><row><entry>YDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGG</entry></row><row><entry> </entry></row><row><entry>GGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKL</entry></row><row><entry> </entry></row><row><entry>LIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>GGGGSGGGGSGREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGG</entry></row><row><entry> </entry></row><row><entry>LSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP</entry></row><row><entry> </entry></row><row><entry>ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLGST</entry></row><row><entry> </entry></row><row><entry>GSGSKPGSGEGSTKGREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVS</entry></row><row><entry> </entry></row><row><entry>LTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTV</entry></row><row><entry> </entry></row><row><entry>DLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAG</entry></row><row><entry> </entry></row><row><entry>LGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGG</entry></row><row><entry> </entry></row><row><entry>LSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP</entry></row><row><entry> </entry></row><row><entry>ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;30:&#x2003;SI-55P4&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTTATGACACAGTCCCCATCCACTCTTAGCGCTTCTGTAGGGGATCGAGTGATTATCA</entry></row><row><entry> </entry></row><row><entry>CATGCCGGGCCTCCCAATCCATAGGAACCAACATACACTGGTATCAACAAAAACCAGGCAAAGC</entry></row><row><entry> </entry></row><row><entry>GCCAAAACTGCTTATCTACTACGCCTCCGAGAGTATTTCTGGAATCCCGAGTCGCTTCTCAGGT</entry></row><row><entry> </entry></row><row><entry>TCTGGAAGCGGCGCTGAGTTTACCCTCACAATTTCTTCACTCCAACCGGATGACTTCGCTACAT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAAAACAATAATTGGCCGACGACCTTTGGCCAGGGCACGAAACTTACGGTACT</entry></row><row><entry> </entry></row><row><entry>TGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGAA</entry></row><row><entry> </entry></row><row><entry>GTACAGCTTGTCGAGTCCGGTGGGGGGCTTGTTCAGCCAGGGGGTTCCTTGAGGCTTTCCTGCT</entry></row><row><entry> </entry></row><row><entry>CCGTCTCTGGGTTTAGCTTGACGAATTACGGCGTTCACTGGGTTAGACAAGCACCGGGGAAGGG</entry></row><row><entry> </entry></row><row><entry>GCTGGAATGGGTCGGTGTGATATGGTCCGGGGGTAATACGGATTACAATACACCTTTCACGTCA</entry></row><row><entry> </entry></row><row><entry>CGCTTTACGATTAGCAGGGACACGTCAAAAAATACAGTCTACTTGCAGATGAACTCTCTTAGGG</entry></row><row><entry> </entry></row><row><entry>CGGAAGATACTGCAGTTTATTACTGCGCAAGGGCTCTGACATACTACGATTATGAATTTGCATA</entry></row><row><entry> </entry></row><row><entry>TTGGGGCCAGGGGACTTTGGTCACGGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>CAAGTGCAGTTGCAAGAAAGTGGTGGTAGACTGGTTCAGCCTGGTGAACCCTTGTCACTGACGT</entry></row><row><entry> </entry></row><row><entry>GTAAAACAAGCGGCATTGATCTGTCCTCTAACGCCATCGGATGGGTCCGACAGGCCCCAGGAAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTGGAGTGGATCGGAGTTATCTTCGGGAGCGGCAATACATACTACGCAAGCTGGGCAAAA</entry></row><row><entry> </entry></row><row><entry>GGGCGATTTACGATATCACGGAGCACCTCTACAGTTTATTTGAAAATGAACTCCCTCCGGTCCG</entry></row><row><entry> </entry></row><row><entry>AGGATACCGCGATATATTACTGTGCCAGAGGGGGGTACTCCTCTGATATCTGGGGGCAGGGTAC</entry></row><row><entry> </entry></row><row><entry>ACTGGTTACAGTTTCATCCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCC</entry></row><row><entry> </entry></row><row><entry>AAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG</entry></row><row><entry> </entry></row><row><entry>TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA</entry></row><row><entry> </entry></row><row><entry>GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAG</entry></row><row><entry> </entry></row><row><entry>ACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCA</entry></row><row><entry> </entry></row><row><entry>AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTC</entry></row><row><entry> </entry></row><row><entry>AGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA</entry></row><row><entry> </entry></row><row><entry>TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG</entry></row><row><entry> </entry></row><row><entry>TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGT</entry></row><row><entry> </entry></row><row><entry>CAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCC</entry></row><row><entry> </entry></row><row><entry>AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC</entry></row><row><entry> </entry></row><row><entry>CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTG</entry></row><row><entry> </entry></row><row><entry>CCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG</entry></row><row><entry> </entry></row><row><entry>AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGC</entry></row><row><entry> </entry></row><row><entry>TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGC</entry></row><row><entry> </entry></row><row><entry>TCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>TGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCG</entry></row><row><entry> </entry></row><row><entry>CCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACT</entry></row><row><entry> </entry></row><row><entry>TACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGT</entry></row><row><entry> </entry></row><row><entry>ATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTT</entry></row><row><entry> </entry></row><row><entry>TTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGA</entry></row><row><entry> </entry></row><row><entry>GGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGA</entry></row><row><entry> </entry></row><row><entry>TGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGC</entry></row><row><entry> </entry></row><row><entry>CAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTC</entry></row><row><entry> </entry></row><row><entry>CTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTG</entry></row><row><entry> </entry></row><row><entry>GGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCA</entry></row><row><entry> </entry></row><row><entry>ACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAA</entry></row><row><entry> </entry></row><row><entry>GGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGAGAGGGCCCCGAGCTGTCTCCTGATGACC</entry></row><row><entry> </entry></row><row><entry>CAGCAGGCCTCTTGGACTTGCGGCAGGGTATGTTCGCTCAACTTGTGGCTCAGAATGTTCTGCT</entry></row><row><entry> </entry></row><row><entry>CATTGATGGACCACTCTCTTGGTATAGTGACCCCGGTCTGGCCGGGGTGAGTCTGACCGGCGGG</entry></row><row><entry> </entry></row><row><entry>CTCTCTTATAAAGAGGATACTAAGGAACTGGTCGTAGCAAAAGCGGGCGTTTATTACGTTTTTT</entry></row><row><entry> </entry></row><row><entry>TTCAGCTGGAGCTCAGGCGCGTGGTGGCCGGCGAGGGCAGTGGCTCTGTGTCCCTGGCCCTGCA</entry></row><row><entry> </entry></row><row><entry>CTTACAGCCCTTGAGAAGCGCTGCAGGTGCTGCCGCACTGGCTTTAACTGTTGACCTCCCTCCG</entry></row><row><entry> </entry></row><row><entry>GCCTCTTCTGAAGCTAGAAACAGCGCTTTCGGCTTCCAAGGGCGCCTGCTGCACCTGAGCGCAG</entry></row><row><entry> </entry></row><row><entry>GCCAGCGCTTAGGTGTGCACCTTCATACAGAGGCCAGGGCCCGACACGCTTGGCAGCTCACACA</entry></row><row><entry> </entry></row><row><entry>GGGTGCCACGGTTCTCGGACTTTTCCGCGTTACTCCCGAGATCCCCGCTGGCCTCGGAAGTACT</entry></row><row><entry> </entry></row><row><entry>GGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGTAGTACTAAAGGACGAGAAGGGCCAGAGTTAA</entry></row><row><entry> </entry></row><row><entry>GTCCAGATGACCCTGCTGGGCTTTTGGACCTGCGGCAGGGCATGTTCGCTCAACTGGTGGCTCA</entry></row><row><entry> </entry></row><row><entry>GAACGTGCTGCTGATCGATGGCCCCCTGAGTTGGTACAGCGATCCCGGGCTGGCAGGCGTGTCA</entry></row><row><entry> </entry></row><row><entry>CTTACAGGGGGCCTCTCTTACAAGGAAGACACCAAGGAGTTAGTGGTCGCTAAGGCTGGCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACGTGTTCTTCCAACTGGAGCTGAGAAGGGTTGTGGCAGGAGAGGGTAGCGGCAGCGTGTC</entry></row><row><entry> </entry></row><row><entry>TTTAGCCCTTCACTTGCAGCCCCTGAGGTCTGCTGCAGGTGCAGCCGCTCTCGCGCTCACCGTG</entry></row><row><entry> </entry></row><row><entry>GATCTCCCCCCAGCCTCATCTGAAGCTAGGAACAGTGCATTTGGCTTTCAGGGACGCTTGCTGC</entry></row><row><entry> </entry></row><row><entry>ACCTCTCCGCTGGACAGAGGCTGGGCGTGCACCTTCACACAGAGGCCCGTGCCAGGCATGCATG</entry></row><row><entry> </entry></row><row><entry>GCAGCTCACTCAGGGGGCAACAGTGCTGGGTCTCTTCCGCGTGACTCCTGAAATACCAGCTGGA</entry></row><row><entry> </entry></row><row><entry>CTTGGCGGTGGAGGCAGCGGCGGAGGAGGATCTCGTGAGGGGCCAGAACTGTCCCCCGATGACC</entry></row><row><entry> </entry></row><row><entry>CAGCCGGACTGCTCGATCTCAGACAGGGCATGTTCGCTCAGCTTGTAGCCCAAAATGTCCTCCT</entry></row><row><entry> </entry></row><row><entry>GATTGACGGCCCTTTGAGCTGGTATAGTGATCCCGGCTTGGCCGGGGTATCTCTGACCGGAGGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCTACAAGGAAGACACCAAAGAGCTGGTGGTGGCAAAAGCGGGGGTGTATTATGTGTTCT</entry></row><row><entry> </entry></row><row><entry>TTCAGCTCGAGCTGCGGAGAGTTGTGGCCGGGGAAGGGTCTGGGAGCGTATCTCTTGCACTTCA</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCCCTGCGCAGCGCCGCTGGAGCCGCCGCCCTTGCTCTTACTGTGGATCTGCCTCCT</entry></row><row><entry> </entry></row><row><entry>GCTTCCTCAGAAGCACGCAACAGCGCCTTCGGCTTTCAAGGACGTCTCCTGCACTTGTCCGCAG</entry></row><row><entry> </entry></row><row><entry>GACAGAGGTTGGGCGTCCATTTACACACTGAGGCACGGGCACGGCACGCTTGGCAGCTTACCCA</entry></row><row><entry> </entry></row><row><entry>GGGAGCCACCGTGCTGGGACTCTTTAGAGTGACACCCGAGATCCCCGCTGGCTTGTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;31:&#x2003;SI-55P4&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DPVLTQSPSSLSASVGDRVTISCQSSQSVAKNNNLAWFQQKPGQAPKLLIYSASTLAAGVPSRF</entry></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLTISSVQPEDFATYYCSARDSGNIQSFGGGTKVEIKRTVAAPSVFIFPPSDEQL</entry></row><row><entry> </entry></row><row><entry>KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH</entry></row><row><entry> </entry></row><row><entry>KVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;32:&#x2003;SI-55P4&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGG</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCC</entry></row><row><entry> </entry></row><row><entry>GATCCAGTTCTGACACAAAGTCCATCCAGCCTGTCTGCCTCAGTCGGCGACAGAGTGACCATCA</entry></row><row><entry> </entry></row><row><entry>GTTGCCAGAGCTCACAGTCTGTGGCTAAGAACAACAACTTGGCGTGGTTCCAACAGAAACCTGG</entry></row><row><entry> </entry></row><row><entry>ACAGGCTCCGAAATTGCTGATCTATTCTGCTTCCACGCTTGCTGCTGGTGTTCCTTCCCGCTTT</entry></row><row><entry> </entry></row><row><entry>TCAGGTAGTGGTAGCGGGACAGACTTCACTTTGACTATAAGCAGCGTGCAGCCTGAAGATTTTG</entry></row><row><entry> </entry></row><row><entry>CGACCTACTATTGTTCTGCTAGAGACAGTGGAAATATTCAGTCCTTTGGGGGGGGAACGAAGGT</entry></row><row><entry> </entry></row><row><entry>CGAAATAAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG</entry></row><row><entry> </entry></row><row><entry>AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC</entry></row><row><entry> </entry></row><row><entry>AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG</entry></row><row><entry> </entry></row><row><entry>CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC</entry></row><row><entry> </entry></row><row><entry>AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA</entry></row><row><entry> </entry></row><row><entry>GGGGAGAGTGTTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;33:&#x2003;SI-55P9&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLTVLGGGGSGGGGSGGGGSGGGGSQ</entry></row><row><entry> </entry></row><row><entry>VQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFTS</entry></row><row><entry> </entry></row><row><entry>RFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSASTKGPSV</entry></row><row><entry> </entry></row><row><entry>FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP</entry></row><row><entry> </entry></row><row><entry>SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI</entry></row><row><entry> </entry></row><row><entry>SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK</entry></row><row><entry> </entry></row><row><entry>EYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW</entry></row><row><entry> </entry></row><row><entry>ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP</entry></row><row><entry> </entry></row><row><entry>GGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIA</entry></row><row><entry> </entry></row><row><entry>AGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTL</entry></row><row><entry> </entry></row><row><entry>VTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQK</entry></row><row><entry> </entry></row><row><entry>PGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGG</entry></row><row><entry> </entry></row><row><entry>GTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEY</entry></row><row><entry> </entry></row><row><entry>IGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTL</entry></row><row><entry> </entry></row><row><entry>VTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQK</entry></row><row><entry> </entry></row><row><entry>PGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFG</entry></row><row><entry> </entry></row><row><entry>GGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;34:&#x2003;SI-55P9&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGCTGACCGTTTT</entry></row><row><entry> </entry></row><row><entry>AGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAA</entry></row><row><entry> </entry></row><row><entry>GTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTA</entry></row><row><entry> </entry></row><row><entry>CTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGG</entry></row><row><entry> </entry></row><row><entry>TTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGT</entry></row><row><entry> </entry></row><row><entry>CGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCG</entry></row><row><entry> </entry></row><row><entry>CGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCT</entry></row><row><entry> </entry></row><row><entry>GTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>GGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAA</entry></row><row><entry> </entry></row><row><entry>GGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGA</entry></row><row><entry> </entry></row><row><entry>GAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAA</entry></row><row><entry> </entry></row><row><entry>CAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGCTAGCACCAAGGGCCCATCGGTC</entry></row><row><entry> </entry></row><row><entry>TTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCA</entry></row><row><entry> </entry></row><row><entry>AGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCA</entry></row><row><entry> </entry></row><row><entry>CACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC</entry></row><row><entry> </entry></row><row><entry>TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGG</entry></row><row><entry> </entry></row><row><entry>TGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC</entry></row><row><entry> </entry></row><row><entry>TGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC</entry></row><row><entry> </entry></row><row><entry>TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGT</entry></row><row><entry> </entry></row><row><entry>TCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA</entry></row><row><entry> </entry></row><row><entry>CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG</entry></row><row><entry> </entry></row><row><entry>GAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAG</entry></row><row><entry> </entry></row><row><entry>CCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAA</entry></row><row><entry> </entry></row><row><entry>GAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCT</entry></row><row><entry> </entry></row><row><entry>CCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTC</entry></row><row><entry> </entry></row><row><entry>ATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCG</entry></row><row><entry> </entry></row><row><entry>GGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCT</entry></row><row><entry> </entry></row><row><entry>TGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGG</entry></row><row><entry> </entry></row><row><entry>GTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCT</entry></row><row><entry> </entry></row><row><entry>GCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAG</entry></row><row><entry> </entry></row><row><entry>ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATA</entry></row><row><entry> </entry></row><row><entry>TTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTG</entry></row><row><entry> </entry></row><row><entry>GTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTG</entry></row><row><entry> </entry></row><row><entry>GAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAG</entry></row><row><entry> </entry></row><row><entry>AGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAA</entry></row><row><entry> </entry></row><row><entry>CCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAA</entry></row><row><entry> </entry></row><row><entry>GGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGA</entry></row><row><entry> </entry></row><row><entry>TTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGA</entry></row><row><entry> </entry></row><row><entry>GGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGG</entry></row><row><entry> </entry></row><row><entry>TGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGG</entry></row><row><entry> </entry></row><row><entry>ATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTAC</entry></row><row><entry> </entry></row><row><entry>ATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCA</entry></row><row><entry> </entry></row><row><entry>TCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACAC</entry></row><row><entry> </entry></row><row><entry>GGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTG</entry></row><row><entry> </entry></row><row><entry>GTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCG</entry></row><row><entry> </entry></row><row><entry>GTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAG</entry></row><row><entry> </entry></row><row><entry>AGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAA</entry></row><row><entry> </entry></row><row><entry>CCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAA</entry></row><row><entry> </entry></row><row><entry>GGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGA</entry></row><row><entry> </entry></row><row><entry>TGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGC</entry></row><row><entry> </entry></row><row><entry>GGAGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;35:&#x2003;SI-55P9&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKRTVAAPSVFIFPPSDE</entry></row><row><entry> </entry></row><row><entry>QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE</entry></row><row><entry> </entry></row><row><entry>KHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;36:&#x2003;SI-55P9&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGG</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG</entry></row><row><entry> </entry></row><row><entry>CAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCA</entry></row><row><entry> </entry></row><row><entry>AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCA</entry></row><row><entry> </entry></row><row><entry>GGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAG</entry></row><row><entry> </entry></row><row><entry>AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCT</entry></row><row><entry> </entry></row><row><entry>TCAACAGGGGAGAGTGTTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;37:&#x2003;SI-55P10&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLTVLGGGGSGGGGSGGGGSGGGGSQ</entry></row><row><entry> </entry></row><row><entry>VQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFTS</entry></row><row><entry> </entry></row><row><entry>RFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWIGVITGRDITYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSASTKGPSV</entry></row><row><entry> </entry></row><row><entry>FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP</entry></row><row><entry> </entry></row><row><entry>SSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMI</entry></row><row><entry> </entry></row><row><entry>SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK</entry></row><row><entry> </entry></row><row><entry>EYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEW</entry></row><row><entry> </entry></row><row><entry>ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP</entry></row><row><entry> </entry></row><row><entry>GGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIA</entry></row><row><entry> </entry></row><row><entry>AGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTL</entry></row><row><entry> </entry></row><row><entry>VTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQK</entry></row><row><entry> </entry></row><row><entry>PGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGG</entry></row><row><entry> </entry></row><row><entry>GTKVEIKGGGGSGGGGSGREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA</entry></row><row><entry> </entry></row><row><entry>GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA</entry></row><row><entry> </entry></row><row><entry>LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEI</entry></row><row><entry> </entry></row><row><entry>PAGLGSTGSGSKPGSGEGSTKGREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSD</entry></row><row><entry> </entry></row><row><entry>PGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGA</entry></row><row><entry> </entry></row><row><entry>AALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRV</entry></row><row><entry> </entry></row><row><entry>TPEIPAGLGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLA</entry></row><row><entry> </entry></row><row><entry>GVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALA</entry></row><row><entry> </entry></row><row><entry>LTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEI</entry></row><row><entry> </entry></row><row><entry>PAGL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;38:&#x2003;SI-55P10&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGCTGACCGTTTT</entry></row><row><entry> </entry></row><row><entry>AGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAA</entry></row><row><entry> </entry></row><row><entry>GTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTA</entry></row><row><entry> </entry></row><row><entry>CTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGG</entry></row><row><entry> </entry></row><row><entry>TTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGT</entry></row><row><entry> </entry></row><row><entry>CGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCG</entry></row><row><entry> </entry></row><row><entry>CGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCT</entry></row><row><entry> </entry></row><row><entry>GTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>GGGGCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAA</entry></row><row><entry> </entry></row><row><entry>GGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGA</entry></row><row><entry> </entry></row><row><entry>GAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAA</entry></row><row><entry> </entry></row><row><entry>CAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCCTCAGCTAGCACCAAGGGCCCATCGGTC</entry></row><row><entry> </entry></row><row><entry>TTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCA</entry></row><row><entry> </entry></row><row><entry>AGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCA</entry></row><row><entry> </entry></row><row><entry>CACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC</entry></row><row><entry> </entry></row><row><entry>TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGG</entry></row><row><entry> </entry></row><row><entry>TGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACC</entry></row><row><entry> </entry></row><row><entry>TGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC</entry></row><row><entry> </entry></row><row><entry>TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGT</entry></row><row><entry> </entry></row><row><entry>TCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA</entry></row><row><entry> </entry></row><row><entry>CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAG</entry></row><row><entry> </entry></row><row><entry>GAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAG</entry></row><row><entry> </entry></row><row><entry>CCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAA</entry></row><row><entry> </entry></row><row><entry>GAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>GAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCT</entry></row><row><entry> </entry></row><row><entry>CCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTC</entry></row><row><entry> </entry></row><row><entry>ATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCG</entry></row><row><entry> </entry></row><row><entry>GGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCT</entry></row><row><entry> </entry></row><row><entry>TGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGG</entry></row><row><entry> </entry></row><row><entry>GTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCT</entry></row><row><entry> </entry></row><row><entry>GCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAG</entry></row><row><entry> </entry></row><row><entry>ACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATA</entry></row><row><entry> </entry></row><row><entry>TTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTG</entry></row><row><entry> </entry></row><row><entry>GTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTG</entry></row><row><entry> </entry></row><row><entry>GAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAG</entry></row><row><entry> </entry></row><row><entry>AGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAA</entry></row><row><entry> </entry></row><row><entry>CCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAA</entry></row><row><entry> </entry></row><row><entry>GGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGA</entry></row><row><entry> </entry></row><row><entry>TTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGA</entry></row><row><entry> </entry></row><row><entry>GGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGAGAGGGCC</entry></row><row><entry> </entry></row><row><entry>CCGAGCTGTCTCCTGATGACCCAGCAGGCCTCTTGGACTTGCGGCAGGGTATGTTCGCTCAACT</entry></row><row><entry> </entry></row><row><entry>TGTGGCTCAGAATGTTCTGCTCATTGATGGACCACTCTCTTGGTATAGTGACCCCGGTCTGGCC</entry></row><row><entry> </entry></row><row><entry>GGGGTGAGTCTGACCGGCGGGCTCTCTTATAAAGAGGATACTAAGGAACTGGTCGTAGCAAAAG</entry></row><row><entry> </entry></row><row><entry>CGGGCGTTTATTACGTTTTTTTTCAGCTGGAGCTCAGGCGCGTGGTGGCCGGCGAGGGCAGTGG</entry></row><row><entry> </entry></row><row><entry>CTCTGTGTCCCTGGCCCTGCACTTACAGCCCTTGAGAAGCGCTGCAGGTGCTGCCGCACTGGCT</entry></row><row><entry> </entry></row><row><entry>TTAACTGTTGACCTCCCTCCGGCCTCTTCTGAAGCTAGAAACAGCGCTTTCGGCTTCCAAGGGC</entry></row><row><entry> </entry></row><row><entry>GCCTGCTGCACCTGAGCGCAGGCCAGCGCTTAGGTGTGCACCTTCATACAGAGGCCAGGGCCCG</entry></row><row><entry> </entry></row><row><entry>ACACGCTTGGCAGCTCACACAGGGTGCCACGGTTCTCGGACTTTTCCGCGTTACTCCCGAGATC</entry></row><row><entry> </entry></row><row><entry>CCCGCTGGCCTCGGAAGTACTGGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGTAGTACTAAAG</entry></row><row><entry> </entry></row><row><entry>GACGAGAAGGGCCAGAGTTAAGTCCAGATGACCCTGCTGGGCTTTTGGACCTGCGGCAGGGCAT</entry></row><row><entry> </entry></row><row><entry>GTTCGCTCAACTGGTGGCTCAGAACGTGCTGCTGATCGATGGCCCCCTGAGTTGGTACAGCGAT</entry></row><row><entry> </entry></row><row><entry>CCCGGGCTGGCAGGCGTGTCACTTACAGGGGGCCTCTCTTACAAGGAAGACACCAAGGAGTTAG</entry></row><row><entry> </entry></row><row><entry>TGGTCGCTAAGGCTGGCGTGTATTACGTGTTCTTCCAACTGGAGCTGAGAAGGGTTGTGGCAGG</entry></row><row><entry> </entry></row><row><entry>AGAGGGTAGCGGCAGCGTGTCTTTAGCCCTTCACTTGCAGCCCCTGAGGTCTGCTGCAGGTGCA</entry></row><row><entry> </entry></row><row><entry>GCCGCTCTCGCGCTCACCGTGGATCTCCCCCCAGCCTCATCTGAAGCTAGGAACAGTGCATTTG</entry></row><row><entry> </entry></row><row><entry>GCTTTCAGGGACGCTTGCTGCACCTCTCCGCTGGACAGAGGCTGGGCGTGCACCTTCACACAGA</entry></row><row><entry> </entry></row><row><entry>GGCCCGTGCCAGGCATGCATGGCAGCTCACTCAGGGGGCAACAGTGCTGGGTCTCTTCCGCGTG</entry></row><row><entry> </entry></row><row><entry>ACTCCTGAAATACCAGCTGGACTTGGCGGTGGAGGCAGCGGCGGAGGAGGATCTCGTGAGGGGC</entry></row><row><entry> </entry></row><row><entry>CAGAACTGTCCCCCGATGACCCAGCCGGACTGCTCGATCTCAGACAGGGCATGTTCGCTCAGCT</entry></row><row><entry> </entry></row><row><entry>TGTAGCCCAAAATGTCCTCCTGATTGACGGCCCTTTGAGCTGGTATAGTGATCCCGGCTTGGCC</entry></row><row><entry> </entry></row><row><entry>GGGGTATCTCTGACCGGAGGCCTCTCCTACAAGGAAGACACCAAAGAGCTGGTGGTGGCAAAAG</entry></row><row><entry> </entry></row><row><entry>CGGGGGTGTATTATGTGTTCTTTCAGCTCGAGCTGCGGAGAGTTGTGGCCGGGGAAGGGTCTGG</entry></row><row><entry> </entry></row><row><entry>GAGCGTATCTCTTGCACTTCACCTGCAGCCCCTGCGCAGCGCCGCTGGAGCCGCCGCCCTTGCT</entry></row><row><entry> </entry></row><row><entry>CTTACTGTGGATCTGCCTCCTGCTTCCTCAGAAGCACGCAACAGCGCCTTCGGCTTTCAAGGAC</entry></row><row><entry> </entry></row><row><entry>GTCTCCTGCACTTGTCCGCAGGACAGAGGTTGGGCGTCCATTTACACACTGAGGCACGGGCACG</entry></row><row><entry> </entry></row><row><entry>GCACGCTTGGCAGCTTACCCAGGGAGCCACCGTGCTGGGACTCTTTAGAGTGACACCCGAGATC</entry></row><row><entry> </entry></row><row><entry>CCCGCTGGCTTGTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;39:&#x2003;SI-55P10&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKRTVAAPSVFIFPPSDE</entry></row><row><entry> </entry></row><row><entry>QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE</entry></row><row><entry> </entry></row><row><entry>KHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;40:&#x2003;SI-55P10&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGG</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGAGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG</entry></row><row><entry> </entry></row><row><entry>CAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCA</entry></row><row><entry> </entry></row><row><entry>AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCA</entry></row><row><entry> </entry></row><row><entry>GGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAG</entry></row><row><entry> </entry></row><row><entry>AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCT</entry></row><row><entry> </entry></row><row><entry>TCAACAGGGGAGAGTGTTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;41:&#x2003;SI-77P1&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGQGTKLTVLGGGGSGGGGSGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWVGVITGRDITYYA</entry></row><row><entry> </entry></row><row><entry>SWAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSGGGG</entry></row><row><entry> </entry></row><row><entry>SGGGGSQVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTD</entry></row><row><entry> </entry></row><row><entry>YNTPFTSRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSAST</entry></row><row><entry> </entry></row><row><entry>KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry> </entry></row><row><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPK</entry></row><row><entry> </entry></row><row><entry>DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD</entry></row><row><entry> </entry></row><row><entry>WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD</entry></row><row><entry> </entry></row><row><entry>IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS</entry></row><row><entry> </entry></row><row><entry>LSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEW</entry></row><row><entry> </entry></row><row><entry>IACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLN</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVD</entry></row><row><entry> </entry></row><row><entry>NVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPG</entry></row><row><entry> </entry></row><row><entry>KGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLS</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYV</entry></row><row><entry> </entry></row><row><entry>GGAFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;42:&#x2003;SI-77P1&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTTATGACGCAGAGTCCCTCCACGCTCTCCGCTAGTGTCGGGGATCGCGTCATTATCA</entry></row><row><entry> </entry></row><row><entry>CATGCCAGGCCTCCGAGTCAATCAGCAGCTGGCTTGCATGGTATCAACAGAAGCCGGGAAAAGC</entry></row><row><entry> </entry></row><row><entry>TCCTAAATTGCTGATCTATGAAGCGTCAAAATTGGCGTCTGGTGTCCCATCTAGGTTCTCCGGC</entry></row><row><entry> </entry></row><row><entry>TCTGGGTCTGGTGCGGAATTTACTTTGACAATCTCCAGTCTTCAACCAGACGATTTCGCTACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAAGGGTATTTCTATTTTATAAGCCGGACATATGTAAACTCCTTCGGCCAAGGAAC</entry></row><row><entry> </entry></row><row><entry>AAAGTTGACTGTTCTTGGTGGCGGAGGCAGTGGTGGCGGGGGCAGCGGAGGTGGTGGTTCAGGG</entry></row><row><entry> </entry></row><row><entry>GGTGGTGGGAGCGAAGTCCAATTGGTAGAAAGTGGCGGTGGTCTGGTGCAACCTGGTGGATCTC</entry></row><row><entry> </entry></row><row><entry>TTCGCCTCTCATGCGCCGCTAGTGGCTTTACTATTTCAACTAATGCGATGAGCTGGGTTCGCCA</entry></row><row><entry> </entry></row><row><entry>GGCCCCCGGCAAAGGACTTGAGTGGGTCGGCGTCATCACCGGCAGGGACATTACATACTATGCG</entry></row><row><entry> </entry></row><row><entry>AGTTGGGCAAAGGGCAGGTTCACGATTAGCCGCGATACTTCAAAGAATACCGTTTACCTTCAAA</entry></row><row><entry> </entry></row><row><entry>TGAATAGCTTGAGGGCGGAAGACACAGCTGTGTATTACTGCGCGAGGGATGGAGGTAGTTCCGC</entry></row><row><entry> </entry></row><row><entry>CATAACTTCCAACAACATATGGGGACAAGGCACGCTGGTTACTGTCTCGAGTGGCGGTGGAGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCGGTGGTGGATCACAAGTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTG</entry></row><row><entry> </entry></row><row><entry>AGACGCTTAGTATAACGTGTACTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGAT</entry></row><row><entry> </entry></row><row><entry>TCGGCAGGCACCCGGCAAAGGTTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGAC</entry></row><row><entry> </entry></row><row><entry>TATAACACCCCCTTTACAAGTCGGTTCACAATTAGGAAAGATAATTCCAAAAATCAAGTTTATT</entry></row><row><entry> </entry></row><row><entry>TCAAGTTGAGATCCGTCCGCGCGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTA</entry></row><row><entry> </entry></row><row><entry>CTACGATTACGAATTTGCGTATTGGGGGCAAGGGACTCTTGTAACAGTCTCCAGTGCTAGCACC</entry></row><row><entry> </entry></row><row><entry>AAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCC</entry></row><row><entry> </entry></row><row><entry>TGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCT</entry></row><row><entry> </entry></row><row><entry>GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC</entry></row><row><entry> </entry></row><row><entry>GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC</entry></row><row><entry> </entry></row><row><entry>CCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC</entry></row><row><entry> </entry></row><row><entry>ACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG</entry></row><row><entry> </entry></row><row><entry>GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAG</entry></row><row><entry> </entry></row><row><entry>ACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC</entry></row><row><entry> </entry></row><row><entry>GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC</entry></row><row><entry> </entry></row><row><entry>TGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA</entry></row><row><entry> </entry></row><row><entry>AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG</entry></row><row><entry> </entry></row><row><entry>GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGAC</entry></row><row><entry> </entry></row><row><entry>ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGC</entry></row><row><entry> </entry></row><row><entry>TGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA</entry></row><row><entry> </entry></row><row><entry>GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGG</entry></row><row><entry> </entry></row><row><entry>AGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT</entry></row><row><entry> </entry></row><row><entry>CTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>ATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGT</entry></row><row><entry> </entry></row><row><entry>TCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA</entry></row><row><entry> </entry></row><row><entry>GGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCG</entry></row><row><entry> </entry></row><row><entry>GTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAAC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAG</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGAT</entry></row><row><entry> </entry></row><row><entry>AATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCT</entry></row><row><entry> </entry></row><row><entry>CCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTC</entry></row><row><entry> </entry></row><row><entry>CTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGG</entry></row><row><entry> </entry></row><row><entry>AAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTA</entry></row><row><entry> </entry></row><row><entry>GAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCT</entry></row><row><entry> </entry></row><row><entry>GAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCG</entry></row><row><entry> </entry></row><row><entry>GCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGA</entry></row><row><entry> </entry></row><row><entry>CCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTT</entry></row><row><entry> </entry></row><row><entry>GGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;43:&#x2003;SI-77P1&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLSLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLTVLRTVAAPSVFIFPPSDEQLKSG</entry></row><row><entry> </entry></row><row><entry>TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY</entry></row><row><entry> </entry></row><row><entry>ACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;44:&#x2003;SI-77P1&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTAGG</entry></row><row><entry> </entry></row><row><entry>CGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGCTGACCGTTTT</entry></row><row><entry> </entry></row><row><entry>ACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA</entry></row><row><entry> </entry></row><row><entry>ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGG</entry></row><row><entry> </entry></row><row><entry>TGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG</entry></row><row><entry> </entry></row><row><entry>CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC</entry></row><row><entry> </entry></row><row><entry>GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT</entry></row><row><entry> </entry></row><row><entry>GTTAG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;45:&#x2003;SI-79P2&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLELKGGGGSGGGGSGGGGSGGGGSQ</entry></row><row><entry> </entry></row><row><entry>VQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFTS</entry></row><row><entry> </entry></row><row><entry>RFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>QVQLQESGGRLVQPGEPLSLTCKTSGIDLSSNAIGWVRQAPGKGLEWIGVIFGSGNTYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRSTSTVYLKMNSLRSEDTAIYYCARGGYSSDIWGQGTLVTVSSASTKGPSVFPLAPSS</entry></row><row><entry> </entry></row><row><entry>KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ</entry></row><row><entry> </entry></row><row><entry>TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVT</entry></row><row><entry> </entry></row><row><entry>CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVS</entry></row><row><entry> </entry></row><row><entry>NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE</entry></row><row><entry> </entry></row><row><entry>NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGIT</entry></row><row><entry> </entry></row><row><entry>YDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGG</entry></row><row><entry> </entry></row><row><entry>GGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKL</entry></row><row><entry> </entry></row><row><entry>LIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>GGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKGLEYIGTISSG</entry></row><row><entry> </entry></row><row><entry>GNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSSGG</entry></row><row><entry> </entry></row><row><entry>GGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKL</entry></row><row><entry> </entry></row><row><entry>LIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGGGTKVEI</entry></row><row><entry> </entry></row><row><entry>K</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;46:&#x2003;SI-79P2&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGTTGGAACTGAA</entry></row><row><entry> </entry></row><row><entry>AGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAA</entry></row><row><entry> </entry></row><row><entry>GTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTA</entry></row><row><entry> </entry></row><row><entry>CTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGG</entry></row><row><entry> </entry></row><row><entry>TTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGT</entry></row><row><entry> </entry></row><row><entry>CGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCG</entry></row><row><entry> </entry></row><row><entry>CGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>CAAGTGCAGTTGCAAGAAAGTGGTGGTAGACTGGTTCAGCCTGGTGAACCCTTGTCACTGACGT</entry></row><row><entry> </entry></row><row><entry>GTAAAACAAGCGGCATTGATCTGTCCTCTAACGCCATCGGATGGGTCCGACAGGCCCCAGGAAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTGGAGTGGATCGGAGTTATCTTCGGGAGCGGCAATACATACTACGCAAGCTGGGCAAAA</entry></row><row><entry> </entry></row><row><entry>GGGCGATTTACGATATCACGGAGCACCTCTACAGTTTATTTGAAAATGAACTCCCTCCGGTCCG</entry></row><row><entry> </entry></row><row><entry>AGGATACCGCGATATATTACTGTGCCAGAGGGGGGTACTCCTCTGATATCTGGGGGCAGGGTAC</entry></row><row><entry> </entry></row><row><entry>ACTGGTTACAGTTTCATCCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCC</entry></row><row><entry> </entry></row><row><entry>AAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG</entry></row><row><entry> </entry></row><row><entry>TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA</entry></row><row><entry> </entry></row><row><entry>GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAG</entry></row><row><entry> </entry></row><row><entry>ACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCA</entry></row><row><entry> </entry></row><row><entry>AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTC</entry></row><row><entry> </entry></row><row><entry>AGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA</entry></row><row><entry> </entry></row><row><entry>TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG</entry></row><row><entry> </entry></row><row><entry>TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGT</entry></row><row><entry> </entry></row><row><entry>CAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCC</entry></row><row><entry> </entry></row><row><entry>AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC</entry></row><row><entry> </entry></row><row><entry>CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTG</entry></row><row><entry> </entry></row><row><entry>CCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG</entry></row><row><entry> </entry></row><row><entry>AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGC</entry></row><row><entry> </entry></row><row><entry>TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGC</entry></row><row><entry> </entry></row><row><entry>TCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>TGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCG</entry></row><row><entry> </entry></row><row><entry>CCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACT</entry></row><row><entry> </entry></row><row><entry>TACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGT</entry></row><row><entry> </entry></row><row><entry>ATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTT</entry></row><row><entry> </entry></row><row><entry>TTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGA</entry></row><row><entry> </entry></row><row><entry>GGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGA</entry></row><row><entry> </entry></row><row><entry>TGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGC</entry></row><row><entry> </entry></row><row><entry>CAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTC</entry></row><row><entry> </entry></row><row><entry>CTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTG</entry></row><row><entry> </entry></row><row><entry>GGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCA</entry></row><row><entry> </entry></row><row><entry>ACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAA</entry></row><row><entry> </entry></row><row><entry>GGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGG</entry></row><row><entry> </entry></row><row><entry>TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCA</entry></row><row><entry> </entry></row><row><entry>CATGCAGTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGT</entry></row><row><entry> </entry></row><row><entry>GGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGA</entry></row><row><entry> </entry></row><row><entry>ACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAG</entry></row><row><entry> </entry></row><row><entry>AGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGT</entry></row><row><entry> </entry></row><row><entry>GGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGA</entry></row><row><entry> </entry></row><row><entry>TGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGC</entry></row><row><entry> </entry></row><row><entry>CAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTC</entry></row><row><entry> </entry></row><row><entry>CTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTG</entry></row><row><entry> </entry></row><row><entry>GGACAGATTTCACTCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCA</entry></row><row><entry> </entry></row><row><entry>GTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATC</entry></row><row><entry> </entry></row><row><entry>AAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;47:&#x2003;SI-79P2&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DPVLTQSPSSLSASVGDRVTISCQSSQSVAKNNNLAWFQQKPGQAPKLLIYSASTLAAGVPSRF</entry></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLTISSVQPEDFATYYCSARDSGNIQSFGGGTKVEIKRTVAAPSVFIFPPSDEQL</entry></row><row><entry> </entry></row><row><entry>KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH</entry></row><row><entry> </entry></row><row><entry>KVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;48:&#x2003;SI-79P2&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGG</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCC</entry></row><row><entry> </entry></row><row><entry>GATCCAGTTCTGACACAAAGTCCATCCAGCCTGTCTGCCTCAGTCGGCGACAGAGTGACCATCA</entry></row><row><entry> </entry></row><row><entry>GTTGCCAGAGCTCACAGTCTGTGGCTAAGAACAACAACTTGGCGTGGTTCCAACAGAAACCTGG</entry></row><row><entry> </entry></row><row><entry>ACAGGCTCCGAAATTGCTGATCTATTCTGCTTCCACGCTTGCTGCTGGTGTTCCTTCCCGCTTT</entry></row><row><entry> </entry></row><row><entry>TCAGGTAGTGGTAGCGGGACAGACTTCACTTTGACTATAAGCAGCGTGCAGCCTGAAGATTTTG</entry></row><row><entry> </entry></row><row><entry>CGACCTACTATTGTTCTGCTAGAGACAGTGGAAATATTCAGTCCTTTGGGGGGGGAACGAAGGT</entry></row><row><entry> </entry></row><row><entry>CGAAATAAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG</entry></row><row><entry> </entry></row><row><entry>AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC</entry></row><row><entry> </entry></row><row><entry>AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG</entry></row><row><entry> </entry></row><row><entry>CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC</entry></row><row><entry> </entry></row><row><entry>AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA</entry></row><row><entry> </entry></row><row><entry>GGGGAGAGTGTTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;49:&#x2003;SI-79P3&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLELKGGGGSGGGGSGGGGSGGGGSQ</entry></row><row><entry> </entry></row><row><entry>VQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFTS</entry></row><row><entry> </entry></row><row><entry>RFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>QVQLQESGGRLVQPGEPLSLTCKTSGIDLSSNAIGWVRQAPGKGLEWIGVIFGSGNTYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRSTSTVYLKMNSLRSEDTAIYYCARGGYSSDIWGQGTLVTVSSASTKGPSVFPLAPSS</entry></row><row><entry> </entry></row><row><entry>KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ</entry></row><row><entry> </entry></row><row><entry>TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVT</entry></row><row><entry> </entry></row><row><entry>CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCAVS</entry></row><row><entry> </entry></row><row><entry>NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE</entry></row><row><entry> </entry></row><row><entry>NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEWIACIAAGSAGIT</entry></row><row><entry> </entry></row><row><entry>YDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSSGG</entry></row><row><entry> </entry></row><row><entry>GGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKL</entry></row><row><entry> </entry></row><row><entry>LIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>GGGGSGGGGSGREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGG</entry></row><row><entry> </entry></row><row><entry>LSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP</entry></row><row><entry> </entry></row><row><entry>ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLGST</entry></row><row><entry> </entry></row><row><entry>GSGSKPGSGEGSTKGREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVS</entry></row><row><entry> </entry></row><row><entry>LTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTV</entry></row><row><entry> </entry></row><row><entry>DLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAG</entry></row><row><entry> </entry></row><row><entry>LGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGG</entry></row><row><entry> </entry></row><row><entry>LSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPP</entry></row><row><entry> </entry></row><row><entry>ASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;50:&#x2003;SI-79P3&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGTTGGAACTGAA</entry></row><row><entry> </entry></row><row><entry>AGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAA</entry></row><row><entry> </entry></row><row><entry>GTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTA</entry></row><row><entry> </entry></row><row><entry>CTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGG</entry></row><row><entry> </entry></row><row><entry>TTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGT</entry></row><row><entry> </entry></row><row><entry>CGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCG</entry></row><row><entry> </entry></row><row><entry>CGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>CAAGTGCAGTTGCAAGAAAGTGGTGGTAGACTGGTTCAGCCTGGTGAACCCTTGTCACTGACGT</entry></row><row><entry> </entry></row><row><entry>GTAAAACAAGCGGCATTGATCTGTCCTCTAACGCCATCGGATGGGTCCGACAGGCCCCAGGAAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTGGAGTGGATCGGAGTTATCTTCGGGAGCGGCAATACATACTACGCAAGCTGGGCAAAA</entry></row><row><entry> </entry></row><row><entry>GGGCGATTTACGATATCACGGAGCACCTCTACAGTTTATTTGAAAATGAACTCCCTCCGGTCCG</entry></row><row><entry> </entry></row><row><entry>AGGATACCGCGATATATTACTGTGCCAGAGGGGGGTACTCCTCTGATATCTGGGGGCAGGGTAC</entry></row><row><entry> </entry></row><row><entry>ACTGGTTACAGTTTCATCCGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCC</entry></row><row><entry> </entry></row><row><entry>AAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGG</entry></row><row><entry> </entry></row><row><entry>TGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA</entry></row><row><entry> </entry></row><row><entry>GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAG</entry></row><row><entry> </entry></row><row><entry>ACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCA</entry></row><row><entry> </entry></row><row><entry>AATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTC</entry></row><row><entry> </entry></row><row><entry>AGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACA</entry></row><row><entry> </entry></row><row><entry>TGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCG</entry></row><row><entry> </entry></row><row><entry>TGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGT</entry></row><row><entry> </entry></row><row><entry>CAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCC</entry></row><row><entry> </entry></row><row><entry>AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC</entry></row><row><entry> </entry></row><row><entry>CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTG</entry></row><row><entry> </entry></row><row><entry>CCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG</entry></row><row><entry> </entry></row><row><entry>AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGC</entry></row><row><entry> </entry></row><row><entry>TCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGC</entry></row><row><entry> </entry></row><row><entry>TCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGC</entry></row><row><entry> </entry></row><row><entry>GGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>TGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCG</entry></row><row><entry> </entry></row><row><entry>CCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACT</entry></row><row><entry> </entry></row><row><entry>TACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGT</entry></row><row><entry> </entry></row><row><entry>ATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTT</entry></row><row><entry> </entry></row><row><entry>TTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGA</entry></row><row><entry> </entry></row><row><entry>GGCGGATCTGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGA</entry></row><row><entry> </entry></row><row><entry>TGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGC</entry></row><row><entry> </entry></row><row><entry>CAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTC</entry></row><row><entry> </entry></row><row><entry>CTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTG</entry></row><row><entry> </entry></row><row><entry>GGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCA</entry></row><row><entry> </entry></row><row><entry>ACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAA</entry></row><row><entry> </entry></row><row><entry>GGCGGTGGAGGGTCCGGCGGTGGTGGCTCCGGACGAGAGGGCCCCGAGCTGTCTCCTGATGACC</entry></row><row><entry> </entry></row><row><entry>CAGCAGGCCTCTTGGACTTGCGGCAGGGTATGTTCGCTCAACTTGTGGCTCAGAATGTTCTGCT</entry></row><row><entry> </entry></row><row><entry>CATTGATGGACCACTCTCTTGGTATAGTGACCCCGGTCTGGCCGGGGTGAGTCTGACCGGCGGG</entry></row><row><entry> </entry></row><row><entry>CTCTCTTATAAAGAGGATACTAAGGAACTGGTCGTAGCAAAAGCGGGCGTTTATTACGTTTTTT</entry></row><row><entry> </entry></row><row><entry>TTCAGCTGGAGCTCAGGCGCGTGGTGGCCGGCGAGGGCAGTGGCTCTGTGTCCCTGGCCCTGCA</entry></row><row><entry> </entry></row><row><entry>CTTACAGCCCTTGAGAAGCGCTGCAGGTGCTGCCGCACTGGCTTTAACTGTTGACCTCCCTCCG</entry></row><row><entry> </entry></row><row><entry>GCCTCTTCTGAAGCTAGAAACAGCGCTTTCGGCTTCCAAGGGCGCCTGCTGCACCTGAGCGCAG</entry></row><row><entry> </entry></row><row><entry>GCCAGCGCTTAGGTGTGCACCTTCATACAGAGGCCAGGGCCCGACACGCTTGGCAGCTCACACA</entry></row><row><entry> </entry></row><row><entry>GGGTGCCACGGTTCTCGGACTTTTCCGCGTTACTCCCGAGATCCCCGCTGGCCTCGGAAGTACT</entry></row><row><entry> </entry></row><row><entry>GGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGTAGTACTAAAGGACGAGAAGGGCCAGAGTTAA</entry></row><row><entry> </entry></row><row><entry>GTCCAGATGACCCTGCTGGGCTTTTGGACCTGCGGCAGGGCATGTTCGCTCAACTGGTGGCTCA</entry></row><row><entry> </entry></row><row><entry>GAACGTGCTGCTGATCGATGGCCCCCTGAGTTGGTACAGCGATCCCGGGCTGGCAGGCGTGTCA</entry></row><row><entry> </entry></row><row><entry>CTTACAGGGGGCCTCTCTTACAAGGAAGACACCAAGGAGTTAGTGGTCGCTAAGGCTGGCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACGTGTTCTTCCAACTGGAGCTGAGAAGGGTTGTGGCAGGAGAGGGTAGCGGCAGCGTGTC</entry></row><row><entry> </entry></row><row><entry>TTTAGCCCTTCACTTGCAGCCCCTGAGGTCTGCTGCAGGTGCAGCCGCTCTCGCGCTCACCGTG</entry></row><row><entry> </entry></row><row><entry>GATCTCCCCCCAGCCTCATCTGAAGCTAGGAACAGTGCATTTGGCTTTCAGGGACGCTTGCTGC</entry></row><row><entry> </entry></row><row><entry>ACCTCTCCGCTGGACAGAGGCTGGGCGTGCACCTTCACACAGAGGCCCGTGCCAGGCATGCATG</entry></row><row><entry> </entry></row><row><entry>GCAGCTCACTCAGGGGGCAACAGTGCTGGGTCTCTTCCGCGTGACTCCTGAAATACCAGCTGGA</entry></row><row><entry> </entry></row><row><entry>CTTGGCGGTGGAGGCAGCGGCGGAGGAGGATCTCGTGAGGGGCCAGAACTGTCCCCCGATGACC</entry></row><row><entry> </entry></row><row><entry>CAGCCGGACTGCTCGATCTCAGACAGGGCATGTTCGCTCAGCTTGTAGCCCAAAATGTCCTCCT</entry></row><row><entry> </entry></row><row><entry>GATTGACGGCCCTTTGAGCTGGTATAGTGATCCCGGCTTGGCCGGGGTATCTCTGACCGGAGGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCTACAAGGAAGACACCAAAGAGCTGGTGGTGGCAAAAGCGGGGGTGTATTATGTGTTCT</entry></row><row><entry> </entry></row><row><entry>TTCAGCTCGAGCTGCGGAGAGTTGTGGCCGGGGAAGGGTCTGGGAGCGTATCTCTTGCACTTCA</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCCCTGCGCAGCGCCGCTGGAGCCGCCGCCCTTGCTCTTACTGTGGATCTGCCTCCT</entry></row><row><entry> </entry></row><row><entry>GCTTCCTCAGAAGCACGCAACAGCGCCTTCGGCTTTCAAGGACGTCTCCTGCACTTGTCCGCAG</entry></row><row><entry> </entry></row><row><entry>GACAGAGGTTGGGCGTCCATTTACACACTGAGGCACGGGCACGGCACGCTTGGCAGCTTACCCA</entry></row><row><entry> </entry></row><row><entry>GGGAGCCACCGTGCTGGGACTCTTTAGAGTGACACCCGAGATCCCCGCTGGCTTGTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;51:&#x2003;SI-79P3&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DPVLTQSPSSLSASVGDRVTISCQSSQSVAKNNNLAWFQQKPGQAPKLLIYSASTLAAGVPSRF</entry></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLTISSVQPEDFATYYCSARDSGNIQSFGGGTKVEIKRTVAAPSVFIFPPSDEQL</entry></row><row><entry> </entry></row><row><entry>KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKH</entry></row><row><entry> </entry></row><row><entry>KVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;52:&#x2003;SI-79P3&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACGGTACTGGG</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCC</entry></row><row><entry> </entry></row><row><entry>GATCCAGTTCTGACACAAAGTCCATCCAGCCTGTCTGCCTCAGTCGGCGACAGAGTGACCATCA</entry></row><row><entry> </entry></row><row><entry>GTTGCCAGAGCTCACAGTCTGTGGCTAAGAACAACAACTTGGCGTGGTTCCAACAGAAACCTGG</entry></row><row><entry> </entry></row><row><entry>ACAGGCTCCGAAATTGCTGATCTATTCTGCTTCCACGCTTGCTGCTGGTGTTCCTTCCCGCTTT</entry></row><row><entry> </entry></row><row><entry>TCAGGTAGTGGTAGCGGGACAGACTTCACTTTGACTATAAGCAGCGTGCAGCCTGAAGATTTTG</entry></row><row><entry> </entry></row><row><entry>CGACCTACTATTGTTCTGCTAGAGACAGTGGAAATATTCAGTCCTTTGGGGGGGGAACGAAGGT</entry></row><row><entry> </entry></row><row><entry>CGAAATAAAGCGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG</entry></row><row><entry> </entry></row><row><entry>AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC</entry></row><row><entry> </entry></row><row><entry>AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG</entry></row><row><entry> </entry></row><row><entry>CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC</entry></row><row><entry> </entry></row><row><entry>AAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA</entry></row><row><entry> </entry></row><row><entry>GGGGAGAGTGTTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;53:&#x2003;SI-55H11&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSC<u style="single">RASQSIGTNIH</u>WYQQKPGKPPRLLIK<u style="single">YASESIS</u>GIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYC<u style="single">QQNNNWPTT</u>FGPGTKLTVLGGGGSGGGGSGGGGSGGGGSQ</entry></row><row><entry> </entry></row><row><entry>VQLQQSGPGLVKPSETLSITCTVSGFSLT<u style="single">NYGVH</u>WIRQAPGKGLEWLG<u style="single">VIWSGGNTDYNTPFTS</u></entry></row><row><entry> </entry></row><row><entry>RFTITKDNSKNQVYFKLRSVRADDTAIYYCAR<u style="single">ALTYYDYEFAY</u>WGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>GGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTIS<u style="single">TNAMS</u>WVREAPGKCLEWIG<u style="single">VITGR</u></entry></row><row><entry> </entry></row><row><entry><u style="single">DITYYASWAKG</u>RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR<u style="single">DGGSSAITSNNI</u>WGQGTLVTV</entry></row><row><entry> </entry></row><row><entry>SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL</entry></row><row><entry> </entry></row><row><entry>YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLF</entry></row><row><entry> </entry></row><row><entry>PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT</entry></row><row><entry> </entry></row><row><entry>VLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG</entry></row><row><entry> </entry></row><row><entry>FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH</entry></row><row><entry> </entry></row><row><entry>YTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSF<u style="single">SSGYDMC</u>WVRQAPG</entry></row><row><entry> </entry></row><row><entry>KGLEWIA<u style="single">CIAAGSAGITYDANWAKG</u>RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR<u style="single">SAFSFDY</u></entry></row><row><entry> </entry></row><row><entry><u style="single">AMDLW</u>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITC<u style="single">QASQSI</u></entry></row><row><entry> </entry></row><row><entry><u style="single">SSHLN</u>WYQQKPGKAPKLLIY<u style="single">KASTLAS</u>GVPSRFSGSGSGTEFTLTISSLQPDDFATYYC<u style="single">QQGYS</u></entry></row><row><entry> </entry></row><row><entry><u style="single">WGNVDNV</u>FGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTIS<u style="single">SYHMQ</u>WV</entry></row><row><entry> </entry></row><row><entry>RQAPGKGLEYIG<u style="single">TISSGGNVYYASSARG</u>RFTISRPSSKNTVDLQMNSLRAEDTAVYYCAR<u style="single">DSGY</u></entry></row><row><entry> </entry></row><row><entry><u style="single">SDPM</u>WGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITC<u style="single">QASQNI</u></entry></row><row><entry> </entry></row><row><entry><u style="single">RTYLS</u>WYQQKPGKAPKLLIY<u style="single">AAANLAS</u>GVPSRFSGSGSGTDFTLTISDLEPGDAATYYC<u style="single">QSTYL</u></entry></row><row><entry> </entry></row><row><entry><u style="single">GTDYVGGA</u>FGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;54:&#x2003;SI-55H11&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGCTGACCGTTTT</entry></row><row><entry> </entry></row><row><entry>AGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAA</entry></row><row><entry> </entry></row><row><entry>GTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTA</entry></row><row><entry> </entry></row><row><entry>CTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGG</entry></row><row><entry> </entry></row><row><entry>TTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGT</entry></row><row><entry> </entry></row><row><entry>CGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCG</entry></row><row><entry> </entry></row><row><entry>CGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGG</entry></row><row><entry> </entry></row><row><entry>TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGC</entry></row><row><entry> </entry></row><row><entry>AATGAGCTGGGTCCGCGAGGCTCCAGGGAAGTGTCTGGAGTGGATCGGAGTCATTACTGGTCGT</entry></row><row><entry> </entry></row><row><entry>GATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGA</entry></row><row><entry> </entry></row><row><entry>ACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAG</entry></row><row><entry> </entry></row><row><entry>AGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTG</entry></row><row><entry> </entry></row><row><entry>TCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTG</entry></row><row><entry> </entry></row><row><entry>GGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTG</entry></row><row><entry> </entry></row><row><entry>GAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC</entry></row><row><entry> </entry></row><row><entry>TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCA</entry></row><row><entry> </entry></row><row><entry>ACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAA</entry></row><row><entry> </entry></row><row><entry>AACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTC</entry></row><row><entry> </entry></row><row><entry>CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGG</entry></row><row><entry> </entry></row><row><entry>ACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA</entry></row><row><entry> </entry></row><row><entry>TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC</entry></row><row><entry> </entry></row><row><entry>GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCC</entry></row><row><entry> </entry></row><row><entry>CAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACAC</entry></row><row><entry> </entry></row><row><entry>CCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC</entry></row><row><entry> </entry></row><row><entry>TTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA</entry></row><row><entry> </entry></row><row><entry>CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAA</entry></row><row><entry> </entry></row><row><entry>GAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC</entry></row><row><entry> </entry></row><row><entry>TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCG</entry></row><row><entry> </entry></row><row><entry>AGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTG</entry></row><row><entry> </entry></row><row><entry>TGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGG</entry></row><row><entry> </entry></row><row><entry>AAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACT</entry></row><row><entry> </entry></row><row><entry>GGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAA</entry></row><row><entry> </entry></row><row><entry>CAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTAC</entry></row><row><entry> </entry></row><row><entry>GCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCG</entry></row><row><entry> </entry></row><row><entry>GAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCC</entry></row><row><entry> </entry></row><row><entry>TTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATT</entry></row><row><entry> </entry></row><row><entry>AGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGG</entry></row><row><entry> </entry></row><row><entry>CATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTAC</entry></row><row><entry> </entry></row><row><entry>TCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGT</entry></row><row><entry> </entry></row><row><entry>TGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGT</entry></row><row><entry> </entry></row><row><entry>CCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGG</entry></row><row><entry> </entry></row><row><entry>GTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTC</entry></row><row><entry> </entry></row><row><entry>CGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACT</entry></row><row><entry> </entry></row><row><entry>ACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCT</entry></row><row><entry> </entry></row><row><entry>TCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTAT</entry></row><row><entry> </entry></row><row><entry>AGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGG</entry></row><row><entry> </entry></row><row><entry>GAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCC</entry></row><row><entry> </entry></row><row><entry>ATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATT</entry></row><row><entry> </entry></row><row><entry>AGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTG</entry></row><row><entry> </entry></row><row><entry>CAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCAC</entry></row><row><entry> </entry></row><row><entry>TCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTT</entry></row><row><entry> </entry></row><row><entry>GGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;55:&#x2003;SI-55H11&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITC<u style="single">SASSSVSYM</u>HWYQQKPGQAPKLWIY<u style="single">DTSKLAS</u>GVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYC<u style="single">FQGSVYPFT</u>FGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLSLTCAFSGFSLS<u style="single">TSGMGVG</u>WIRQPPGKGLEWLA<u style="single">HIWWDDDKRYNPALK</u></entry></row><row><entry> </entry></row><row><entry><u style="single">S</u>RLTISKDTSKNQVYLQMNSLDAEDTAVYYCAR<u style="single">MELWSYYFDY</u>WGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DVVMTQSPSTLSASVGDRVTINC<u style="single">QASESISSWLA</u>WYQQKPGKAPKLLIY<u style="single">EASKLAS</u>GVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYC<u style="single">QGYFYFISRTYVNS</u>FGCGTKVEIKRTVAAPSVFIFPPSDE</entry></row><row><entry> </entry></row><row><entry>QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE</entry></row><row><entry> </entry></row><row><entry>KHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISC</entry></row><row><entry> </entry></row><row><entry><u style="single">TGTSSDVGGYNFVS</u>WYQQHPGKAPKLMIY<u style="single">DVSDRPS</u>GVSDRFSGSKSGNTASLIISGLQADDEA</entry></row><row><entry> </entry></row><row><entry>DYYC<u style="single">SSYGSSSTHVI</u>FGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLS</entry></row><row><entry> </entry></row><row><entry>LSCAASGFTFS<u style="single">SYWMS</u>WVRQAPGKGLEWVA<u style="single">NINRDGSASYYVDSVKG</u>RFTISRDDAKNSLYLQM</entry></row><row><entry> </entry></row><row><entry>NSLRAEDTAVYYCAR<u style="single">DRGVGYFDL</u>WGRGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;56:&#x2003;SI-55H11&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTAGG</entry></row><row><entry> </entry></row><row><entry>CGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCTGTGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG</entry></row><row><entry> </entry></row><row><entry>CAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCA</entry></row><row><entry> </entry></row><row><entry>AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCA</entry></row><row><entry> </entry></row><row><entry>GGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAG</entry></row><row><entry> </entry></row><row><entry>AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCT</entry></row><row><entry> </entry></row><row><entry>TCAACAGGGGAGAGTGTGGCGGTGGCGGTAGCGGTGGCGGCGGAAGTGGTGGCGGAGGATCCCA</entry></row><row><entry> </entry></row><row><entry>GTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGC</entry></row><row><entry> </entry></row><row><entry>ACTGGAACCAGCAGTGACGTTGGTGGTTATAACTTTGTCTCCTGGTACCAACAACACCCAGGCA</entry></row><row><entry> </entry></row><row><entry>AAGCCCCCAAACTCATGATCTATGATGTCAGTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTC</entry></row><row><entry> </entry></row><row><entry>CGGCTCCAAGTCTGGCAACACGGCCTCCCTGATCATCTCTGGCCTCCAGGCTGACGACGAGGCT</entry></row><row><entry> </entry></row><row><entry>GATTATTACTGCAGCTCATATGGGAGCAGCAGCACTCATGTGATTTTCGGCGGAGGGACCAAGG</entry></row><row><entry> </entry></row><row><entry>TGACCGTCCTAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGG</entry></row><row><entry> </entry></row><row><entry>CGGCTCTCAGGTGCAATTGCAGGAGTCGGGGGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGT</entry></row><row><entry> </entry></row><row><entry>CTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTC</entry></row><row><entry> </entry></row><row><entry>CAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCGCGATGGAAGTGCGAGTTACTATGTGGA</entry></row><row><entry> </entry></row><row><entry>CTCTGTGAAGGGCCGATTCACCATCTCCAGAGACGACGCCAAGAACTCACTGTATCTGCAAATG</entry></row><row><entry> </entry></row><row><entry>AACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATCGTGGGGTGGGCTACT</entry></row><row><entry> </entry></row><row><entry>TCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCTAGCTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;57:&#x2003;SI-55H12&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLTVLGGGGSGGGGSGGGGSGGGGSQ</entry></row><row><entry> </entry></row><row><entry>VQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFTS</entry></row><row><entry> </entry></row><row><entry>RFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>GGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVREAPGKGLEWIGVITGR</entry></row><row><entry> </entry></row><row><entry>DITYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTV</entry></row><row><entry> </entry></row><row><entry>SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL</entry></row><row><entry> </entry></row><row><entry>YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLF</entry></row><row><entry> </entry></row><row><entry>PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT</entry></row><row><entry> </entry></row><row><entry>VLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG</entry></row><row><entry> </entry></row><row><entry>FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH</entry></row><row><entry> </entry></row><row><entry>YTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPG</entry></row><row><entry> </entry></row><row><entry>KGLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDY</entry></row><row><entry> </entry></row><row><entry>AMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSI</entry></row><row><entry> </entry></row><row><entry>SSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYS</entry></row><row><entry> </entry></row><row><entry>WGNVDNVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWV</entry></row><row><entry> </entry></row><row><entry>RQAPGKGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGY</entry></row><row><entry> </entry></row><row><entry>SDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNI</entry></row><row><entry> </entry></row><row><entry>RTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYL</entry></row><row><entry> </entry></row><row><entry>GTDYVGGAFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;58:&#x2003;SI-55H12&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGACCCGGTACAAAGCTGACCGTTTT</entry></row><row><entry> </entry></row><row><entry>AGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAA</entry></row><row><entry> </entry></row><row><entry>GTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGTGTA</entry></row><row><entry> </entry></row><row><entry>CTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAAAGG</entry></row><row><entry> </entry></row><row><entry>TTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACAAGT</entry></row><row><entry> </entry></row><row><entry>CGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCCGCG</entry></row><row><entry> </entry></row><row><entry>CGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGCGTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAAGGGACTCTTGTAACAGTCTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGG</entry></row><row><entry> </entry></row><row><entry>TCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCATCAGTACCAATGC</entry></row><row><entry> </entry></row><row><entry>AATGAGCTGGGTCCGCGAGGCTCCAGGGAAGGGCCTGGAGTGGATCGGAGTCATTACTGGTCGT</entry></row><row><entry> </entry></row><row><entry>GATATCACATACTACGCGAGCTGGGCGAAAGGCAGATTCACCATCTCCAGAGACAATTCCAAGA</entry></row><row><entry> </entry></row><row><entry>ACACGCTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAG</entry></row><row><entry> </entry></row><row><entry>AGACGGTGGTTCTTCTGCTATTACTAGTAACAACATTTGGGGCCAGGGAACCCTGGTCACCGTG</entry></row><row><entry> </entry></row><row><entry>TCCTCAGCTAGCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTG</entry></row><row><entry> </entry></row><row><entry>GGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTG</entry></row><row><entry> </entry></row><row><entry>GAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTC</entry></row><row><entry> </entry></row><row><entry>TACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCA</entry></row><row><entry> </entry></row><row><entry>ACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAA</entry></row><row><entry> </entry></row><row><entry>AACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTC</entry></row><row><entry> </entry></row><row><entry>CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGG</entry></row><row><entry> </entry></row><row><entry>ACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA</entry></row><row><entry> </entry></row><row><entry>TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACC</entry></row><row><entry> </entry></row><row><entry>GTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCC</entry></row><row><entry> </entry></row><row><entry>CAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACAC</entry></row><row><entry> </entry></row><row><entry>CCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGC</entry></row><row><entry> </entry></row><row><entry>TTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGA</entry></row><row><entry> </entry></row><row><entry>CCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAA</entry></row><row><entry> </entry></row><row><entry>GAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCAC</entry></row><row><entry> </entry></row><row><entry>TACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCG</entry></row><row><entry> </entry></row><row><entry>AGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTG</entry></row><row><entry> </entry></row><row><entry>TGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGG</entry></row><row><entry> </entry></row><row><entry>AAGGGGCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACT</entry></row><row><entry> </entry></row><row><entry>GGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAA</entry></row><row><entry> </entry></row><row><entry>CAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTAC</entry></row><row><entry> </entry></row><row><entry>GCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCG</entry></row><row><entry> </entry></row><row><entry>GAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCC</entry></row><row><entry> </entry></row><row><entry>TTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATT</entry></row><row><entry> </entry></row><row><entry>AGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGG</entry></row><row><entry> </entry></row><row><entry>CATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTAC</entry></row><row><entry> </entry></row><row><entry>TCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGT</entry></row><row><entry> </entry></row><row><entry>TGGGGTAATGTTGATAATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGT</entry></row><row><entry> </entry></row><row><entry>CCGGCGGTGGTGGCTCCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGG</entry></row><row><entry> </entry></row><row><entry>GTCCCTGAGACTCTCCTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTC</entry></row><row><entry> </entry></row><row><entry>CGCCAGGCTCCAGGGAAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACT</entry></row><row><entry> </entry></row><row><entry>ACGCAAGCTCCGCTAGAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCT</entry></row><row><entry> </entry></row><row><entry>TCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTAT</entry></row><row><entry> </entry></row><row><entry>AGTGATCCTATGTGGGGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGG</entry></row><row><entry> </entry></row><row><entry>GAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCC</entry></row><row><entry> </entry></row><row><entry>ATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATT</entry></row><row><entry> </entry></row><row><entry>AGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTG</entry></row><row><entry> </entry></row><row><entry>CAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCAC</entry></row><row><entry> </entry></row><row><entry>TCTCACCATCAGCGACCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTT</entry></row><row><entry> </entry></row><row><entry>GGTACTGATTATGTTGGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;59:&#x2003;SI-55H12&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLSLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DVVMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGGGTKVEIKRTVAAPSVFIFPPSDE</entry></row><row><entry> </entry></row><row><entry>QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE</entry></row><row><entry> </entry></row><row><entry>KHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISC</entry></row><row><entry> </entry></row><row><entry>TGTSSDVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEA</entry></row><row><entry> </entry></row><row><entry>DYYCSSYGSSSTHVIFGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLS</entry></row><row><entry> </entry></row><row><entry>LSCAASGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQM</entry></row><row><entry> </entry></row><row><entry>NSLRAEDTAVYYCARDRGVGYFDLWGRGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;60:&#x2003;SI-55H12&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTAGG</entry></row><row><entry> </entry></row><row><entry>CGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCGGCGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAG</entry></row><row><entry> </entry></row><row><entry>CAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCA</entry></row><row><entry> </entry></row><row><entry>AAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCA</entry></row><row><entry> </entry></row><row><entry>GGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAG</entry></row><row><entry> </entry></row><row><entry>AAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCT</entry></row><row><entry> </entry></row><row><entry>TCAACAGGGGAGAGTGTGGCGGTGGCGGTAGCGGTGGCGGCGGAAGTGGTGGCGGAGGATCCCA</entry></row><row><entry> </entry></row><row><entry>GTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGC</entry></row><row><entry> </entry></row><row><entry>ACTGGAACCAGCAGTGACGTTGGTGGTTATAACTTTGTCTCCTGGTACCAACAACACCCAGGCA</entry></row><row><entry> </entry></row><row><entry>AAGCCCCCAAACTCATGATCTATGATGTCAGTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTC</entry></row><row><entry> </entry></row><row><entry>CGGCTCCAAGTCTGGCAACACGGCCTCCCTGATCATCTCTGGCCTCCAGGCTGACGACGAGGCT</entry></row><row><entry> </entry></row><row><entry>GATTATTACTGCAGCTCATATGGGAGCAGCAGCACTCATGTGATTTTCGGCGGAGGGACCAAGG</entry></row><row><entry> </entry></row><row><entry>TGACCGTCCTAGGTGGAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGG</entry></row><row><entry> </entry></row><row><entry>CGGCTCTCAGGTGCAATTGCAGGAGTCGGGGGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGT</entry></row><row><entry> </entry></row><row><entry>CTCTCCTGTGCAGCCTCTGGATTCACCTTTAGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTC</entry></row><row><entry> </entry></row><row><entry>CAGGGAAGGGGCTGGAGTGGGTGGCCAACATAAACCGCGATGGAAGTGCGAGTTACTATGTGGA</entry></row><row><entry> </entry></row><row><entry>CTCTGTGAAGGGCCGATTCACCATCTCCAGAGACGACGCCAAGAACTCACTGTATCTGCAAATG</entry></row><row><entry> </entry></row><row><entry>AACAGCCTGAGAGCTGAGGACACGGCTGTGTATTACTGTGCGAGAGATCGTGGGGTGGGCTACT</entry></row><row><entry> </entry></row><row><entry>TCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCTAGCTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;61:&#x2003;SI-77H4&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGQGTKLTVLGGGGSGGGGSGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWVGVITGRDITYYA</entry></row><row><entry> </entry></row><row><entry>SWAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSGGGG</entry></row><row><entry> </entry></row><row><entry>SGGGGSQVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKCLEWLGVIWSGGNTD</entry></row><row><entry> </entry></row><row><entry>YNTPFTSRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSSAST</entry></row><row><entry> </entry></row><row><entry>KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry> </entry></row><row><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPK</entry></row><row><entry> </entry></row><row><entry>DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD</entry></row><row><entry> </entry></row><row><entry>WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD</entry></row><row><entry> </entry></row><row><entry>IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS</entry></row><row><entry> </entry></row><row><entry>LSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEW</entry></row><row><entry> </entry></row><row><entry>IACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLN</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVD</entry></row><row><entry> </entry></row><row><entry>NVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPG</entry></row><row><entry> </entry></row><row><entry>KGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLS</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYV</entry></row><row><entry> </entry></row><row><entry>GGAFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;62:&#x2003;SI-77H4&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTTATGACGCAGAGTCCCTCCACGCTCTCCGCTAGTGTCGGGGATCGCGTCATTATCA</entry></row><row><entry> </entry></row><row><entry>CATGCCAGGCCTCCGAGTCAATCAGCAGCTGGCTTGCATGGTATCAACAGAAGCCGGGAAAAGC</entry></row><row><entry> </entry></row><row><entry>TCCTAAATTGCTGATCTATGAAGCGTCAAAATTGGCGTCTGGTGTCCCATCTAGGTTCTCCGGC</entry></row><row><entry> </entry></row><row><entry>TCTGGGTCTGGTGCGGAATTTACTTTGACAATCTCCAGTCTTCAACCAGACGATTTCGCTACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAAGGGTATTTCTATTTTATAAGCCGGACATATGTAAACTCCTTCGGCCAAGGAAC</entry></row><row><entry> </entry></row><row><entry>AAAGTTGACTGTTCTTGGTGGCGGAGGCAGTGGTGGCGGGGGCAGCGGAGGTGGTGGTTCAGGG</entry></row><row><entry> </entry></row><row><entry>GGTGGTGGGAGCGAAGTCCAATTGGTAGAAAGTGGCGGTGGTCTGGTGCAACCTGGTGGATCTC</entry></row><row><entry> </entry></row><row><entry>TTCGCCTCTCATGCGCCGCTAGTGGCTTTACTATTTCAACTAATGCGATGAGCTGGGTTCGCCA</entry></row><row><entry> </entry></row><row><entry>GGCCCCCGGCAAAGGACTTGAGTGGGTCGGCGTCATCACCGGCAGGGACATTACATACTATGCG</entry></row><row><entry> </entry></row><row><entry>AGTTGGGCAAAGGGCAGGTTCACGATTAGCCGCGATACTTCAAAGAATACCGTTTACCTTCAAA</entry></row><row><entry> </entry></row><row><entry>TGAATAGCTTGAGGGCGGAAGACACAGCTGTGTATTACTGCGCGAGGGATGGAGGTAGTTCCGC</entry></row><row><entry> </entry></row><row><entry>CATAACTTCCAACAACATATGGGGACAAGGCACGCTGGTTACTGTCTCGAGTGGCGGTGGAGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCGGTGGTGGATCACAAGTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTG</entry></row><row><entry> </entry></row><row><entry>AGACGCTTAGTATAACGTGTACTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGAT</entry></row><row><entry> </entry></row><row><entry>TCGGCAGGCACCCGGCAAATGTTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGAC</entry></row><row><entry> </entry></row><row><entry>TATAACACCCCCTTTACAAGTCGGTTCACAATTAGGAAAGATAATTCCAAAAATCAAGTTTATT</entry></row><row><entry> </entry></row><row><entry>TCAAGTTGAGATCCGTCCGCGCGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTA</entry></row><row><entry> </entry></row><row><entry>CTACGATTACGAATTTGCGTATTGGGGGCAAGGGACTCTTGTAACAGTCTCCAGTGCTAGCACC</entry></row><row><entry> </entry></row><row><entry>AAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCC</entry></row><row><entry> </entry></row><row><entry>TGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCT</entry></row><row><entry> </entry></row><row><entry>GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC</entry></row><row><entry> </entry></row><row><entry>GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC</entry></row><row><entry> </entry></row><row><entry>CCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC</entry></row><row><entry> </entry></row><row><entry>ACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG</entry></row><row><entry> </entry></row><row><entry>GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAG</entry></row><row><entry> </entry></row><row><entry>ACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC</entry></row><row><entry> </entry></row><row><entry>GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC</entry></row><row><entry> </entry></row><row><entry>TGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA</entry></row><row><entry> </entry></row><row><entry>AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG</entry></row><row><entry> </entry></row><row><entry>GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGAC</entry></row><row><entry> </entry></row><row><entry>ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGC</entry></row><row><entry> </entry></row><row><entry>TGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA</entry></row><row><entry> </entry></row><row><entry>GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGG</entry></row><row><entry> </entry></row><row><entry>AGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT</entry></row><row><entry> </entry></row><row><entry>CTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>ATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGT</entry></row><row><entry> </entry></row><row><entry>TCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA</entry></row><row><entry> </entry></row><row><entry>GGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCG</entry></row><row><entry> </entry></row><row><entry>GTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAAC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAG</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGAT</entry></row><row><entry> </entry></row><row><entry>AATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCT</entry></row><row><entry> </entry></row><row><entry>CCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTC</entry></row><row><entry> </entry></row><row><entry>CTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGG</entry></row><row><entry> </entry></row><row><entry>AAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTA</entry></row><row><entry> </entry></row><row><entry>GAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCT</entry></row><row><entry> </entry></row><row><entry>GAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCG</entry></row><row><entry> </entry></row><row><entry>GCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGA</entry></row><row><entry> </entry></row><row><entry>CCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTT</entry></row><row><entry> </entry></row><row><entry>GGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;63:&#x2003;SI-77H4&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLSLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGCGTKLTVLRTVAAPSVFIFPPSDEQLKSG</entry></row><row><entry> </entry></row><row><entry>TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY</entry></row><row><entry> </entry></row><row><entry>ACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSS</entry></row><row><entry> </entry></row><row><entry>DVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCS</entry></row><row><entry> </entry></row><row><entry>SYGSSSTHVIFGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLSLSCAA</entry></row><row><entry> </entry></row><row><entry>SGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRA</entry></row><row><entry> </entry></row><row><entry>EDTAVYYCARDRGVGYFDLWGRGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;64:&#x2003;SI-77H4&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTAGG</entry></row><row><entry> </entry></row><row><entry>CGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGATGCGGTACAAAGCTGACCGTTTT</entry></row><row><entry> </entry></row><row><entry>ACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA</entry></row><row><entry> </entry></row><row><entry>ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGG</entry></row><row><entry> </entry></row><row><entry>TGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG</entry></row><row><entry> </entry></row><row><entry>CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC</entry></row><row><entry> </entry></row><row><entry>GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT</entry></row><row><entry> </entry></row><row><entry>GTGGCGGTGGCGGTAGCGGTGGCGGCGGAAGTGGTGGCGGAGGATCCCAGTCTGCCCTGACTCA</entry></row><row><entry> </entry></row><row><entry>GCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGT</entry></row><row><entry> </entry></row><row><entry>GACGTTGGTGGTTATAACTTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCA</entry></row><row><entry> </entry></row><row><entry>TGATCTATGATGTCAGTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTCCGGCTCCAAGTCTGG</entry></row><row><entry> </entry></row><row><entry>CAACACGGCCTCCCTGATCATCTCTGGCCTCCAGGCTGACGACGAGGCTGATTATTACTGCAGC</entry></row><row><entry> </entry></row><row><entry>TCATATGGGAGCAGCAGCACTCATGTGATTTTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTG</entry></row><row><entry> </entry></row><row><entry>GAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTGCA</entry></row><row><entry> </entry></row><row><entry>ATTGCAGGAGTCGGGGGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGTCTCTCCTGTGCAGCC</entry></row><row><entry> </entry></row><row><entry>TCTGGATTCACCTTTAGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGG</entry></row><row><entry> </entry></row><row><entry>AGTGGGTGGCCAACATAAACCGCGATGGAAGTGCGAGTTACTATGTGGACTCTGTGAAGGGCCG</entry></row><row><entry> </entry></row><row><entry>ATTGAGCATCTCCAGAGACGAGGCCAAGAACTGAGTGTATCTGCAAATGAACAGCCTGAGAGCT</entry></row><row><entry> </entry></row><row><entry>GAGGACACGGCTGTGTATTACTGTGCGAGAGATCGTGGGGTGGGCTACTTCGATCTCTGGGGCC</entry></row><row><entry> </entry></row><row><entry>GTGGCACCCTGGTCACCGTCTCTAGCTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;65:&#x2003;SI-77H5&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGQGTKLTVLGGGGSGGGGSGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSEVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWVGVITGRDITYYA</entry></row><row><entry> </entry></row><row><entry>SWAKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSSGGGG</entry></row><row><entry> </entry></row><row><entry>SGGGGSQVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKCLEWLGVIWSGGNTD</entry></row><row><entry> </entry></row><row><entry>YNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSSAST</entry></row><row><entry> </entry></row><row><entry>KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS</entry></row><row><entry> </entry></row><row><entry>VVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPK</entry></row><row><entry> </entry></row><row><entry>DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD</entry></row><row><entry> </entry></row><row><entry>WLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSD</entry></row><row><entry> </entry></row><row><entry>IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS</entry></row><row><entry> </entry></row><row><entry>LSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKGLEW</entry></row><row><entry> </entry></row><row><entry>IACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCQASQSISSHLN</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVD</entry></row><row><entry> </entry></row><row><entry>NVFGGGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPG</entry></row><row><entry> </entry></row><row><entry>KGLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMW</entry></row><row><entry> </entry></row><row><entry>GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVGDRVTITCQASQNIRTYLS</entry></row><row><entry> </entry></row><row><entry>WYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYV</entry></row><row><entry> </entry></row><row><entry>GGAFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;66:&#x2003;SI-77H5&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTTATGACGCAGAGTCCCTCCACGCTCTCCGCTAGTGTCGGGGATCGCGTCATTATCA</entry></row><row><entry> </entry></row><row><entry>CATGCCAGGCCTCCGAGTCAATCAGCAGCTGGCTTGCATGGTATCAACAGAAGCCGGGAAAAGC</entry></row><row><entry> </entry></row><row><entry>TCCTAAATTGCTGATCTATGAAGCGTCAAAATTGGCGTCTGGTGTCCCATCTAGGTTCTCCGGC</entry></row><row><entry> </entry></row><row><entry>TCTGGGTCTGGTGCGGAATTTACTTTGACAATCTCCAGTCTTCAACCAGACGATTTCGCTACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAAGGGTATTTCTATTTTATAAGCCGGACATATGTAAACTCCTTCGGCCAAGGAAC</entry></row><row><entry> </entry></row><row><entry>AAAGTTGACTGTTCTTGGTGGCGGAGGCAGTGGTGGCGGGGGCAGCGGAGGTGGTGGTTCAGGG</entry></row><row><entry> </entry></row><row><entry>GGTGGTGGGAGCGAAGTCCAATTGGTAGAAAGTGGCGGTGGTCTGGTGCAACCTGGTGGATCTC</entry></row><row><entry> </entry></row><row><entry>TTCGCCTCTCATGCGCCGCTAGTGGCTTTACTATTTCAACTAATGCGATGAGCTGGGTTCGCCA</entry></row><row><entry> </entry></row><row><entry>GGCCCCCGGCAAAGGACTTGAGTGGGTCGGCGTCATCACCGGCAGGGACATTACATACTATGCG</entry></row><row><entry> </entry></row><row><entry>AGTTGGGCAAAGGGCAGGTTCACGATTAGCCGCGATACTTCAAAGAATACCGTTTACCTTCAAA</entry></row><row><entry> </entry></row><row><entry>TGAATAGCTTGAGGGCGGAAGACACAGCTGTGTATTACTGCGCGAGGGATGGAGGTAGTTCCGC</entry></row><row><entry> </entry></row><row><entry>CATAACTTCCAACAACATATGGGGACAAGGCACGCTGGTTACTGTCTCGAGTGGCGGTGGAGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCGGTGGTGGATCACAGGTGCAGCTGAAGCAGTCAGGACCTGGCCTAGTGCAGCCCTCAC</entry></row><row><entry> </entry></row><row><entry>AGAGCCTGTCCATCACCTGCACAGTCTCTGGTTTCTCATTAACTAACTATGGTGTACACTGGGT</entry></row><row><entry> </entry></row><row><entry>TCGCCAGTCTCCAGGAAAGTGTCTGGAGTGGCTGGGAGTGATATGGAGTGGTGGAAACACAGAC</entry></row><row><entry> </entry></row><row><entry>TATAATACACCTTTCACATCCAGACTGAGCATCAACAAGGACAATTCCAAGAGCCAAGTTTTCT</entry></row><row><entry> </entry></row><row><entry>TTAAAATGAACAGTCTGCAATCTAATGACACAGCCATATATTACTGTGCCAGAGCCCTCACCTA</entry></row><row><entry> </entry></row><row><entry>CTATGATTACGAGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCGAGTGCTAGCACC</entry></row><row><entry> </entry></row><row><entry>AAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCC</entry></row><row><entry> </entry></row><row><entry>TGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCT</entry></row><row><entry> </entry></row><row><entry>GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC</entry></row><row><entry> </entry></row><row><entry>GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC</entry></row><row><entry> </entry></row><row><entry>CCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCC</entry></row><row><entry> </entry></row><row><entry>ACCGTGCCCAGCACCTGAAGCCGCGGGGGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG</entry></row><row><entry> </entry></row><row><entry>GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAG</entry></row><row><entry> </entry></row><row><entry>ACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCC</entry></row><row><entry> </entry></row><row><entry>GCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGAC</entry></row><row><entry> </entry></row><row><entry>TGGCTGAATGGCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGA</entry></row><row><entry> </entry></row><row><entry>AAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG</entry></row><row><entry> </entry></row><row><entry>GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGAC</entry></row><row><entry> </entry></row><row><entry>ATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGC</entry></row><row><entry> </entry></row><row><entry>TGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCA</entry></row><row><entry> </entry></row><row><entry>GGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC</entry></row><row><entry> </entry></row><row><entry>CTCTCCCTGTCTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGG</entry></row><row><entry> </entry></row><row><entry>AGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT</entry></row><row><entry> </entry></row><row><entry>CTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGG</entry></row><row><entry> </entry></row><row><entry>ATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGT</entry></row><row><entry> </entry></row><row><entry>TCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGA</entry></row><row><entry> </entry></row><row><entry>GGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTGTCGAGCGGTGGAGGCGGATCTGGCGGAGGTGGTTCCGGCG</entry></row><row><entry> </entry></row><row><entry>GTGGCGGCTCCGGTGGAGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAAC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAG</entry></row><row><entry> </entry></row><row><entry>CCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGAT</entry></row><row><entry> </entry></row><row><entry>AATGTTTTCGGCGGAGGGACCAAGGTGGAGATCAAAGGCGGTGGAGGGTCCGGCGGTGGTGGCT</entry></row><row><entry> </entry></row><row><entry>CCGGACGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTC</entry></row><row><entry> </entry></row><row><entry>CTGTACTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGCCAGGCTCCAGGG</entry></row><row><entry> </entry></row><row><entry>AAGGGGCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTA</entry></row><row><entry> </entry></row><row><entry>GAGGCAGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCT</entry></row><row><entry> </entry></row><row><entry>GAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGG</entry></row><row><entry> </entry></row><row><entry>GGCCAGGGAACCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCG</entry></row><row><entry> </entry></row><row><entry>GCGGAGGGTCCGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGC</entry></row><row><entry> </entry></row><row><entry>ATCTGTAGGAGACAGAGTCACCATCACCTGTGAGGCGAGTCAGAACATTAGGAGTTACTTATCC</entry></row><row><entry> </entry></row><row><entry>TGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCAT</entry></row><row><entry> </entry></row><row><entry>CTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGA</entry></row><row><entry> </entry></row><row><entry>CCTGGAGCCTGGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTT</entry></row><row><entry> </entry></row><row><entry>GGCGGTGCTTTCGGCGGAGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;67:&#x2003;SI-77H5&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVLGGGGSGGGGSGGGGSGGGGSQV</entry></row><row><entry> </entry></row><row><entry>TLKESGPGLVQPGQTLSLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALK</entry></row><row><entry> </entry></row><row><entry>SRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGCGTKLELKRTVAAPSVFIFPPSDEQLKSG</entry></row><row><entry> </entry></row><row><entry>TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVY</entry></row><row><entry> </entry></row><row><entry>ACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSS</entry></row><row><entry> </entry></row><row><entry>DVGGYNFVSWYQQHPGKAPKLMIYDVSDRPSGVSDRFSGSKSGNTASLIISGLQADDEADYYCS</entry></row><row><entry> </entry></row><row><entry>SYGSSSTHVIFGGGTKVTVLGGGGSGGGGSGGGGSGGGGSQVQLQESGGGLVKPGGSLSLSCAA</entry></row><row><entry> </entry></row><row><entry>SGFTFSSYWMSWVRQAPGKGLEWVANINRDGSASYYVDSVKGRFTISRDDAKNSLYLQMNSLRA</entry></row><row><entry> </entry></row><row><entry>EDTAVYYCARDRGVGYFDLWGRGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;68:&#x2003;SI-77H5&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTAGG</entry></row><row><entry> </entry></row><row><entry>CGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTCCGGCGGTGGAGGATCACAGGTC</entry></row><row><entry> </entry></row><row><entry>ACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCTGTGCCT</entry></row><row><entry> </entry></row><row><entry>TCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAA</entry></row><row><entry> </entry></row><row><entry>AGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTG</entry></row><row><entry> </entry></row><row><entry>ACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTTTGATTA</entry></row><row><entry> </entry></row><row><entry>TTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCA</entry></row><row><entry> </entry></row><row><entry>GACATCTTGCTGACTCAGTCTCCAGTCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGTTTCT</entry></row><row><entry> </entry></row><row><entry>CCTGCAGGGCCAGTCAGAGTATTGGCACAAACATACACTGGTATCAGCAAAGAACAAATGGTTC</entry></row><row><entry> </entry></row><row><entry>TCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATCTCTGGGATTCCTTCCAGGTTTAGTGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCAGGGACAGATTTTACTCTTAGCATCAACAGTGTGGAGTCTGAAGATATTGCAGATT</entry></row><row><entry> </entry></row><row><entry>ATTACTGTCAACAAAATAATAACTGGCCAACCACGTTCGGTTGTGGGACCAAGCTGGAGCTGAA</entry></row><row><entry> </entry></row><row><entry>ACGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA</entry></row><row><entry> </entry></row><row><entry>ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGG</entry></row><row><entry> </entry></row><row><entry>TGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAG</entry></row><row><entry> </entry></row><row><entry>CACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC</entry></row><row><entry> </entry></row><row><entry>GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT</entry></row><row><entry> </entry></row><row><entry>GTGGCGGTGGCGGTAGCGGTGGCGGCGGAAGTGGTGGCGGAGGATCCCAGTCTGCCCTGACTCA</entry></row><row><entry> </entry></row><row><entry>GCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGAACCAGCAGT</entry></row><row><entry> </entry></row><row><entry>GACGTTGGTGGTTATAACTTTGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTCA</entry></row><row><entry> </entry></row><row><entry>TGATCTATGATGTCAGTGATCGGCCCTCAGGGGTGTCTGATCGCTTCTCCGGCTCCAAGTCTGG</entry></row><row><entry> </entry></row><row><entry>CAACACGGCCTCCCTGATCATCTCTGGCCTCCAGGCTGACGACGAGGCTGATTATTACTGCAGC</entry></row><row><entry> </entry></row><row><entry>TCATATGGGAGCAGCAGCACTCATGTGATTTTCGGCGGAGGGACCAAGGTGACCGTCCTAGGTG</entry></row><row><entry> </entry></row><row><entry>GAGGCGGTTCAGGCGGAGGTGGTTCCGGCGGTGGCGGCTCCGGTGGAGGCGGCTCTCAGGTGCA</entry></row><row><entry> </entry></row><row><entry>ATTGCAGGAGTCGGGGGGAGGCCTGGTCAAGCCTGGAGGGTCCCTGAGTCTCTCCTGTGCAGCC</entry></row><row><entry> </entry></row><row><entry>TCTGGATTCACCTTTAGTAGTTATTGGATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGG</entry></row><row><entry> </entry></row><row><entry>AGTGGGTGGCCAACATAAACCGCGATGGAAGTGCGAGTTACTATGTGGACTCTGTGAAGGGCCG</entry></row><row><entry> </entry></row><row><entry>ATTGAGCATCTCCAGAGACGAGGCCAAGAACTGAGTGTATCTGCAAATGAACAGCCTGAGAGCT</entry></row><row><entry> </entry></row><row><entry>GAGGACACGGCTGTGTATTACTGTGCGAGAGATCGTGGGGTGGGCTACTTCGATCTCTGGGGCC</entry></row><row><entry> </entry></row><row><entry>GTGGCACCCTGGTCACCGTCTCTAGCTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;69:&#x2003;&#x3b1;EGFR&#x2003;H1&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCKVSGFSLTNYGVHWVRQAPGKGLEWVGVIWSGGNTDYNTPFT</entry></row><row><entry> </entry></row><row><entry>SRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARALTYYDYEFAYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;70:&#x2003;&#x3b1;EGFR&#x2003;H1&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAGTTCAGCTGGTGGAATCCGGCGGAGGATTGGTTCAACCTGGCGGCTCTCTGAGACTGTCCT</entry></row><row><entry> </entry></row><row><entry>GTAAGGTGTCTGGCTTCTCCCTGACCAACTACGGCGTGCACTGGGTCCGACAGGCACCTGGAAA</entry></row><row><entry> </entry></row><row><entry>AGGACTGGAATGGGTCGGAGTGATTTGGAGCGGCGGCAACACCGACTACAACACCCCTTTCACC</entry></row><row><entry> </entry></row><row><entry>AGCCGGTTCACCATCTCTCGGGACACCTCCAAGAACACCGTGTACCTGCAGATGAACTCCCTGA</entry></row><row><entry> </entry></row><row><entry>GAGCCGAGGACACCGCCGTGTACTATTGTGCTAGAGCCCTGACCTACTATGACTACGAGTTCGC</entry></row><row><entry> </entry></row><row><entry>CTATTGGGGCCAGGGAACCCTGGTCACAGTCTCCTCT</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;71:&#x2003;&#x3b1;EGFR&#x2003;H1&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCRASQSIGTNIHWYQQKPGKAPKLLIYYASESISGIPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQQNNNWPTTFGQGTKLTVL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;72:&#x2003;&#x3b1;EGFR&#x2003;H1&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGATGACCCAGTCTCCTTCCACACTGTCCGCCTCTGTGGGCGACAGAGTGATCATCA</entry></row><row><entry> </entry></row><row><entry>CCTGTAGAGCCAGCCAGTCCATCGGCACCAACATCCACTGGTATCAGCAGAAGCCTGGCAAGGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTGCTGATCTACTACGCCTCCGAGTCTATCAGCGGCATCCCCTCCAGATTCTCCGGC</entry></row><row><entry> </entry></row><row><entry>TCTGGATCTGGCGCTGAGTTTACCCTGACAATCTCCAGCCTGCAGCCTGACGACTTCGCCACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTTGGCCAGGGCACCAAACTGACAGTTCT</entry></row><row><entry> </entry></row><row><entry>T</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;73:&#x2003;&#x3b1;EGFR&#x2003;H4&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFT</entry></row><row><entry> </entry></row><row><entry>SRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;74:&#x2003;CEGFR&#x2003;H4&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAAGTTCAGTTGCAGCAGTCTGGCCCTGGCCTGGTCAAGCCTTCTGAGACACTGTCCATCACCT</entry></row><row><entry> </entry></row><row><entry>GTACCGTGTCCGGCTTCTCCCTGACCAATTACGGCGTGCACTGGATCAGACAGGCCCCTGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGACTGGAATGGCTGGGAGTGATTTGGAGCGGCGGCAACACCGACTACAACACCCCTTTCACC</entry></row><row><entry> </entry></row><row><entry>AGCCGGTTCACCATCACCAAGGACAACTCCAAGAACCAGGTGTACTTCAAGCTGCGGAGCGTGC</entry></row><row><entry> </entry></row><row><entry>GGGCTGATGACACCGCCATCTACTACTGTGCTCGGGCCCTGACCTACTACGACTACGAGTTTGC</entry></row><row><entry> </entry></row><row><entry>TTACTGGGGCCAGGGCACCCTGGTCACAGTTTCTTCT</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;75:&#x2003;&#x3b1;EGFR&#x2003;H4&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLELK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;76:&#x2003;&#x3b1;EGFR&#x2003;H4&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGCTGACCCAGTCTCCTTCCACACTGTCTGTGTCTCCCGGCGAGAGAGCCACCTTCA</entry></row><row><entry> </entry></row><row><entry>GCTGTAGAGCCTCTCAGTCCATCGGCACCAACATCCACTGGTATCAGCAGAAGCCCGGCAAGCC</entry></row><row><entry> </entry></row><row><entry>TCCTCGGCTGCTGATTAAGTACGCCTCCGAGTCCATCAGCGGCATCCCTGACAGATTCTCCGGC</entry></row><row><entry> </entry></row><row><entry>TCTGGCTCTGGCACCGAGTTTACCCTGACCATCTCCTCCGTGCAGTCCGAGGATTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTTGGACCCGGCACCAAGCTGGAATTGAA</entry></row><row><entry> </entry></row><row><entry>A</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;77:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKGLEWLGVIWSGGNTDYNTPFT</entry></row><row><entry> </entry></row><row><entry>SRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;78:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAAGTTCAGTTGCAGCAGTCTGGCCCTGGCCTGGTCAAGCCTTCTGAGACACTGTCCATCACCT</entry></row><row><entry> </entry></row><row><entry>GTACCGTGTCCGGCTTCTCCCTGACCAATTACGGCGTGCACTGGATCAGACAGGCCCCTGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGACTGGAATGGCTGGGAGTGATTTGGAGCGGCGGCAACACCGACTACAACACCCCTTTCACC</entry></row><row><entry> </entry></row><row><entry>AGCCGGTTCACCATCACCAAGGACAACTCCAAGAACCAGGTGTACTTCAAGCTGCGGAGCGTGC</entry></row><row><entry> </entry></row><row><entry>GGGCTGATGACACCGCCATCTACTACTGTGCTCGGGCCCTGACCTACTACGACTACGAGTTTGC</entry></row><row><entry> </entry></row><row><entry>TTACTGGGGCCAGGGCACCCTGGTCACAGTTTCTTCT</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;79:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGPGTKLTVL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;80:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGCTGACCCAGTCTCCTTCCACACTGTCTGTGTCTCCCGGCGAGAGAGCCACCTTCA</entry></row><row><entry> </entry></row><row><entry>GCTGTAGAGCCTCTCAGTCCATCGGCACCAACATCCACTGGTATCAGCAGAAGCCCGGCAAGCC</entry></row><row><entry> </entry></row><row><entry>TCCTCGGCTGCTGATTAAGTACGCCTCCGAGTCCATCAGCGGCATCCCTGACAGATTCTCCGGC</entry></row><row><entry> </entry></row><row><entry>TCTGGCTCTGGCACCGAGTTTACCCTGACCATCTCCTCCGTGCAGTCCGAGGATTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAGCAGAACAACAACTGGCCCACCACCTTTGGACCCGGCACCAAGCTGACAGTTCT</entry></row><row><entry> </entry></row><row><entry>T</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;81:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VH&#x2003;staple&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QVQLQQSGPGLVKPSETLSITCTVSGFSLTNYGVHWIRQAPGKCLEWLGVIWSGGNTDYNTPFT</entry></row><row><entry> </entry></row><row><entry>SRFTITKDNSKNQVYFKLRSVRADDTAIYYCARALTYYDYEFAYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;82:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VH&#x2003;staple&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAAGTACAGTTGCAGCAATCCGGTCCCGGTCTCGTCAAACCGAGTGAGACGCTTAGTATAACGT</entry></row><row><entry> </entry></row><row><entry>GTACTGTTTCAGGCTTTAGCCTTACGAACTATGGAGTTCACTGGATTCGGCAGGCACCCGGCAA</entry></row><row><entry> </entry></row><row><entry>ATGTTTGGAATGGCTGGGTGTTATTTGGTCAGGTGGAAATACAGACTATAACACCCCCTTTACA</entry></row><row><entry> </entry></row><row><entry>AGTCGGTTCACAATTACGAAAGATAATTCCAAAAATCAAGTTTATTTCAAGTTGAGATCCGTCC</entry></row><row><entry> </entry></row><row><entry>GCGCGGACGACACTGCGATCTACTATTGTGCGAGGGCACTGACCTACTACGATTACGAATTTGC</entry></row><row><entry> </entry></row><row><entry>GTATTGGGGGCAAGGGACTCTTGTAACAGTCTCCAGT</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;83:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VL&#x2003;staple&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVLTQSPSTLSVSPGERATFSCRASQSIGTNIHWYQQKPGKPPRLLIKYASESISGIPDRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSVQSEDFAVYYCQQNNNWPTTFGCGTKLTVL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;84:&#x2003;&#x3b1;EGFR&#x2003;H7&#x2003;VL&#x2003;staple&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTCCTTACACAATCTCCTAGCACACTGAGTGTGAGCCCCGGCGAACGCGCGACTTTCT</entry></row><row><entry> </entry></row><row><entry>CTTGCAGGGCAAGTCAATCCATAGGGACTAATATACATTGGTATCAACAAAAGCCAGGTAAACC</entry></row><row><entry> </entry></row><row><entry>ACCCAGGCTTTTGATTAAGTATGCAAGTGAGTCTATTTCCGGTATCCCTGACCGCTTCTCTGGA</entry></row><row><entry> </entry></row><row><entry>TCAGGCAGTGGCACAGAGTTCACACTCACCATATCTAGTGTGCAATCAGAGGACTTCGCCGTGT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGAATAATAACTGGCCGACTACCTTCGGATGCGGTACAAAGCTGACCGTTTT</entry></row><row><entry> </entry></row><row><entry>A</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;85:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;H1&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QVTLKESGPGLVQPGQTLSLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPA</entry></row><row><entry> </entry></row><row><entry>LKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;86:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;H1&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGCCTCACCT</entry></row><row><entry> </entry></row><row><entry>GTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCC</entry></row><row><entry> </entry></row><row><entry>CGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCC</entry></row><row><entry> </entry></row><row><entry>TTGAAAAGTCGGCTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATA</entry></row><row><entry> </entry></row><row><entry>GCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCTCGGATGGAACTCTGGTCTTACTACTT</entry></row><row><entry> </entry></row><row><entry>TGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGT</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;87:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;H1&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKVTVL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;88:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;H1&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAAGTGACCGTCCTA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;89:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;staple&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKCLEWIGVITGRDITYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVST</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;90:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;staple&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCT</entry></row><row><entry> </entry></row><row><entry>GTGCAGCCTCTGGATTCACCATCAGTACCAATGCAATGAGCTGGGTCCGCCAGGCTCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>GTGCCTGGAGTGGATCGGAGTCATTACTGGTCGTGATATCACATACTACGCGAGCTGGGCGAAA</entry></row><row><entry> </entry></row><row><entry>GGCAGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGA</entry></row><row><entry> </entry></row><row><entry>GAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGACGGTGGTTCTTCTGCTATTACTAGTAA</entry></row><row><entry> </entry></row><row><entry>CAACATTTGGGGCCAGGGAACCCTGGTCACCGTGTCGACA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;91:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;staple&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DNNMTQSPSTLSASVGDRVTINCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;92:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;staple&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACGTCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>ATTGCCAAGCCAGTGAGAGCATTAGCAGTTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGAAGCATCCAAACTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAAGGCTATTTTTATTTTATTAGTCGTACTTATGTAAATTCTTTCGGCTGTGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGAGATCAAA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;93:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCAASGFTISTNAMSWVRQAPGKGLEWVGVITGRDITYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;94:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAGTCCAATTGGTAGAAAGTGGCGGTGGTCTGGTGCAACCTGGTGGATCTCTTCGCCTCTCAT</entry></row><row><entry> </entry></row><row><entry>GCGCCGCTAGTGGCTTTACTATTTCAACTAATGCGATGAGCTGGGTTCGCCAGGCCCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>AGGACTTGAGTGGGTCGGCGTCATCACCGGCAGGGACATTACATACTATGCGAGTTGGGCAAAG</entry></row><row><entry> </entry></row><row><entry>GGCAGGTTCACGATTAGCCGCGATACTTCAAAGAATACCGTTTACCTTCAAATGAATAGCTTGA</entry></row><row><entry> </entry></row><row><entry>GGGCGGAAGACACAGCTGTGTATTACTGCGCGAGGGATGGAGGTAGTTCCGCCATAACTTCCAA</entry></row><row><entry> </entry></row><row><entry>CAACATATGGGGACAAGGCACGCTGGTTACTGTCTCGAGT</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;95:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGQGTKLTVL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;96:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAATCGTTATGACGCAGAGTCCCTCCACGCTCTCCGCTAGTGTCGGGGATCGCGTCATTATCA</entry></row><row><entry> </entry></row><row><entry>CATGCCAGGCCTCCGAGTCAATCAGCAGCTGGCTTGCATGGTATCAACAGAAGCCGGGAAAAGC</entry></row><row><entry> </entry></row><row><entry>TCCTAAATTGCTGATCTATGAAGCGTCAAAATTGGCGTCTGGTGTCCCATCTAGGTTCTCCGGC</entry></row><row><entry> </entry></row><row><entry>TCTGGGTCTGGTGCGGAATTTACTTTGACAATCTCCAGTCTTCAACCAGACGATTTCGCTACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAAGGGTATTTCTATTTTATAAGCCGGACATATGTAAACTCCTTCGGCCAAGGAAC</entry></row><row><entry> </entry></row><row><entry>AAAGTTGACTGTTCTT</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;97:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;staple&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EVQLVESGGGLVQPGGSLRLSCTASGFTISTNAMSWVRQAPGKCLEWVGVITGRDITYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVST</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;98:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;staple&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGGCTGAGCT</entry></row><row><entry> </entry></row><row><entry>GCACCGCCAGCGGCTTCACCATCAGCACCAACGCCATGAGCTGGGTGAGGCAGGCCCCCGGCAA</entry></row><row><entry> </entry></row><row><entry>GTGCCTGGAGTGGGTGGGCGTGATCACCGGCAGGGACATCACCTACTACGCCAGCTGGGCCAAG</entry></row><row><entry> </entry></row><row><entry>GGCAGGTTCACCATCAGCAGGGACACCAGCAAGAACACCGTGTACCTGCAGATGAACAGCCTGA</entry></row><row><entry> </entry></row><row><entry>GGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGGACGGCGGCAGCAGCGCCATCACCAGCAA</entry></row><row><entry> </entry></row><row><entry>CAACATCTGGGGCCAGGGCACCCTGGTGACCGTGTCGACA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;99:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;staple&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKLTVL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;100:&#x2003;&#x3b1;CD3&#x2003;284A10&#x2003;H1&#x2003;staple&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGATGACCCAGAGCCCCAGCACCCTGAGCGCCAGCGTGGGCGACAGGGTGATCATCA</entry></row><row><entry> </entry></row><row><entry>CCTGCCAGGCCAGCGAGAGCATCAGCAGCTGGCTGGCCTGGTACCAGCAGAAGCCCGGCAAGGC</entry></row><row><entry> </entry></row><row><entry>CCCCAAGCTGCTGATCTACGAGGCCAGCAAGCTGGCCAGCGGCGTGCCCAGCAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGCGGCAGCGGCGCCGAGTTCACCCTGACCATCAGCAGCCTGCAGCCCGACGACTTCGCCACCT</entry></row><row><entry> </entry></row><row><entry>ACTACTGCCAGGGCTACTTCTACTTCATCAGCAGGACCTACGTGAACAGCTTCGGCTGCGGCAC</entry></row><row><entry> </entry></row><row><entry>CAAGCTGACCGTGCTG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;101:&#x2003;&#x3b1;CD3&#x2003;283E3&#x2003;H1&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QVQLQESGGRLVQPGEPLSLTCKTSGIDLSSNAIGWVRQAPGKGLEWIGVIFGSGNTYYASWAK</entry></row><row><entry> </entry></row><row><entry>GRFTISRSTSTVYLKMNSLRSEDTAIYYCARGGYSSDIWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;102:&#x2003;&#x3b1;CD3&#x2003;283E3&#x2003;H1&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAAGTGCAGTTGCAAGAAAGTGGTGGTAGACTGGTTCAGCCTGGTGAACCCTTGTCACTGACGT</entry></row><row><entry> </entry></row><row><entry>GTAAAACAAGCGGCATTGATCTGTCCTCTAACGCCATCGGATGGGTCCGACAGGCCCCAGGAAA</entry></row><row><entry> </entry></row><row><entry>AGGTCTGGAGTGGATCGGAGTTATCTTCGGGAGCGGCAATACATACTACGCAAGCTGGGCAAAA</entry></row><row><entry> </entry></row><row><entry>GGGCGATTTACGATATCACGGAGCACCTCTACAGTTTATTTGAAAATGAACTCCCTCCGGTCCG</entry></row><row><entry> </entry></row><row><entry>AGGATACCGCGATATATTACTGTGCCAGAGGGGGGTACTCCTCTGATATCTGGGGGCAGGGTAC</entry></row><row><entry> </entry></row><row><entry>ACTGGTTACAGTTTCATCC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;103:&#x2003;&#x3b1;CD3&#x2003;283E3&#x2003;H1&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DPVLTQSPSSLSASVGDRVTISCQSSQSVAKNNNLAWFQQKPGQAPKLLIYSASTLAAGVPSRF</entry></row><row><entry> </entry></row><row><entry>SGSGSGTDFTLTISSVQPEDFATYYCSARDSGNIQSFGGGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;104:&#x2003;&#x3b1;CD3&#x2003;283E3&#x2003;H1&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GATCCAGTTCTGACACAAAGTCCATCCAGCCTGTCTGCCTCAGTCGGCGACAGAGTGACCATCA</entry></row><row><entry> </entry></row><row><entry>GTTGCCAGAGCTCACAGTCTGTGGCTAAGAACAACAACTTGGCGTGGTTCCAACAGAAACCTGG</entry></row><row><entry> </entry></row><row><entry>ACAGGCTCCGAAATTGCTGATCTATTCTGCTTCCACGCTTGCTGCTGGTGTTCCTTCCCGCTTT</entry></row><row><entry> </entry></row><row><entry>TCAGGTAGTGGTAGCGGGACAGACTTCACTTTGACTATAAGCAGCGTGCAGCCTGAAGATTTTG</entry></row><row><entry> </entry></row><row><entry>CGACCTACTATTGTTCTGCTAGAGACAGTGGAAATATTCAGTCCTTTGGGGGGGGAACGAAGGT</entry></row><row><entry> </entry></row><row><entry>CGAAATAAAG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;105:&#x2003;&#x3b1;PDL1&#x2003;PL221G5&#x2003;staple&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EVQLLESGGGLVQPGGSLRLSCAASGFSFSSGYDMCWVRQAPGKCLEWIACIAAGSAGITYDAN</entry></row><row><entry> </entry></row><row><entry>WAKGRETISRDNSKNTLYLQMNSLRAEDTAVYYCARSAFSFDYAMDLWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;106:&#x2003;&#x3b1;PDL1&#x2003;PL221G5&#x2003;staple&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCT</entry></row><row><entry> </entry></row><row><entry>GTGCAGCCTCTGGATTCTCCTTCAGTAGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGG</entry></row><row><entry> </entry></row><row><entry>GAAGTGCCTGGAGTGGATCGCATGCATTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAAC</entry></row><row><entry> </entry></row><row><entry>TGGGCGAAAGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA</entry></row><row><entry> </entry></row><row><entry>ACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTA</entry></row><row><entry> </entry></row><row><entry>CGCCATGGACCTCTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;107:&#x2003;&#x3b1;PDL1&#x2003;PL221G5&#x2003;staple&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DIQMTQSPSTLSASVGDRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTEFTLTISSLQPDDFATYYCQQGYSWGNVDNVFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;108:&#x2003;&#x3b1;PDL1&#x2003;PL221G5&#x2003;staple&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCGGCTGCGGGACCAAGGT</entry></row><row><entry> </entry></row><row><entry>GGAGATCAAA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;109:&#x2003;&#x3b1;41BB&#x2003;466F6&#x2003;staple&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>RSLVESGGGLVQPGGSLRLSCTASGFTISSYHMQWVRQAPGKCLEYIGTISSGGNVYYASSARG</entry></row><row><entry> </entry></row><row><entry>RFTISRPSSKNTVDLQMNSLRAEDTAVYYCARDSGYSDPMWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;110:&#x2003;&#x3b1;41BB&#x2003;466F6&#x2003;staple&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CGGTCGCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTA</entry></row><row><entry> </entry></row><row><entry>CTGCCTCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGGCAGGCACCTGGGAAGTG</entry></row><row><entry> </entry></row><row><entry>CCTGGAGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGC</entry></row><row><entry> </entry></row><row><entry>AGATTCACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAG</entry></row><row><entry> </entry></row><row><entry>CCGAGGACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCA</entry></row><row><entry> </entry></row><row><entry>GGGAACCCTGGTCACCGTCTCTTCA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;111:&#x2003;&#x3b1;41BB&#x2003;466F6&#x2003;staple&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>DVVMTQSPSSVSASVGDRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTDFTLTISDLEPGDAATYYCQSTYLGTDYVGGAFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;112:&#x2003;&#x3b1;41BB&#x2003;466F6&#x2003;staple&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>CCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCCATCAAGGTTCAGCGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACTTGGAACCTGGCGATGCTGCAACTT</entry></row><row><entry> </entry></row><row><entry>ACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTTTCGGCTGTGGGACCAA</entry></row><row><entry> </entry></row><row><entry>GGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;113:&#x2003;4-1BB&#x2003;ligand&#x2003;trimer&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV</entry></row><row><entry> </entry></row><row><entry>VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFG</entry></row><row><entry> </entry></row><row><entry>FQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLGSTGSGSKPGSGEG</entry></row><row><entry> </entry></row><row><entry>STKGREGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDT</entry></row><row><entry> </entry></row><row><entry>KELVVAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARN</entry></row><row><entry> </entry></row><row><entry>SAFGFQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGLGGGGSGGGGS</entry></row><row><entry> </entry></row><row><entry>REGPELSPDDPAGLLDLRQGMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELV</entry></row><row><entry> </entry></row><row><entry>VAKAGVYYVFFQLELRRVVAGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFG</entry></row><row><entry> </entry></row><row><entry>FQGRLLHLSAGQRLGVHLHTEARARHAWQLTQGATVLGLFRVTPEIPAGL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;114:&#x2003;4-1BB&#x2003;ligand&#x2003;trimer&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CGAGAGGGCCCCGAGCTGTCTCCTGATGACCCAGCAGGCCTCTTGGACTTGCGGCAGGGTATGT</entry></row><row><entry> </entry></row><row><entry>TCGCTCAACTTGTGGCTCAGAATGTTCTGCTCATTGATGGACCACTCTCTTGGTATAGTGACCC</entry></row><row><entry> </entry></row><row><entry>CGGTCTGGCCGGGGTGAGTCTGACCGGCGGGCTCTCTTATAAAGAGGATACTAAGGAACTGGTC</entry></row><row><entry> </entry></row><row><entry>GTAGCAAAAGCGGGCGTTTATTACGTTTTTTTTCAGCTGGAGCTCAGGCGCGTGGTGGCCGGCG</entry></row><row><entry> </entry></row><row><entry>AGGGCAGTGGCTCTGTGTCCCTGGCCCTGCACTTACAGCCCTTGAGAAGCGCTGCAGGTGCTGC</entry></row><row><entry> </entry></row><row><entry>CGCACTGGCTTTAACTGTTGACCTCCCTCCGGCCTCTTCTGAAGCTAGAAACAGCGCTTTCGGC</entry></row><row><entry> </entry></row><row><entry>TTCCAAGGGCGCCTGCTGCACCTGAGCGCAGGCCAGCGCTTAGGTGTGCACCTTCATACAGAGG</entry></row><row><entry> </entry></row><row><entry>CCAGGGCCCGACACGCTTGGCAGCTCACACAGGGTGCCACGGTTCTCGGACTTTTCCGCGTTAC</entry></row><row><entry> </entry></row><row><entry>TCCCGAGATCCCCGCTGGCCTCGGAAGTACTGGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGT</entry></row><row><entry> </entry></row><row><entry>AGTACTAAAGGACGAGAAGGGCCAGAGTTAAGTCCAGATGACCCTGCTGGGCTTTTGGACCTGC</entry></row><row><entry> </entry></row><row><entry>GGCAGGGCATGTTCGCTCAACTGGTGGCTCAGAACGTGCTGCTGATCGATGGCCCCCTGAGTTG</entry></row><row><entry> </entry></row><row><entry>GTACAGCGATCCCGGGCTGGCAGGCGTGTCACTTACAGGGGGCCTCTCTTACAAGGAAGACACC</entry></row><row><entry> </entry></row><row><entry>AAGGAGTTAGTGGTCGCTAAGGCTGGCGTGTATTACGTGTTCTTCCAACTGGAGCTGAGAAGGG</entry></row><row><entry> </entry></row><row><entry>TTGTGGCAGGAGAGGGTAGCGGCAGCGTGTCTTTAGCCCTTCACTTGCAGCCCCTGAGGTCTGC</entry></row><row><entry> </entry></row><row><entry>TGCAGGTGCAGCCGCTCTCGCGCTCACCGTGGATCTCCCCCCAGCCTCATCTGAAGCTAGGAAC</entry></row><row><entry> </entry></row><row><entry>AGTGCATTTGGCTTTCAGGGACGCTTGCTGCACCTCTCCGCTGGACAGAGGCTGGGCGTGCACC</entry></row><row><entry> </entry></row><row><entry>TTCACACAGAGGCCCGTGCCAGGCATGCATGGCAGCTCACTCAGGGGGCAACAGTGCTGGGTCT</entry></row><row><entry> </entry></row><row><entry>CTTCCGCGTGACTCCTGAAATACCAGCTGGACTTGGCGGTGGAGGCAGCGGCGGAGGAGGATCT</entry></row><row><entry> </entry></row><row><entry>CGTGAGGGGCCAGAACTGTCCCCCGATGACCCAGCCGGACTGCTCGATCTCAGACAGGGCATGT</entry></row><row><entry> </entry></row><row><entry>TCGCTCAGCTTGTAGCCCAAAATGTCCTCCTGATTGACGGCCCTTTGAGCTGGTATAGTGATCC</entry></row><row><entry> </entry></row><row><entry>CGGCTTGGCCGGGGTATCTCTGACCGGAGGCCTCTCCTACAAGGAAGACACCAAAGAGCTGGTG</entry></row><row><entry> </entry></row><row><entry>GTGGCAAAAGCGGGGGTGTATTATGTGTTCTTTCAGCTCGAGCTGCGGAGAGTTGTGGCCGGGG</entry></row><row><entry> </entry></row><row><entry>AAGGGTCTGGGAGCGTATCTCTTGCACTTCACCTGCAGCCCCTGCGCAGCGCCGCTGGAGCCGC</entry></row><row><entry> </entry></row><row><entry>CGCCCTTGCTCTTACTGTGGATCTGCCTCCTGCTTCCTCAGAAGCACGCAACAGCGCCTTCGGC</entry></row><row><entry> </entry></row><row><entry>TTTCAAGGACGTCTCCTGCACTTGTCCGCAGGACAGAGGTTGGGCGTCCATTTACACACTGAGG</entry></row><row><entry> </entry></row><row><entry>CACGGGCACGGCACGCTTGGCAGCTTACCCAGGGAGCCACCGTGCTGGGACTCTTTAGAGTGAC</entry></row><row><entry> </entry></row><row><entry>ACCCGAGATCCCCGCTGGCTTGTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;115:&#x2003;NKG2D&#x2003;dimer&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>FLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKE</entry></row><row><entry> </entry></row><row><entry>DQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCST</entry></row><row><entry> </entry></row><row><entry>PNTYICMQRTVGGGGSGGGGSGGGGSGGGGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNC</entry></row><row><entry> </entry></row><row><entry>YQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSIL</entry></row><row><entry> </entry></row><row><entry>SPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;116:&#x2003;NKG2D&#x2003;dimer&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>TTTCTTAATTCCCTTTTCAACCAAGAGGTTCAGATCCCCTTGACTGAAAGCTATTGCGGCCCTT</entry></row><row><entry> </entry></row><row><entry>GTCCGAAAAACTGGATATGTTACAAGAATAATTGTTACCAATTCTTCGACGAAAGCAAGAACTG</entry></row><row><entry> </entry></row><row><entry>GTATGAGAGTCAGGCGTCTTGTATGAGTCAGAATGCCAGCCTGCTTAAGGTTTATTCAAAAGAA</entry></row><row><entry> </entry></row><row><entry>GACCAGGATCTGCTTAAGTTGGTAAAGAGCTACCACTGGATGGGGCTGGTACATATCCCAACGA</entry></row><row><entry> </entry></row><row><entry>ATGGGTCATGGCAGTGGGAGGACGGTTCTATTCTGAGTCCAAATCTCCTGACGATCATCGAAAT</entry></row><row><entry> </entry></row><row><entry>GCAGAAAGGGGACTGTGCCCTGTATGCATCATCCTTCAAGGGGTACATCGAGAACTGCAGTACC</entry></row><row><entry> </entry></row><row><entry>CCAAATACCTACATTTGTATGCAAAGAACGGTTGGAGGCGGTGGCTCAGGCGGAGGCGGCTCAG</entry></row><row><entry> </entry></row><row><entry>GAGGTGGCGGTTCAGGAGGCGGCGGATCTTTCCTAAACTCATTATTCAACCAAGAAGTTCAAAT</entry></row><row><entry> </entry></row><row><entry>TCCCTTGACCGAAAGTTACTGTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGC</entry></row><row><entry> </entry></row><row><entry>TACCAATTTTTTGATGAGAGTAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATG</entry></row><row><entry> </entry></row><row><entry>CCAGCCTTCTGAAAGTATACAGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCA</entry></row><row><entry> </entry></row><row><entry>TTGGATGGGACTAGTACACATTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTC</entry></row><row><entry> </entry></row><row><entry>TCACCCAACCTACTAACAATAATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCT</entry></row><row><entry> </entry></row><row><entry>TTAAAGGCTATATAGAAAACTGTTCAACTCCAAATACGTACATCTGCATGCAAAGGACTGTGTA</entry></row><row><entry> </entry></row><row><entry>G</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;117:&#x2003;SI-49P10&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKLTVLGSTGSGSKPGSGEGST</entry></row><row><entry> </entry></row><row><entry>KGEVQLVESGGGLVQPGGSLRLSCTASGFTISTNAMSWVRQAPGKCLEWVGVITGRDITYYASW</entry></row><row><entry> </entry></row><row><entry>AKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSTGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKV</entry></row><row><entry> </entry></row><row><entry>YSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIE</entry></row><row><entry> </entry></row><row><entry>NCSTPNTYICMQRTVASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG</entry></row><row><entry> </entry></row><row><entry>VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP</entry></row><row><entry> </entry></row><row><entry>APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE</entry></row><row><entry> </entry></row><row><entry>QYASTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL</entry></row><row><entry> </entry></row><row><entry>TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV</entry></row><row><entry> </entry></row><row><entry>FSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFS</entry></row><row><entry> </entry></row><row><entry>SGYDMCWVRQAPGKCLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTA</entry></row><row><entry> </entry></row><row><entry>VYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVG</entry></row><row><entry> </entry></row><row><entry>DRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQP</entry></row><row><entry> </entry></row><row><entry>DDFATYYCQQGYSWGNVDNVFGCGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTA</entry></row><row><entry> </entry></row><row><entry>SGFTISSYHMQWVRQAPGKCLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAE</entry></row><row><entry> </entry></row><row><entry>DTAVYYCARDSGYSDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVG</entry></row><row><entry> </entry></row><row><entry>DRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEP</entry></row><row><entry> </entry></row><row><entry>GDAATYYCQSTYLGTDYVGGAFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;118:&#x2003;SI-49P10&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGATGACACAATCTCCATCTACGCTCTCCGCCTCAGTGGGCGATAGAGTAATTATTA</entry></row><row><entry> </entry></row><row><entry>CTTGTCAAGCCTCAGAGAGCATTTCATCATGGCTCGCCTGGTATCAGCAAAAGCCTGGGAAGGC</entry></row><row><entry> </entry></row><row><entry>CCCCAAACTTCTCATCTATGAAGCATCAAAGCTGGCCTCTGGGGTTCCGTCTCGCTTCTCCGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCAGTGGTGCAGAGTTTACGTTGACTATATCTTCTTTGCAACCTGACGATTTCGCAACAT</entry></row><row><entry> </entry></row><row><entry>ATTATTGCCAGGGATACTTTTATTTTATTTCCCGAACATATGTTAACTCTTTTGGGTGCGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAACTCACTGTGCTGGGGTCTACCGGTAGTGGTTCTAAGCCTGGTTCAGGCGAAGGCAGTACG</entry></row><row><entry> </entry></row><row><entry>AAAGGGGAAGTGCAACTGGTCGAAAGCGGTGGAGGGCTTGTTCAACCTGGAGGAAGCCTCCGCT</entry></row><row><entry> </entry></row><row><entry>TGTCCTGCACGGCTAGCGGCTTTACAATAAGTACGAACGCCATGAGCTGGGTCCGGCAGGCTCC</entry></row><row><entry> </entry></row><row><entry>AGGTAAGTGTCTCGAATGGGTGGGGGTCATAACAGGCAGGGACATTACCTACTACGCCAGTTGG</entry></row><row><entry> </entry></row><row><entry>GCCAAGGGTCGATTTACCATTTCTAGAGATACATCCAAGAACACGGTGTACCTCCAGATGAATT</entry></row><row><entry> </entry></row><row><entry>CTCTTAGGGCGGAAGACACAGCAGTATACTACTGCGCGCGAGATGGCGGGAGCAGTGCGATCAC</entry></row><row><entry> </entry></row><row><entry>ATCCAACAACATCTGGGGTCAGGGCACTCTTGTCACGGTGTCGACTGGTGGTGGGGGTAGTGGC</entry></row><row><entry> </entry></row><row><entry>GGCGGAGGTAGCTTTCTTAATTCCCTTTTCAACCAAGAGGTTCAGATCCCCTTGACTGAAAGCT</entry></row><row><entry> </entry></row><row><entry>ATTGCGGCCCTTGTCCGAAAAACTGGATATGTTACAAGAATAATTGTTACCAATTCTTCGACGA</entry></row><row><entry> </entry></row><row><entry>AAGCAAGAACTGGTATGAGAGTCAGGCGTCTTGTATGAGTCAGAATGCCAGCCTGCTTAAGGTT</entry></row><row><entry> </entry></row><row><entry>TATTCAAAAGAAGACCAGGATCTGCTTAAGTTGGTAAAGAGCTACCACTGGATGGGGCTGGTAC</entry></row><row><entry> </entry></row><row><entry>ATATCCCAACGAATGGGTCATGGCAGTGGGAGGACGGTTCTATTCTGAGTCCAAATCTCCTGAC</entry></row><row><entry> </entry></row><row><entry>GATCATCGAAATGCAGAAAGGGGACTGTGCCCTGTATGCATCATCCTTCAAGGGGTACATCGAG</entry></row><row><entry> </entry></row><row><entry>AACTGCAGTACCCCAAATACCTACATTTGTATGCAAAGAACGGTTGCTAGCACCAAGGGCCCAT</entry></row><row><entry> </entry></row><row><entry>CGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCT</entry></row><row><entry> </entry></row><row><entry>GGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC</entry></row><row><entry> </entry></row><row><entry>GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCG</entry></row><row><entry> </entry></row><row><entry>TGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCA</entry></row><row><entry> </entry></row><row><entry>GCACCTGAAGCCGCGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA</entry></row><row><entry> </entry></row><row><entry>TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGT</entry></row><row><entry> </entry></row><row><entry>CAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG</entry></row><row><entry> </entry></row><row><entry>CAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG</entry></row><row><entry> </entry></row><row><entry>GCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC</entry></row><row><entry> </entry></row><row><entry>CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTG</entry></row><row><entry> </entry></row><row><entry>ACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGG</entry></row><row><entry> </entry></row><row><entry>AGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGA</entry></row><row><entry> </entry></row><row><entry>CGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC</entry></row><row><entry> </entry></row><row><entry>TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT</entry></row><row><entry> </entry></row><row><entry>CTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGG</entry></row><row><entry> </entry></row><row><entry>AGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGT</entry></row><row><entry> </entry></row><row><entry>AGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGTGCCTGGAGTGGATCGCATGCA</entry></row><row><entry> </entry></row><row><entry>TTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTC</entry></row><row><entry> </entry></row><row><entry>CAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCC</entry></row><row><entry> </entry></row><row><entry>GTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>CCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGTGGAAGTGGTGGTGGCGGCTC</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGCGGATCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGA</entry></row><row><entry> </entry></row><row><entry>GACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGC</entry></row><row><entry> </entry></row><row><entry>AGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>ATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCT</entry></row><row><entry> </entry></row><row><entry>GATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCG</entry></row><row><entry> </entry></row><row><entry>GCTGCGGGACCAAGGTGGAGATCAAAGGTGGTGGCGGCTCTGGAGGAGGAGGGTCCGGACGGTC</entry></row><row><entry> </entry></row><row><entry>GCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCC</entry></row><row><entry> </entry></row><row><entry>TCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGGCAGGCACCTGGGAAGTGCCTGG</entry></row><row><entry> </entry></row><row><entry>AGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATT</entry></row><row><entry> </entry></row><row><entry>CACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAG</entry></row><row><entry> </entry></row><row><entry>GACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>CCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTC</entry></row><row><entry> </entry></row><row><entry>CGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGA</entry></row><row><entry> </entry></row><row><entry>GACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGC</entry></row><row><entry> </entry></row><row><entry>AGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>ATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACTTGGAACCT</entry></row><row><entry> </entry></row><row><entry>GGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTT</entry></row><row><entry> </entry></row><row><entry>TCGGCTGTGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;119:&#x2003;SI-49P10&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid</entry></row><row><entry>sequence</entry></row><row><entry>DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIKGSTGSGSKPGSGEGSTKGQVQ</entry></row><row><entry> </entry></row><row><entry>LQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKS</entry></row><row><entry> </entry></row><row><entry>RLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSSGGGGSGGGGSGG</entry></row><row><entry> </entry></row><row><entry>GGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVY</entry></row><row><entry> </entry></row><row><entry>SKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIEN</entry></row><row><entry> </entry></row><row><entry>CSTPNTYICMQRTVRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG</entry></row><row><entry> </entry></row><row><entry>NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;120:&#x2003;SI-49P10&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide</entry></row><row><entry>sequence</entry></row><row><entry>GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCCAGGCGAGTCAGGACATCAGCAACTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGC</entry></row><row><entry> </entry></row><row><entry>CCCTAAACTCCTGATCTACGATGCATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGA</entry></row><row><entry> </entry></row><row><entry>AGTGGATCTGGGACAGATTTTACTTTCACCATCAGCAGCCTGCAGCCTGAAGATATTGCAACAT</entry></row><row><entry> </entry></row><row><entry>ATTTCTGTCAACACTTTGATCATCTCCCGCTCGCTTTCGGCGGAGGGACCAAGGTGGAAATTAA</entry></row><row><entry> </entry></row><row><entry>AGGAAGTACTGGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGTAGTACTAAAGGACAGGTGCAG</entry></row><row><entry> </entry></row><row><entry>CTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCT</entry></row><row><entry> </entry></row><row><entry>CTGGTGGCTCCGTCAGCAGTGGTGATTACTACTGGACCTGGATCCGGCAGTCCCCAGGGAAGGG</entry></row><row><entry> </entry></row><row><entry>ACTGGAGTGGATTGGACACATCTATTACAGTGGGAACACCAATTATAACCCCTCCCTCAAGAGC</entry></row><row><entry> </entry></row><row><entry>CGACTCACCATATCAATTGACACGTCCAAGACTCAGTTCTCCCTGAAGCTGAGTTCTGTGACCG</entry></row><row><entry> </entry></row><row><entry>CTGCGGACACGGCCATTTATTACTGTGTGCGAGATCGAGTGACTGGTGCTTTTGATATCTGGGG</entry></row><row><entry> </entry></row><row><entry>CCAAGGGACAATGGTCACCGTCTCGAGCGGTGGCGGCGGCTCCGGGGGTGGCGGATCAGGTGGT</entry></row><row><entry> </entry></row><row><entry>GGAGGCTCTTTCCTAAACTCATTATTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACT</entry></row><row><entry> </entry></row><row><entry>GTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAG</entry></row><row><entry> </entry></row><row><entry>TAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATAC</entry></row><row><entry> </entry></row><row><entry>AGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACA</entry></row><row><entry> </entry></row><row><entry>TTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAAT</entry></row><row><entry> </entry></row><row><entry>AATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAAC</entry></row><row><entry> </entry></row><row><entry>TGTTCAACTCCAAATACGTACATCTGCATGCAAAGGACTGTGCGTACGGTGGCTGCACCATCTG</entry></row><row><entry> </entry></row><row><entry>TCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCT</entry></row><row><entry> </entry></row><row><entry>GAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGT</entry></row><row><entry> </entry></row><row><entry>AACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCC</entry></row><row><entry> </entry></row><row><entry>TGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG</entry></row><row><entry> </entry></row><row><entry>CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;121:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;VH&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>QVTLKESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPA</entry></row><row><entry> </entry></row><row><entry>LKSRLTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;122:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;VH&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>CAGGTCACATTGAAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCT</entry></row><row><entry> </entry></row><row><entry>GTGCCTTCAGTGGTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCC</entry></row><row><entry> </entry></row><row><entry>CGGCAAAGGTCTTGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCC</entry></row><row><entry> </entry></row><row><entry>TTGAAAAGTCGGCTGAGCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATA</entry></row><row><entry> </entry></row><row><entry>GCCTTGACGCCGAGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTT</entry></row><row><entry> </entry></row><row><entry>TGATTATTGGGGGCAGGGGACTCTCGTCACGGTCTCGAGC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;123:&#x2003;SI-49P6&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKLTVLGSTGSGSKPGSGEGST</entry></row><row><entry> </entry></row><row><entry>KGEVQLVESGGGLVQPGGSLRLSCTASGFTISTNAMSWVRQAPGKCLEWVGVITGRDITYYASW</entry></row><row><entry> </entry></row><row><entry>AKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSTGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKV</entry></row><row><entry> </entry></row><row><entry>YSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIE</entry></row><row><entry> </entry></row><row><entry>NCSTPNTYICMQRTVASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG</entry></row><row><entry> </entry></row><row><entry>VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP</entry></row><row><entry> </entry></row><row><entry>APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE</entry></row><row><entry> </entry></row><row><entry>QYASTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL</entry></row><row><entry> </entry></row><row><entry>TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV</entry></row><row><entry> </entry></row><row><entry>FSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFS</entry></row><row><entry> </entry></row><row><entry>SGYDMCWVRQAPGKCLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTA</entry></row><row><entry> </entry></row><row><entry>VYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVG</entry></row><row><entry> </entry></row><row><entry>DRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQP</entry></row><row><entry> </entry></row><row><entry>DDFATYYCQQGYSWGNVDNVFGCGTKVEIKGGGGSGGGGSGRSLVESGGGLVQPGGSLRLSCTA</entry></row><row><entry> </entry></row><row><entry>SGFTISSYHMQWVRQAPGKCLEYIGTISSGGNVYYASSARGRFTISRPSSKNTVDLQMNSLRAE</entry></row><row><entry> </entry></row><row><entry>DTAVYYCARDSGYSDPMWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDVVMTQSPSSVSASVG</entry></row><row><entry> </entry></row><row><entry>DRVTITCQASQNIRTYLSWYQQKPGKAPKLLIYAAANLASGVPSRFSGSGSGTDFTLTISDLEP</entry></row><row><entry> </entry></row><row><entry>GDAATYYCQSTYLGTDYVGGAFGCGTKVEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;124:&#x2003;SI-49P6&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGATGACACAATCTCCATCTACGCTCTCCGCCTCAGTGGGCGATAGAGTAATTATTA</entry></row><row><entry> </entry></row><row><entry>CTTGTCAAGCCTCAGAGAGCATTTCATCATGGCTCGCCTGGTATCAGCAAAAGCCTGGGAAGGC</entry></row><row><entry> </entry></row><row><entry>CCCCAAACTTCTCATCTATGAAGCATCAAAGCTGGCCTCTGGGGTTCCGTCTCGCTTCTCCGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCAGTGGTGCAGAGTTTACGTTGACTATATCTTCTTTGCAACCTGACGATTTCGCAACAT</entry></row><row><entry> </entry></row><row><entry>ATTATTGCCAGGGATACTTTTATTTTATTTCCCGAACATATGTTAACTCTTTTGGGTGCGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAACTCACTGTGCTGGGGTCTACCGGTAGTGGTTCTAAGCCTGGTTCAGGCGAAGGCAGTACG</entry></row><row><entry> </entry></row><row><entry>AAAGGGGAAGTGCAACTGGTCGAAAGCGGTGGAGGGCTTGTTCAACCTGGAGGAAGCCTCCGCT</entry></row><row><entry> </entry></row><row><entry>TGTCCTGCACGGCTAGCGGCTTTACAATAAGTACGAACGCCATGAGCTGGGTCCGGCAGGCTCC</entry></row><row><entry> </entry></row><row><entry>AGGTAAGTGTCTCGAATGGGTGGGGGTCATAACAGGCAGGGACATTACCTACTACGCCAGTTGG</entry></row><row><entry> </entry></row><row><entry>GCCAAGGGTCGATTTACCATTTCTAGAGATACATCCAAGAACACGGTGTACCTCCAGATGAATT</entry></row><row><entry> </entry></row><row><entry>CTCTTAGGGCGGAAGACACAGCAGTATACTACTGCGCGCGAGATGGCGGGAGCAGTGCGATCAC</entry></row><row><entry> </entry></row><row><entry>ATCCAACAACATCTGGGGTCAGGGCACTCTTGTCACGGTGTCGACTGGTGGTGGGGGTAGTGGC</entry></row><row><entry> </entry></row><row><entry>GGCGGAGGTAGCTTTCTTAATTCCCTTTTCAACCAAGAGGTTCAGATCCCCTTGACTGAAAGCT</entry></row><row><entry> </entry></row><row><entry>ATTGCGGCCCTTGTCCGAAAAACTGGATATGTTACAAGAATAATTGTTACCAATTCTTCGACGA</entry></row><row><entry> </entry></row><row><entry>AAGCAAGAACTGGTATGAGAGTCAGGCGTCTTGTATGAGTCAGAATGCCAGCCTGCTTAAGGTT</entry></row><row><entry> </entry></row><row><entry>TATTCAAAAGAAGACCAGGATCTGCTTAAGTTGGTAAAGAGCTACCACTGGATGGGGCTGGTAC</entry></row><row><entry> </entry></row><row><entry>ATATCCCAACGAATGGGTCATGGCAGTGGGAGGACGGTTCTATTCTGAGTCCAAATCTCCTGAC</entry></row><row><entry> </entry></row><row><entry>GATCATCGAAATGCAGAAAGGGGACTGTGCCCTGTATGCATCATCCTTCAAGGGGTACATCGAG</entry></row><row><entry> </entry></row><row><entry>AACTGCAGTACCCCAAATACCTACATTTGTATGCAAAGAACGGTTGCTAGCACCAAGGGCCCAT</entry></row><row><entry> </entry></row><row><entry>CGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCT</entry></row><row><entry> </entry></row><row><entry>GGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC</entry></row><row><entry> </entry></row><row><entry>GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCG</entry></row><row><entry> </entry></row><row><entry>TGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCA</entry></row><row><entry> </entry></row><row><entry>GCACCTGAAGCCGCGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA</entry></row><row><entry> </entry></row><row><entry>TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGT</entry></row><row><entry> </entry></row><row><entry>CAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG</entry></row><row><entry> </entry></row><row><entry>CAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG</entry></row><row><entry> </entry></row><row><entry>GCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC</entry></row><row><entry> </entry></row><row><entry>CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTG</entry></row><row><entry> </entry></row><row><entry>ACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGG</entry></row><row><entry> </entry></row><row><entry>AGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGA</entry></row><row><entry> </entry></row><row><entry>CGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC</entry></row><row><entry> </entry></row><row><entry>TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT</entry></row><row><entry> </entry></row><row><entry>CTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGG</entry></row><row><entry> </entry></row><row><entry>AGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGT</entry></row><row><entry> </entry></row><row><entry>AGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGTGCCTGGAGTGGATCGCATGCA</entry></row><row><entry> </entry></row><row><entry>TTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTC</entry></row><row><entry> </entry></row><row><entry>CAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCC</entry></row><row><entry> </entry></row><row><entry>GTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>CCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGTGGAAGTGGTGGTGGCGGCTC</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGCGGATCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGA</entry></row><row><entry> </entry></row><row><entry>GACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGC</entry></row><row><entry> </entry></row><row><entry>AGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>ATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCT</entry></row><row><entry> </entry></row><row><entry>GATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCG</entry></row><row><entry> </entry></row><row><entry>GCTGCGGGACCAAGGTGGAGATCAAAGGTGGTGGCGGCTCTGGAGGAGGAGGGTCCGGACGGTC</entry></row><row><entry> </entry></row><row><entry>GCTGGTGGAGTCTGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTACTGCC</entry></row><row><entry> </entry></row><row><entry>TCTGGATTCACCATCAGTAGCTACCACATGCAGTGGGTCCGGCAGGCACCTGGGAAGTGCCTGG</entry></row><row><entry> </entry></row><row><entry>AGTACATCGGAACCATTAGTAGTGGTGGTAATGTATACTACGCAAGCTCCGCTAGAGGCAGATT</entry></row><row><entry> </entry></row><row><entry>CACCATCTCCAGACCCTCGTCCAAGAACACGGTGGATCTTCAAATGAACAGCCTGAGAGCCGAG</entry></row><row><entry> </entry></row><row><entry>GACACGGCTGTGTATTACTGTGCGAGAGACTCTGGTTATAGTGATCCTATGTGGGGCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>CCCTGGTCACCGTCTCTTCAGGCGGTGGCGGTAGTGGGGGAGGCGGTTCTGGCGGCGGAGGGTC</entry></row><row><entry> </entry></row><row><entry>CGGCGGTGGAGGATCAGACGTTGTGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGA</entry></row><row><entry> </entry></row><row><entry>GACAGAGTCACCATCACCTGTCAGGCCAGTCAGAACATTAGGACTTACTTATCCTGGTATCAGC</entry></row><row><entry> </entry></row><row><entry>AGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCAGCCAATCTGGCATCTGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>ATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCGACTTGGAACCT</entry></row><row><entry> </entry></row><row><entry>GGCGATGCTGCAACTTACTATTGTCAGTCTACCTATCTTGGTACTGATTATGTTGGCGGTGCTT</entry></row><row><entry> </entry></row><row><entry>TCGGCTGTGGGACCAAGGTGGAGATCAAATGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;125:&#x2003;SI-49P6&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIKGSTGSGSKPGSGEGSTKGQVTL</entry></row><row><entry> </entry></row><row><entry>KESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSR</entry></row><row><entry> </entry></row><row><entry>LTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGSGG</entry></row><row><entry> </entry></row><row><entry>GGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVY</entry></row><row><entry> </entry></row><row><entry>SKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIEN</entry></row><row><entry> </entry></row><row><entry>CSTPNTYICMQRTVRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG</entry></row><row><entry> </entry></row><row><entry>NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;126:&#x2003;SI-49P6&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAGGG</entry></row><row><entry> </entry></row><row><entry>AAGTACTGGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGTAGTACTAAAGGACAGGTCACATTG</entry></row><row><entry> </entry></row><row><entry>AAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTG</entry></row><row><entry> </entry></row><row><entry>GTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCT</entry></row><row><entry> </entry></row><row><entry>TGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGG</entry></row><row><entry> </entry></row><row><entry>CTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCG</entry></row><row><entry> </entry></row><row><entry>AGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGG</entry></row><row><entry> </entry></row><row><entry>GCAGGGGACTCTCGTCACGGTGTCCTCTGGTGGCGGCGGCTCCGGGGGTGGCGGATCAGGTGGT</entry></row><row><entry> </entry></row><row><entry>GGAGGATCCTTCCTAAACTCATTATTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTAGT</entry></row><row><entry> </entry></row><row><entry>GTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAG</entry></row><row><entry> </entry></row><row><entry>TAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATAC</entry></row><row><entry> </entry></row><row><entry>AGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACA</entry></row><row><entry> </entry></row><row><entry>TTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAAT</entry></row><row><entry> </entry></row><row><entry>AATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAAC</entry></row><row><entry> </entry></row><row><entry>TGTTCAACTCCAAATACGTACATCTGCATGCAAAGGACTGTGCGTACGGTGGCTGCACCATCTG</entry></row><row><entry> </entry></row><row><entry>TCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCT</entry></row><row><entry> </entry></row><row><entry>GAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGT</entry></row><row><entry> </entry></row><row><entry>AACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCC</entry></row><row><entry> </entry></row><row><entry>TGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG</entry></row><row><entry> </entry></row><row><entry>CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;127:&#x2003;SI-49P7&#x2003;heavy&#x2003;chain&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>EIVMTQSPSTLSASVGDRVIITCQASESISSWLAWYQQKPGKAPKLLIYEASKLASGVPSRFSG</entry></row><row><entry> </entry></row><row><entry>SGSGAEFTLTISSLQPDDFATYYCQGYFYFISRTYVNSFGCGTKLTVLGSTGSGSKPGSGEGST</entry></row><row><entry> </entry></row><row><entry>KGEVQLVESGGGLVQPGGSLRLSCTASGFTISTNAMSWVRQAPGKCLEWVGVITGRDITYYASW</entry></row><row><entry> </entry></row><row><entry>AKGRFTISRDTSKNTVYLQMNSLRAEDTAVYYCARDGGSSAITSNNIWGQGTLVTVSTGGGGSG</entry></row><row><entry> </entry></row><row><entry>GGGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKV</entry></row><row><entry> </entry></row><row><entry>YSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIE</entry></row><row><entry> </entry></row><row><entry>NCSTPNTYICMQRTVASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG</entry></row><row><entry> </entry></row><row><entry>VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCP</entry></row><row><entry> </entry></row><row><entry>APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE</entry></row><row><entry> </entry></row><row><entry>QYASTYRVVSVLTVLHQDWLNGKEYKCAVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL</entry></row><row><entry> </entry></row><row><entry>TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV</entry></row><row><entry> </entry></row><row><entry>FSCSVMHEALHNHYTQKSLSLSPGGGGGSGGGGSEVQLLESGGGLVQPGGSLRLSCAASGFSFS</entry></row><row><entry> </entry></row><row><entry>SGYDMCWVRQAPGKCLEWIACIAAGSAGITYDANWAKGRFTISRDNSKNTLYLQMNSLRAEDTA</entry></row><row><entry> </entry></row><row><entry>VYYCARSAFSFDYAMDLWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVG</entry></row><row><entry> </entry></row><row><entry>DRVTITCQASQSISSHLNWYQQKPGKAPKLLIYKASTLASGVPSRFSGSGSGTEFTLTISSLQP</entry></row><row><entry> </entry></row><row><entry>DDFATYYCQQGYSWGNVDNVFGCGTKVEIKGGGGSGGGGSGREGPELSPDDPAGLLDLRQGMFA</entry></row><row><entry> </entry></row><row><entry>QLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEG</entry></row><row><entry> </entry></row><row><entry>SGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR</entry></row><row><entry> </entry></row><row><entry>ARHAWQLTQGATVLGLFRVTPEIPAGLGSTGSGSKPGSGEGSTKGREGPELSPDDPAGLLDLRQ</entry></row><row><entry> </entry></row><row><entry>GMFAQLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVV</entry></row><row><entry> </entry></row><row><entry>AGEGSGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLH</entry></row><row><entry> </entry></row><row><entry>TEARARHAWQLTQGATVLGLFRVTPEIPAGLGGGGSGGGGSREGPELSPDDPAGLLDLRQGMFA</entry></row><row><entry> </entry></row><row><entry>QLVAQNVLLIDGPLSWYSDPGLAGVSLTGGLSYKEDTKELVVAKAGVYYVFFQLELRRVVAGEG</entry></row><row><entry> </entry></row><row><entry>SGSVSLALHLQPLRSAAGAAALALTVDLPPASSEARNSAFGFQGRLLHLSAGQRLGVHLHTEAR</entry></row><row><entry> </entry></row><row><entry>ARHAWQLTQGATVLGLFRVTPEIPAGL</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;128:&#x2003;SI-49P7&#x2003;heavy&#x2003;chain&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAGATCGTGATGACACAATCTCCATCTACGCTCTCCGCCTCAGTGGGCGATAGAGTAATTATTA</entry></row><row><entry> </entry></row><row><entry>CTTGTCAAGCCTCAGAGAGCATTTCATCATGGCTCGCCTGGTATCAGCAAAAGCCTGGGAAGGC</entry></row><row><entry> </entry></row><row><entry>CCCCAAACTTCTCATCTATGAAGCATCAAAGCTGGCCTCTGGGGTTCCGTCTCGCTTCTCCGGG</entry></row><row><entry> </entry></row><row><entry>TCCGGCAGTGGTGCAGAGTTTACGTTGACTATATCTTCTTTGCAACCTGACGATTTCGCAACAT</entry></row><row><entry> </entry></row><row><entry>ATTATTGCCAGGGATACTTTTATTTTATTTCCCGAACATATGTTAACTCTTTTGGGTGCGGGAC</entry></row><row><entry> </entry></row><row><entry>CAAACTCACTGTGCTGGGGTCTACCGGTAGTGGTTCTAAGCCTGGTTCAGGCGAAGGCAGTACG</entry></row><row><entry> </entry></row><row><entry>AAAGGGGAAGTGCAACTGGTCGAAAGCGGTGGAGGGCTTGTTCAACCTGGAGGAAGCCTCCGCT</entry></row><row><entry> </entry></row><row><entry>TGTCCTGCACGGCTAGCGGCTTTACAATAAGTACGAACGCCATGAGCTGGGTCCGGCAGGCTCC</entry></row><row><entry> </entry></row><row><entry>AGGTAAGTGTCTCGAATGGGTGGGGGTCATAACAGGCAGGGACATTACCTACTACGCCAGTTGG</entry></row><row><entry> </entry></row><row><entry>GCCAAGGGTCGATTTACCATTTCTAGAGATACATCCAAGAACACGGTGTACCTCCAGATGAATT</entry></row><row><entry> </entry></row><row><entry>CTCTTAGGGCGGAAGACACAGCAGTATACTACTGCGCGCGAGATGGCGGGAGCAGTGCGATCAC</entry></row><row><entry> </entry></row><row><entry>ATCCAACAACATCTGGGGTCAGGGCACTCTTGTCACGGTGTCGACTGGTGGTGGGGGTAGTGGC</entry></row><row><entry> </entry></row><row><entry>GGCGGAGGTAGCTTTCTTAATTCCCTTTTCAACCAAGAGGTTCAGATCCCCTTGACTGAAAGCT</entry></row><row><entry> </entry></row><row><entry>ATTGCGGCCCTTGTCCGAAAAACTGGATATGTTACAAGAATAATTGTTACCAATTCTTCGACGA</entry></row><row><entry> </entry></row><row><entry>AAGCAAGAACTGGTATGAGAGTCAGGCGTCTTGTATGAGTCAGAATGCCAGCCTGCTTAAGGTT</entry></row><row><entry> </entry></row><row><entry>TATTCAAAAGAAGACCAGGATCTGCTTAAGTTGGTAAAGAGCTACCACTGGATGGGGCTGGTAC</entry></row><row><entry> </entry></row><row><entry>ATATCCCAACGAATGGGTCATGGCAGTGGGAGGACGGTTCTATTCTGAGTCCAAATCTCCTGAC</entry></row><row><entry> </entry></row><row><entry>GATCATCGAAATGCAGAAAGGGGACTGTGCCCTGTATGCATCATCCTTCAAGGGGTACATCGAG</entry></row><row><entry> </entry></row><row><entry>AACTGCAGTACCCCAAATACCTACATTTGTATGCAAAGAACGGTTGCTAGCACCAAGGGCCCAT</entry></row><row><entry> </entry></row><row><entry>CGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCT</entry></row><row><entry> </entry></row><row><entry>GGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGC</entry></row><row><entry> </entry></row><row><entry>GTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCG</entry></row><row><entry> </entry></row><row><entry>TGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACAC</entry></row><row><entry> </entry></row><row><entry>CAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCA</entry></row><row><entry> </entry></row><row><entry>GCACCTGAAGCCGCGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCA</entry></row><row><entry> </entry></row><row><entry>TGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGT</entry></row><row><entry> </entry></row><row><entry>CAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAG</entry></row><row><entry> </entry></row><row><entry>CAGTACGCCAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATG</entry></row><row><entry> </entry></row><row><entry>GCAAGGAGTACAAGTGCGCGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTC</entry></row><row><entry> </entry></row><row><entry>CAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTG</entry></row><row><entry> </entry></row><row><entry>ACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGG</entry></row><row><entry> </entry></row><row><entry>AGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGA</entry></row><row><entry> </entry></row><row><entry>CGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTC</entry></row><row><entry> </entry></row><row><entry>TTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT</entry></row><row><entry> </entry></row><row><entry>CTCCGGGTGGCGGTGGAGGGTCCGGCGGTGGTGGATCCGAGGTGCAGCTGTTGGAGTCTGGGGG</entry></row><row><entry> </entry></row><row><entry>AGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCTCCTTCAGT</entry></row><row><entry> </entry></row><row><entry>AGCGGGTACGACATGTGCTGGGTCCGCCAGGCTCCAGGGAAGTGCCTGGAGTGGATCGCATGCA</entry></row><row><entry> </entry></row><row><entry>TTGCTGCTGGTAGTGCTGGTATCACTTACGACGCGAACTGGGCGAAAGGCCGGTTCACCATCTC</entry></row><row><entry> </entry></row><row><entry>CAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCC</entry></row><row><entry> </entry></row><row><entry>GTATATTACTGTGCGAGATCGGCGTTTTCGTTCGACTACGCCATGGACCTCTGGGGCCAGGGAA</entry></row><row><entry> </entry></row><row><entry>CCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGTGGAAGTGGTGGTGGCGGCTC</entry></row><row><entry> </entry></row><row><entry>TGGAGGCGGCGGATCTGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGA</entry></row><row><entry> </entry></row><row><entry>GACAGAGTCACCATCACTTGCCAGGCCAGTCAGAGCATTAGTTCCCACTTAAACTGGTATCAGC</entry></row><row><entry> </entry></row><row><entry>AGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCATCCACTCTGGCATCTGGGGTCCC</entry></row><row><entry> </entry></row><row><entry>ATCAAGGTTCAGCGGCAGTGGATCTGGGACAGAATTTACTCTCACCATCAGCAGCCTGCAGCCT</entry></row><row><entry> </entry></row><row><entry>GATGATTTTGCAACTTATTACTGCCAACAGGGTTATAGTTGGGGTAATGTTGATAATGTTTTCG</entry></row><row><entry> </entry></row><row><entry>GCTGCGGGACCAAGGTGGAGATCAAAGGTGGTGGCGGCTCTGGAGGAGGAGGGTCCGGACGAGA</entry></row><row><entry> </entry></row><row><entry>GGGCCCCGAGCTGTCTCCTGATGACCCAGCAGGCCTCTTGGACTTGCGGCAGGGTATGTTCGCT</entry></row><row><entry> </entry></row><row><entry>CAACTTGTGGCTCAGAATGTTCTGCTCATTGATGGACCACTCTCTTGGTATAGTGACCCCGGTC</entry></row><row><entry> </entry></row><row><entry>TGGCCGGGGTGAGTCTGACCGGCGGGCTCTCTTATAAAGAGGATACTAAGGAACTGGTCGTAGC</entry></row><row><entry> </entry></row><row><entry>AAAAGCGGGCGTTTATTACGTTTTTTTTCAGCTGGAGCTCAGGCGCGTGGTGGCCGGCGAGGGC</entry></row><row><entry> </entry></row><row><entry>AGTGGCTCTGTGTCCCTGGCCCTGCACTTACAGCCCTTGAGAAGCGCTGCAGGTGCTGCCGCAC</entry></row><row><entry> </entry></row><row><entry>TGGCTTTAACTGTTGACCTCCCTCCGGCCTCTTCTGAAGCTAGAAACAGCGCTTTCGGCTTCCA</entry></row><row><entry> </entry></row><row><entry>AGGGCGCCTGCTGCACCTGAGCGCAGGCCAGCGCTTAGGTGTGCACCTTCATACAGAGGCCAGG</entry></row><row><entry> </entry></row><row><entry>GCCCGACACGCTTGGCAGCTCACACAGGGTGCCACGGTTCTCGGACTTTTCCGCGTTACTCCCG</entry></row><row><entry> </entry></row><row><entry>AGATCCCCGCTGGCCTCGGAAGTACTGGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGTAGTAC</entry></row><row><entry> </entry></row><row><entry>TAAAGGACGAGAAGGGCCAGAGTTAAGTCCAGATGACCCTGCTGGGCTTTTGGACCTGCGGCAG</entry></row><row><entry> </entry></row><row><entry>GGCATGTTCGCTCAACTGGTGGCTCAGAACGTGCTGCTGATCGATGGCCCCCTGAGTTGGTACA</entry></row><row><entry> </entry></row><row><entry>GCGATCCCGGGCTGGCAGGCGTGTCACTTACAGGGGGCCTCTCTTACAAGGAAGACACCAAGGA</entry></row><row><entry> </entry></row><row><entry>GTTAGTGGTCGCTAAGGCTGGCGTGTATTACGTGTTCTTCCAACTGGAGCTGAGAAGGGTTGTG</entry></row><row><entry> </entry></row><row><entry>GCAGGAGAGGGTAGCGGCAGCGTGTCTTTAGCCCTTCACTTGCAGCCCCTGAGGTCTGCTGCAG</entry></row><row><entry> </entry></row><row><entry>GTGCAGCCGCTCTCGCGCTCACCGTGGATCTCCCCCCAGCCTCATCTGAAGCTAGGAACAGTGC</entry></row><row><entry> </entry></row><row><entry>ATTTGGCTTTCAGGGACGCTTGCTGCACCTCTCCGCTGGACAGAGGCTGGGCGTGCACCTTCAC</entry></row><row><entry> </entry></row><row><entry>ACAGAGGCCCGTGCCAGGCATGCATGGCAGCTCACTCAGGGGGCAACAGTGCTGGGTCTCTTCC</entry></row><row><entry> </entry></row><row><entry>GCGTGACTCCTGAAATACCAGCTGGACTTGGCGGTGGAGGCAGCGGCGGAGGAGGATCTCGTGA</entry></row><row><entry> </entry></row><row><entry>GGGGCCAGAACTGTCCCCCGATGACCCAGCCGGACTGCTCGATCTCAGACAGGGCATGTTCGCT</entry></row><row><entry> </entry></row><row><entry>CAGCTTGTAGCCCAAAATGTCCTCCTGATTGACGGCCCTTTGAGCTGGTATAGTGATCCCGGCT</entry></row><row><entry> </entry></row><row><entry>TGGCCGGGGTATCTCTGACCGGAGGCCTCTCCTACAAGGAAGACACCAAAGAGCTGGTGGTGGC</entry></row><row><entry> </entry></row><row><entry>AAAAGCGGGGGTGTATTATGTGTTCTTTCAGCTCGAGCTGCGGAGAGTTGTGGCCGGGGAAGGG</entry></row><row><entry> </entry></row><row><entry>TCTGGGAGCGTATCTCTTGCACTTCACCTGCAGCCCCTGCGCAGCGCCGCTGGAGCCGCCGCCC</entry></row><row><entry> </entry></row><row><entry>TTGCTCTTACTGTGGATCTGCCTCCTGCTTCCTCAGAAGCACGCAACAGCGCCTTCGGCTTTCA</entry></row><row><entry> </entry></row><row><entry>AGGACGTCTCCTGCACTTGTCCGCAGGACAGAGGTTGGGCGTCCATTTACACACTGAGGCACGG</entry></row><row><entry> </entry></row><row><entry>GCACGGCACGCTTGGCAGCTTACCCAGGGAGCCACCGTGCTGGGACTCTTTAGAGTGACACCCG</entry></row><row><entry> </entry></row><row><entry>AGATCCCCGCTGGCTTGTGA</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;129:&#x2003;SI-49P7&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIKGSTGSGSKPGSGEGSTKGQVTL</entry></row><row><entry> </entry></row><row><entry>KESGPGLVQPGQTLRLTCAFSGFSLSTSGMGVGWIRQPPGKGLEWLAHIWWDDDKRYNPALKSR</entry></row><row><entry> </entry></row><row><entry>LTISKDTSKNQVYLQMNSLDAEDTAVYYCARMELWSYYFDYWGQGTLVTVSSGGGGSGGGGSGG</entry></row><row><entry> </entry></row><row><entry>GGSFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVY</entry></row><row><entry> </entry></row><row><entry>SKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIEN</entry></row><row><entry> </entry></row><row><entry>CSTPNTYICMQRTVRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG</entry></row><row><entry> </entry></row><row><entry>NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;130:&#x2003;SI-49P7&#x2003;light&#x2003;chain&#x2003;moiety&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAGGG</entry></row><row><entry> </entry></row><row><entry>AAGTACTGGTTCTGGGTCTAAACCCGGTTCCGGCGAAGGTAGTACTAAAGGACAGGTCACATTG</entry></row><row><entry> </entry></row><row><entry>AAGGAATCTGGCCCCGGCCTTGTTCAGCCAGGACAGACCCTTAGGCTCACCTGTGCCTTCAGTG</entry></row><row><entry> </entry></row><row><entry>GTTTTTCTCTTAGCACTAGCGGTATGGGGGTCGGCTGGATTCGGCAGCCTCCCGGCAAAGGTCT</entry></row><row><entry> </entry></row><row><entry>TGAGTGGTTGGCTCACATTTGGTGGGACGACGACAAACGGTATAATCCTGCCTTGAAAAGTCGG</entry></row><row><entry> </entry></row><row><entry>CTGACCATTAGTAAGGATACCTCAAAAAATCAAGTGTACTTGCAAATGAATAGCCTTGACGCCG</entry></row><row><entry> </entry></row><row><entry>AGGATACGGCTGTATATTATTGCGCGCGGATGGAACTCTGGTCTTACTACTTTGATTATTGGGG</entry></row><row><entry> </entry></row><row><entry>GCAGGGGACTCTCGTCACGGTGTCCTCTGGTGGCGGCGGCTCCGGGGGTGGCGGATCAGGTGGT</entry></row><row><entry> </entry></row><row><entry>GGAGGATCCTTCCTAAACTCATTATTCAACCAAGAAGTTCAAATTCCCTTGACCGAAAGTTACT</entry></row><row><entry> </entry></row><row><entry>GTGGCCCATGTCCTAAAAACTGGATATGTTACAAAAATAACTGCTACCAATTTTTTGATGAGAG</entry></row><row><entry> </entry></row><row><entry>TAAAAACTGGTATGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATAC</entry></row><row><entry> </entry></row><row><entry>AGCAAAGAGGACCAGGATTTACTTAAACTGGTGAAGTCATATCATTGGATGGGACTAGTACACA</entry></row><row><entry> </entry></row><row><entry>TTCCAACAAATGGATCTTGGCAGTGGGAAGATGGCTCCATTCTCTCACCCAACCTACTAACAAT</entry></row><row><entry> </entry></row><row><entry>AATTGAAATGCAGAAGGGAGACTGTGCACTCTATGCCTCGAGCTTTAAAGGCTATATAGAAAAC</entry></row><row><entry> </entry></row><row><entry>TGTTCAACTCCAAATACGTACATCTGCATGCAAAGGACTGTGCGTACGGTGGCTGCACCATCTG</entry></row><row><entry> </entry></row><row><entry>TCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCT</entry></row><row><entry> </entry></row><row><entry>GAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGT</entry></row><row><entry> </entry></row><row><entry>AACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCC</entry></row><row><entry> </entry></row><row><entry>TGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGG</entry></row><row><entry> </entry></row><row><entry>CCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;131:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;VL&#x2003;amino&#x2003;acid&#x2003;sequence</entry></row><row><entry>ENVLTQSPASLSASPGERVTITCSASSSVSYMHWYQQKPGQAPKLWIYDTSKLASGVPSRFSGS</entry></row><row><entry> </entry></row><row><entry>GSGNDHTLTISSMEPEDFATYYCFQGSVYPFTFGQGTKLEIK</entry></row><row><entry> </entry></row><row><entry>&#x3e;Sequence&#x2003;ID&#x2003;132:&#x2003;&#x3b1;CD19&#x2003;SI-huBU12&#x2003;VL&#x2003;nucleotide&#x2003;sequence</entry></row><row><entry>GAAAATGTATTGACACAGAGCCCCGCCTCCCTCAGTGCCTCACCTGGGGAAAGGGTAACTATCA</entry></row><row><entry> </entry></row><row><entry>CTTGCTCTGCATCAAGCAGCGTCTCATACATGCATTGGTATCAACAAAAGCCTGGACAGGCCCC</entry></row><row><entry> </entry></row><row><entry>CAAGCTCTGGATATACGATACGAGCAAGCTGGCTTCCGGCGTACCTAGCCGCTTCAGTGGTTCC</entry></row><row><entry> </entry></row><row><entry>GGCTCAGGCAACGATCACACCCTTACGATTTCCAGTATGGAACCCGAAGATTTTGCAACTTATT</entry></row><row><entry> </entry></row><row><entry>ATTGTTTCCAGGGGAGCGTGTACCCATTCACTTTCGGGCAGGGGACAAAATTGGAGATAAAG</entry></row></tbody></tgroup></table></tables></p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002488A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.25"/></us-sequence-list-doc><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A multi-specific antibody-like protein having a N-terminal and a C-terminal, comprising in tandem from the N-terminal to the C-terminal,<claim-text>a first binding domain (D1) at the N-terminal,</claim-text><claim-text>a second binding domain (D2) comprising a light chain moiety,</claim-text><claim-text>a Fc region,</claim-text><claim-text>a third binding domain (D3), and</claim-text><claim-text>a fourth binding domain (D4) at the C-terminal,</claim-text><claim-text>wherein the light chain moiety comprises a fifth binding domain (D5) covalently attached to the C-terminal, a sixth binding domain (D6) covalently attached to the N-terminal, or both, and</claim-text><claim-text>wherein the D1, D2, D3, D4, D5 and D6 each has a binding specificity to a tumor antigen, an immune signaling antigen, or a combination thereof.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D2 comprises a dimer connected to CL and CH1, a Fab region, or a receptor.</claim-text></claim><claim id="CLM-003-4" num="003-4"><claim-text><b>3</b>-<b>4</b>. (canceled)</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D2 comprises NKG2D, or wherein the D2 has a binding specificity to CD3 or a tumor associated antigen (TAA).</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the light chain moiety comprises a fifth binding domain (D5) covalently attached to the C-terminal, and wherein the multi-specific antibody-like protein is penta-specific.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the light chain moiety comprises a sixth binding domain (D6) covalently attached to the N-terminal, and wherein the multi-specific antibody-like protein is penta-specific.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the light chain moiety comprises a fifth binding domain (D5) covalently attached to the C-terminal and a sixth binding domain (D6) covalently attached to the N-terminal, and wherein the multi-specific antibody-like protein is hexa-specific.</claim-text></claim><claim id="CLM-09-10" num="09-10"><claim-text><b>9</b>-<b>10</b>. (canceled)</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D1, D2, D3, D4, D5, and D6 is independently a scFv domain, a receptor, or a ligand, or wherein the D1, D2, D3, D4, D5, and D6 independently has a binding specificity to an antigen selected from a receptor on a T cell, an immune checkpoint receptor, a co-stimulation receptor, a receptor of a lymphocyte or a myeloid cell, a tumor associated antigen (TAA), a tissue antigen, a neoantigen, a tumor-specific antigen (TSA), a glycoprotein, or a combination thereof.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the binding domain for the receptor on the T cell is adjacent to the binding domain for the tumor associated antigen (TAA).</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the binding domain for the receptor on the T cell is adjacent to the binding domain for the receptor of a lymphocyte or a myeloid cell.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein the receptor on the T cell comprises CD3, T cell receptor, or a complex thereof, wherein the immune checkpoint receptor comprises PD-L1, PD-1, TIGIT, TIM-3, LAG-3, CTLA4, BTLA, VISTA, PDL2, CD160, LOX-1, siglec-15, CD47, SIRP&#x3b1;, or a combination thereof, wherein the co-stimulating receptor comprises 4-1BB, CD28, OX40, GITR, CD40, ICOS, CD27, CD30, CD226, or a combination thereof, or wherein the tumor associated antigen (TAA) comprises EGFR, HER2, HER3, HER4, EGRFVIII, CD19, claudin 18.2, BCMA, CD20, CD33, CD123, CD22, CD30, ROR1, CEA, cMET, LMP1, LMP2A, Mesothelin, PSMA, EpCAM, glypican-3, gpA33, GD2, TACI, TROP2, NKG2D ligands, PD-L1, or a combination thereof.</claim-text></claim><claim id="CLM-15-17" num="15-17"><claim-text><b>15</b>-<b>17</b>. (canceled)</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D1 has a binding specificity to CD3, CD20, EGFR, or their derivative thereof.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D2 has the binding specificity to EGFR, CD3, HER2, MSLN, NKG2D ligands, or their derivative thereof.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D3 has a binding specificity to PD-L1.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D4 comprise a 4-1BBL trimer or has a binding specificity to 4-1BB or its derivative thereof.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D5 has a binding specificity to HER3, CD19, NKG2D ligands, or their derivative thereof.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the D6 has a binding specificity to CD19.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. (canceled)</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A guidance and navigation control protein, comprising a dimer of the multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. An isolated nucleic acid sequence, encoding an amino acid sequence of the multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. An expression vector, comprising the isolated nucleic acid sequence of <claim-ref idref="CLM-00026">claim 26</claim-ref>.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. A host cell comprising the isolated nucleic acid sequence of <claim-ref idref="CLM-00026">claim 26</claim-ref>, wherein the host cell is a prokaryotic cell or a eukaryotic cell.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. A method for producing a multi-specific antibody or monomer, comprising culturing a host cell comprising an isolated nucleic acid sequence such that the DNA sequence encoding the multi-specific antibody-like protein of <claim-ref idref="CLM-00001">claim 1</claim-ref> is expressed, and purifying said multi-specific antibody-like protein.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. A method for treating or preventing a cancer, an autoimmune disease, or an infectious disease, said method comprising administering a pharmaceutical composition comprising a purified multi-specific antibody of <claim-ref idref="CLM-00029">claim 29</claim-ref>.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. An immuno-conjugate comprising a cytotoxic agent or an imaging agent linked to the multi-specific antibody of <claim-ref idref="CLM-00029">claim 29</claim-ref> through a linker, wherein the linker comprises an ester bond, an ether bond, an amid bond, a disulphide bond, an imide bond, a sulfone bond, a phosphate bond, a phosphorus ester bond, a peptide bond, a hydrophobic poly(ethylene glycol) linker, or a combination thereof.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and one of the multi-specific antibodies of <claim-ref idref="CLM-00029">claim 29</claim-ref>, the immuno-conjugate of <claim-ref idref="CLM-00031">claim 31</claim-ref>, or both.</claim-text></claim></claims></us-patent-application>